

# VALENTIN FUSTER, M.D., PH.D.

## Curriculum Vitae

**Address:** The Mount Sinai Medical Center  
One Gustave L. Levy Place, Box 1030  
New York, NY 10029-6574

**Date of Birth:** January 20, 1943

**Place of Birth:** Barcelona, Spain

### Education:

1954-1961 B.S. Colegio Jesuitas, Barcelona, Spain (Baccalaureate)  
1961-1967 M.D. Faculty of Medicine, Barcelona University, Barcelona, Spain  
1971 Ph.D. University of Edinburgh, Edinburgh, Scotland

### Postdoctoral Training:

#### Internship, Residencies, and Fellowships:

1967-1968 Internship (Straight Medical), Hospital Clinico, Barcelona, Spain  
1968-1971 Research Fellow in Cardiovascular Diseases, Department of Medicine, Royal Infirmary, University of Edinburgh, Edinburgh, Scotland  
1971-1972 Resident in Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota

### Licensure and Certification:

1967 Internal Medicine Licensure, University of Barcelona, Spain  
1970 Educational Council for Foreign Medical Graduates  
1974 Minnesota State Board of Medical Examiners  
1976 Internal Medicine Board Certification  
1977 Cardiovascular Diseases Board Certification  
1982 New York State Medicine and Surgery  
1991 Massachusetts State Medicine and Surgery

### Military Service:

1966-1968 Spanish Army, Second Lt., Barcelona, Spain; Active Duty - 10 months, Reserve - 2 years

### Academic Appointments:

2009- General Director, CNIC-Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain  
2007-2009 Scientific Director, CNIC-Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain  
2006- Director, Mount Sinai Heart, , Mount Sinai School of Medicine, New York, New York  
1997- Richard Gorlin, M.D./Heart Research Foundation Professor of Cardiology, Mount Sinai School of Medicine, New York, New York  
1994-1997 Arthur M. and Hilda A. Master Professor of Medicine, Mount Sinai School of Medicine, New York, New York  
1994 Dean for Academic Affairs, Mount Sinai Medical Center, New York, New York  
1991-1994 Mallinckrodt Professor of Medicine, Harvard Medical School, Boston, Massachusetts

- 1982-1991 Arthur M. and Hilda A. Master Professor of Medicine, Mount Sinai School of Medicine, New York, New York
- 1981-1982 Professor of Medicine and Cardiovascular Diseases, Mayo Medical School, Rochester, Minnesota
- 1980 Associate Professor of Pediatrics, Mayo Medical School, Rochester, Minnesota
- 1978-1981 Associate Professor of Medicine and Cardiovascular Diseases, Mayo Medical School, Rochester, Minnesota
- 1974-1977 Assistant Professor of Medicine and Cardiovascular Diseases, Mayo Medical School, Rochester, Minnesota

**Hospital Appointments:**

- 2011- Physician-in-Chief, The Mount Sinai Medical Center, New York, New York
- 2006- Director, Mount Sinai Heart, New York, New York
- 2002- Director, The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, New York, New York
- 1997- Director, The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Medical Center, New York, New York
- 1994-1997 Director, The Zena and Michael A. Wiener Cardiovascular Institute and Vice-Chairman of Medicine, Mount Sinai Medical Center, New York, New York
- 1991-1994 Chief, Cardiac Unit, Massachusetts General Hospital, Boston, Massachusetts
- 1982-1991 Chief, Division of Cardiology, Mount Sinai Medical Center, New York, New York
- 1975-1982 Consultant in Internal Medicine and Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota

**Awards and Honors:**

- 1967 Prize Diputation of Barcelona: Graduated first in the class of the Medical School of Barcelona (Magna Cum Laude in 20 subjects with honors in 18)
- 1968 Fundacion Juan March Research Fellowship Award M.D. Thesis, University of Barcelona, Magna Cum Laude
- 1969-1971 University of Edinburgh Research Fellowship Award
- 1971 Ph.D. Thesis, University of Edinburgh - Presented in Barcelona, "New Orientation for the Study of Platelet Function - Detection of Platelet Factor 4 - Methods and Clinical Relevance"
- 1972-1974 Minnesota Heart Association Grant Award
- 1974 Mayo Clinic - Donald C. Balfour Award for Outstanding Research Achievement
- 1976 Miguel Servet 1<sup>st</sup> International Award for Cardiovascular Research, Madrid, Spain (to the best investigator from Spain working in a foreign country)
- 1985 The Solomon A. Berson Teaching Award
- 1985 The Simon Dack Award for the Best Teacher (chosen by Cardiology Fellows at Mount Sinai Medical Center)
- 1987 Honorary Member, Argentinean Society of Cardiology
- 1987 Honorary Member, Spanish Society of Cardiology
- 1991 Honorary Member, Venezuelan Society of Cardiology
- 1991 Honorary Member, Peruvian Society of Cardiology
- 1991 Honorary Member, Mexican Society of Cardiology
- 1991 New York Heart Research Foundation 1991 Medical Science Award
- 1991 Outstanding Faculty Physician of the Year, Mt. Sinai School of Medicine
- 1991 Awarded the 1992 Andres Bello Medal of Distinction of the Government of Venezuela

1991 Distinguished Physician Award, Dept. of Medicine, Mt. Sinai Medical Center, New York  
 1992 Isabel LaCatolica Medal (Encomienda), Awarded by the Spanish Government  
 1992 Honorary Master's Degree, Harvard Medical School  
 1992 The 1992 Distinguished Scientist Gruntzig Award of the European Society of Cardiology  
 1993 Honorary Member, French Society of Cardiology  
 1993 Honorary Member, Ecuatorana Society of Cardiology  
 1993 Fellow of the Royal College of Physicians at Edinburgh  
 1993 The 1993 Award of the Catalan Foundation for Research  
 1993 The 1993 Distinguished Scientist Award, American College of Cardiology  
 1993 The 1993 Lewis A. Conner Distinguished Presidential Lecture, American Heart Association  
 1993 CINE 1993 Golden Eagle Award for the production "Lipids, Plaque Rupture and the Evolution of Coronary Artery Disease," selected for excellence to represent the United States of America in international film and video events abroad  
 1993 Fundacion Fernandez-Cruz Award, Universidad Complutense, Madrid  
 1994 The 1994 Distinguished Bishop Lecture of the American College of Cardiology  
 1994 The 1994 Narcis Monturiol Catalonia Award  
 1994 Doctor Honorary Degree, Universitat Autonoma de Barcelona  
 1994 The 1994 Presidential Lecture of the Cardiac Society of Australia and New Zealand  
 1994 The 1994 Presidential Lecture of the Japanese College of Cardiology  
 1994 The 50<sup>th</sup> Anniversary Presidential Lecture of the Spanish Society of Cardiology  
 1995 Keynote Plenary Address of the 2<sup>nd</sup> International Conference of Nuclear Cardiology, Cannes, France  
 1995 Jacobi Medallion Award, Mount Sinai Alumni Association  
 1995 Award Fundacion Vila Casas, Barcelona, Spain  
 1995 Honorary Member, Vasco-Navarra Society of Cardiology  
 1995 Honorary Member, Colombian Society of Cardiology  
 1995 NHLBI-Distinguished Speaker-18<sup>th</sup> Ann. National Cholesterol Educational Program  
 1995 Doctor Honorary Degree, Universitat Autonoma de Barcelona  
 1995 Co-Chairman, 27<sup>th</sup> Bethesda Conference  
 1995 Llico Joan d'Alos Award, Barcelona, Spain  
 1996 The 1996 Presidential Lecture, Canadian Heart Association  
 1996 46<sup>th</sup> Annual Scientific Sessions of the Maine Affiliate of the American Heart Association  
 Drake Award  
 1996 Doctor Honorary Degree, Universidad Nacional de Cordoba, Argentina  
 1996 Doctor Honorary Degree, University of Barcelona, Spain  
 1996 Principe de Asturias Award of Science and Technology (the highest award to Spanish speaking scientists, given by the son of the King of Spain), Fundacion Principe de Asturias, Oviedo, Spain  
 1996 Doctor Honorary Degree, Universidad Nacional de Cordoba, Argentina  
 1996 Jimenez Diaz Research Award (Madrid)  
 1996 Rivkah Laufer Bikur Cholim Jewish Foundation Doctor of the Year Award  
 1996 Mount Sinai School of Medicine Excellence in Teaching Award  
 1996 Globus Award (Mount Sinai Journal of Medicine)  
 1997-1998 President-Elect, American Heart Association  
 1997 Honorary Member, Sociedad Espanola de Medicina Intensiva Y Unidades Coronarias  
 1997 Honorary Member, Fundacio Universal de la Sardana, Barcelona, Spain  
 1997 Member, Mount Sinai Medical Center Faculty Practice Associates Board of Governors  
 1997 Doctor Honorary Degree, University of Barcelona, Spain

1997 The Simon Dack Award for the Best Teacher (chosen by Cardiology Fellows at Mount Sinai Medical Center)

1997 American Heart Association Scientific Councils Distinguished Achievement Award

1997 Spanish Society of Cardiology Gold Medal Recipient, Granada, Spain

1998 American Heart Association NYC Affiliate Achievement Award in CV Science and Medicine

1998 The J. Lester Gabrilove Award, Mount Sinai Alumni

1998 Member of Honor, National Academy of Medicine, Madrid, Spain

1998 Doctor Honorary Degree, Universidad de Valladolid, Spain

1998 Doctor Honorary Degree, Universidade Federal do Rio de Janeiro, Brazil

1998 Gill Heart Institute Award for Outstanding Cardiovascular Research, Lexington, Kentucky

1998 Spanish Institute Gold Medal (given by Queen Sofia of Spain), New York

1998 Bristol-Myers Squibb Cardiovascular/Metabolic Diseases Nonrestrictive 5 Year Research Grant Award For Excellence

1999 Heart of Gold Award - American Heart Association - NYC Heritage Affiliate

1998-1999 Honorary Member, La Sociedad Mexicana para el Estudio de la Hipertension Arterial

1998-1999 American Heart Association - President

1999-2000 American Heart Association - Past Immediate President

2000 Distinguished Service Award from the American College of Cardiology

2000 The Marquis Who's Who in the World - Millenium Edition

2000 Member, Institute of Medicine, National Academy of Science

2001 Doctor Honorary Degree, University of Buenos Aires, Argentina

2001 American Heart Association – Herrick Award

2002 Distinguished Alumni Award, Mayo Clinic Medical School, Rochester, Minnesota

2002 University of Miami, Division of Cardiology “The Thinker” Award,

2002 Andreas Gruntzig Award of the International Society of Interventionalists(Paris)

2002 Doctor Honorary Degree, University of Murcia, Spain

2002 Pregoner Festes de la Mercè, Barcelona, Spain

2002 “Giovanni Battista Morgagni” Lecture, Rome, Italy

2003 Distinguished Career Award, 11<sup>th</sup> ISTH Biennial Awards for Contributions to Hemostasis

2003–2004 President-Elect – World Heart Federation

2003 Hatter Award, Cape Town, South Africa

2003 AHA Gold Heart Award, Washington, D.C.

2003 Distinguished Career Award, International Society of Thrombosis and Hemostasis, UK

2003 Chazov Gold Medal for Exceptional Achievement in Cardiology, St. Petersburg, Russia

2003 Chairman, NHLBI SPARK II Meeting, Bethesda, MD

2003 AHA/ASA Distinguished Scientist, presented to only 15 scientists who have made major contributions to cardiovascular research in recent years

2004 President, Paul Dudley White Society, Boston, MA

2004 Appointed to Editor-in-Chief, Nature Cardiovascular Medicine Journal

2005 Distinguished Researcher Award, Interamerican Society of Cardiology

2005 International Gabarron Award, Gaharron Foundation, Valladolid, Spain

2005 Chair, Genomics and Cardiovascular Symposium, Philadelphia, PA

2005 Doctor Honorary Degree, University of Miguel Hernandez, Alicante, Spain

2005 Doctor Honorary Degree, University of Ramon Llull, Barcelona, Spain

2005 John Paul II Hospital Gold Medal, Krakow, Poland

2006 Honorary member of the Mexican Society of Cardiology

2006 World Congress of Cardiology President, Barcelona, Spain

2006 Catalan Award for Communication, Barcelona, Spain

2006 Chairman, NHLBI Review Committee of the CV Program, Bethesda, MD  
 2006 InterAmerican Society of Cardiology Research Achievement Award, Cancun, Mexico  
 2006 Distinguished Scientific Award. American Heart Association, Heart of the Hamptons Gala, New York  
 2007 Honorary Degree, Jaume I Castellon University, Castellon, Spain  
 2007 Honorary Degree, University del Salvador, Buenos Aires, Argentina  
 2007 Distinguished Award, AEEPP, Madrid, Spain  
 2007 Distinguished Award, Villa of Osuna, Seville, Spain  
 2007 20 years of Catalonia, 20 Awardees, Recoletos, Barcelona, Spain  
 2007 Chair, International Symposium on Burden of Atherothrombotic Disease, New York  
 2007 Co-Chair, International Meeting on Biomarkers, Berlin, Germany  
 2007 Distinguished Award, AEFÉ, Barcelona, Spain  
 2007 Gold Medal Award, Catalan Society of Cardiology, Barcelona, Spain  
 2007 Gold Medal Award, European Society of Cardiology, Vienna, Austria  
 2007 Time Magazine Award (Spain) - one of the eight main contributors to the country for the last 25 years  
 2007 Living Legend Award in Cardiovascular Diseases, University of Ottawa, Ottawa, Canada  
 2007 The Maimonides Chair, European Academy of Yuste, Yuste, Spain  
 2007 Honorary Degree, (Complutense) University of Madrid, Madrid, Spain  
 2007 Joan Codina Award, Barcelona, Spain  
 2007 15<sup>th</sup> Year as Chair of ACC New York Cardiovascular Symposium (2000 Attendees 2006)  
 2007 5<sup>th</sup> Year as Chair of NHBLI/ACC/AHA of How to Become a Cardiovascular Investigator Meeting (Bi-Annual for Fellows)  
 2007 Chair, High Risk Plaque International Imaging Board, New York  
 2008 Since 1992, 15 consecutive years nominated as Best Doctors of America, as well as New York Best Doctor  
 2008 Member, European Academy of Science and Arts  
 2008 Polzer Prize, European Academy of Science and Arts  
 2008 Honorary Degree, Castellon University, Castellon Spain  
 2008 Honorary Degree, Catholic University of Buenos Aires, Argentina  
 2008 Honorary Degree, European University, Madrid, Spain  
 2008 Honorary Degree, University of Valencia, Spain  
 2008 Ellis Island Medal of Honor, New York, NY  
 2008 Teaching Excellence Award, Department of Medicine (MSSM), New York, NY  
 2008 Award for Health and Wellness, Madrid, Spain  
 2008 Universal Spaniard Award, U.S./Spain Chamber of Commerce, Miami, FL  
 2009 Libin Prize, Calgary, Canada  
 2009 ACC Distinguished Teacher Award, Orlando, FL  
 2009 National Recognition Award for Sports and Science bestowed by the King of Spain & Superior Sports Council of Spain  
 2009 Arrigo Recordati International Prize, Milan, Italy  
 2009 Honorary Degree, University of Edinburgh, Edinburgh, Scotland  
 2009 Distinguished Investigator Award, XXII Interamerican Cong. of Card., San Juan, PR  
 2009 Honorary Degree, Salvador University, Buenos Aires, Argentina  
 2010 Honorary Degree, International University of Catalonia, Barcelona, Spain  
 2010 Honorary Degree, Menéndez Pelayo International University, Santander, Spain  
 2010 Cadeci Award for Cardiovascular Research (Europe)

- 2010 Master of the American College of Cardiology
- 2010 The Paul Wood Honorary Lecturer Award (United Kingdom)
- 2010 Honorary Member, Japanese Circulation Society
- 2010 Erasmus University “In Praise of Medicine” Award (Holland)
- 2011 The LeFoulon Delalande Grand Prize, Institute of France, Paris, France
- 2011 Universal Spaniard Award, Madrid, Spain
- 2011 CNIC (Dr. Valentin Fuster – Director) Severo Ochoa (Nominated as the highest of excellence by the European Committee Members which include three Nobel Laureates)
- 2011 Honorary Citizen of Buenos Aires, Argentina
- 2012 ACC Legends (1 of 2 Americans honored), Chicago, IL
- 2012 NYPD Honorary Police Surgeon, New York, NY
- 2012 Honorary Degree, University of Cadiz, Cadiz, Spain
- 2012 Honorary Degree, La Plata University, La Plaza, Argentina
- 2012 Research Cultural Award, Catalonia, Spain
- 2012 John F. Kenney Award, Institute of North American Studies, Barcelona, Spain
- 2012 AHA Research Achievement Award, Los Angeles, CA
- 2012 Honorary Degree, University of Zaragoza, Zaragoza, Spain
- 2013 Munster Heart Center Lecture Award, Munster, Germany
- 2013 Honoris Causa, Universidad de VIC, Barcelona, Spain
- 2013 Simon Dack Lecture Award, American College of Cardiology (ACC), San Francisco, CA
- 2013 Honoris Causa, Universidad CEU Cardenal Herrera, Castellón, Spain
- 2013 International Impact Achievement Award, American Heart Association, Houston, TX
- 2013 Health Care Delivery Excellent Award, European Institute and Welfare, Spain
- 2013 Arthur S. Agatston Cardiovascular Disease Prevention Award, Society of Cardiovascular Computed Tomography (SCCT), Montreal, Canada
- 2013 Camino Real Award, Instituto Franklin-Universidad de Alcala, Spain
- 2014 Frontier in Science Award, American Association of Clinical Endocrinologists, Las Vegas, NV
- 2014 Marques of Fuster: Awarded by King Juan Carlos I of Spain, Spain

### **Honorary Lectureships**

- 1983 The 1983 Roon Professorship Lecture, San Diego, CA
- 1986 The Joseph E. Walker Professorship Lecture, Kansas City, MO
- 1987 The 1987 David Scharf Memorial Lecture, Lenox Hill Hospital, New York
- 1988 The 1988 Presidential Citation Lectureship of the American College and World Congress of Chest Physicians, Boston, MA
- 1989 The 1989 Pfizer Visiting Professorship in Cardiovascular Medicine, Medical University of South Carolina, Charleston, SC
- 1989 The 1989 Littman Professorship Lecture, Boston, MA
- 1989 The 1989 Hugo Roesler Memorial Lecture, Temple University, Philadelphia, PA
- 1990 The 1990 Carl J. Wiggers Memorial Lecture, The Cleveland Clinic Foundation, Cleveland, OH
- 1990 Theodore S. Zimmerman Memorial Lecture, La Jolla, CA
- 1990 The 1990 Pfizer Visiting Professorship in CV Medicine, Washington, DC
- 1990 1990 Neuton Stern Honorary Lecture, The Univ. of Tennessee, Memphis, TN
- 1990 1990 Max Stein Honorary Lecture, The Brookdale Hospital Medical Center, Brooklyn, NY
- 1990 1990 Paul Dudley White Honorary Lect. American College of Cardiology, New York, NY
- 1991 Honorary Lecture in Honor of the 500<sup>th</sup> Anniversary of the Discovery of America, San Juan,

PR

- 1991 The 1991 James B. Herrick Honorary Lecture, American Heart Association, Chicago, IL
- 1991 The 1991 Jesse E. Edwards Honorary Lecture, University of Minnesota
- 1991 The 1991 Pfizer Visiting Professor at the City University of New York, Stony Brook, NY
- 1992 The 1992 Grollman Lecture, University of Virginia
- 1992 The 1992 Henry Neufeld Memorial Lecture, Israel Heart Society, Tel Aviv, Israel
- 1992 The 1992 Distinguished Basic Research Lecture, American College of Cardiology Postgraduate Course, Washington, D.C.
- 1992 Theodore S. Zimmerman Memorial Lecture, La Jolla, CA
- 1992 The 1992 Mayo Clinic Cardiovascular Visiting Professor
- 1992 State of the Art Lecture at the International Congress, King Faisal Hospital and Research Center, Saudi Arabia
- 1992 State of the Art Lecture at the International Paavo Nurmi Symposium, Helsinki, Finland
- 1992 Magistral Lecture, International Society of Cardiovascular Surgery, Seville
- 1992 NHLBI Lecture Honoring Dr. Gardner McMillan, "Future Directions in Atherosclerosis"
- 1992 1992 State of the Art Lecture, International Conference on Interventional Cardiology and Cardiac Surgery, Long Beach, California
- 1992 1992 Gruntzig Memorial Lecture, European Society of Cardiology, Barcelona
- 1993 The Distinguished Fraser Mustard Lectureship, McMaster University, Ontario, Canada
- 1993 The Twentieth Annual Arvilla Berger Lecture, New York State Chapter, American College of Cardiology
- 1993 Lewis A Conner Distinguished Lecture, American Heart Association
- 1993 Second HJC Swan Honorary Lecture, Cedar Sinai Hospital, Los Angeles, California
- 1993 Pfizer Traveling Fellow, Clinical Research Institute of Montreal, Montreal, Canada
- 1993 Distinguished Speaker, The Centre for Cardiovascular Research, Toronto, Canada
- 1994 The Distinguished Bishop Lecture of the American College of Cardiology
- 1994 The RT Hall Lecture of the Cardiac Society of Australia and New Zealand
- 1995 The First Distinguished Lectures in Cardiovascular Medicine - McMaster University (Hamilton Civic Hospitals Research Centre)
- 1995 Keynote Speaker, AHA The Lipid Nurse Task Force, Arlington, Virginia
- 1995 Distinguished Speaker - NHLBI - 10<sup>th</sup> Anniversary National Cholesterol Education Program - Bethesda, Maryland
- 1996 The Fourth Annual Miriam Lemberg Visiting Professorship in Cardiovascular Disease, University of Miami School of Medicine
- 1996 Martin Lowenthal Memorial Lecture, Mountainside Hospital, Montclair, New Jersey
- 1996 Hahnemann University/AOA Chapter Visiting Professorship, Philadelphia, Pennsylvania
- 1996 Distinguished Speaker, 46<sup>th</sup> Annual Scientific Sessions of the Maine Affiliate of the American Heart Association, Bethel, Maine
- 1996 Distinguished Speaker, Symposium Honoring Dr. Henry Blackburn, University of Minnesota, Minneapolis, Minnesota
- 1996 Calabresi Lectureship, Yale University, New Haven, Connecticut
- 1996 Keynote Speaker, 11<sup>th</sup> Annual Meeting American Association of Cardiovascular & Pulmonary Rehabilitation, Baltimore, Maryland
- 1996 State of the Art Plenary Lecture, European Nuclear Medicine Congress, Copenhagen, Denmark
- 1996 Keynote Speaker, 12<sup>th</sup> Annual Cardiovascular Symposium, Hartford Hospital, Hartford, Connecticut
- 1996 Keynote Speaker, 2<sup>nd</sup> Annual Lecture in Thrombosis, University of Oklahoma Health

- Sciences Center, Oklahoma City, Oklahoma
- 1996 Keynote Speaker, IX Congreso Nacional de la Sociedad Espanola de Arteriosclerosis, Cordoba, Spain
- 1997 The Don C. and George C. Sutton Memorial Lecture in Cardiology, The Evanston and Glenbrook Hospitals, Evanston, IL
- 1997 Bicentennial Professor Lecture, Dartmouth-Hitchcock Med. Sch., Lebanon, NH
- 1997 Marion Barnhart Plenary Lecture, XVI Congress of the International Society on Thrombosis and Haemostasis, Florence, Italy
- 1997 Keynote Speaker, Los Cursos de Verano de la Fundacion General de la Universidad Complutense, Madrid, Spain
- 1997 XVI Interamerican Congress of Cardiology International Society and Federation of Cardiology Special Lecture, Fajardo, Puerto Rico
- 1997 26<sup>th</sup> Annual Paul Ware Lecture, Saint Vincent Hospital, Worcester, Massachusetts
- 1997 The Distinguished Lecturer of the Spanish Society of Cardiology, Granada, Spain
- 1997 George Herrmann Scholar, The University of Texas Medical Branch at Galveston, Galveston, TX
- 1998 Anna Borun and Harry Borun Foundation Visiting Professor in Cardiology, UCLA School of Medicine, Los Angeles, CA
- 1998 Bloomfield-Arnold Lecture, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH
- 1998 XXIII Lorenzini Annual Lecture, XIII International Symposium on Drugs Affecting Lipid Metabolism, Florence, Italy
- 1998 Robert L. Frye Lecturer, Mayo Clinic, Rochester, MN
- 1998 Laurence H. Green Lecture, Harvard Medical School, The Brigham and Women's Hospital, Boston, MA
- 1998 State of the Art Lecture, 2<sup>nd</sup> International Conference on Coronary Atherosclerosis, Lugano, Switzerland
- 1998 Lockhart B. McGuire, M.D. Memorial Lecture, University of Virginia School of Medicine, Charlottesville, VA
- 1998 Keynote Speaker, 28<sup>th</sup> AHA Michigan Cardiovascular Research Forum, Detroit, Michigan
- 1999 Keynote Address, Plaque stability: an update. John Hopkins School of Medicine, Baltimore, MD
- 1998-2000 Distinguished Scientist Award Honorary Lecture, Sociedade Portuguesa de Cardiologia
- 1999 Keynote Address, The Heart Institute at Medical Center Bayonet Point, Tampa, FL
- 1999 Visiting Professor, Emory University, Atlanta, GA
- 1999 Interamerican Society of Cardiology Lecture, Buenos Aires, Argentina
- 1999 Keynote Speaker, "New Advances in Antiplatelet Therapy", Baylor University, Dallas, TX
- 1999 Keynote Address, "New Insights into Thrombogenesis", 1<sup>st</sup> Annual Ronnie Campbell Meeting, Edinburgh, Scotland
- 1999 Keynote Address, Turkish Society of Cardiology, Istanbul, Turkey
- 1999 Richter Lecture, Indiana Heart Institute, Indianapolis, IN
- 2000 Keynote Speaker, John Hopkins Hospital, Baltimore, MD
- 2000 Distinguished Visiting Scientist, Duke University, Durham, NC
- 2000 Fellows Visiting Professor, Krannert Institute of Cardiology, Indianapolis, IN
- 2000 2000 Abbott Lecture, Society of Cardiovascular Anesthesiologists, Orlando, FL
- 2000 4<sup>th</sup> Annual Potiker Professor, Cleveland Clinic
- 2000 The 2000 Robert Reneman CARIM Lecturer, Maastrich University, Netherlands
- 2000 The 11<sup>th</sup> Anniversary Lecturer of the Society for Vascular Medicine & Biology, Toronto,



## Canada

- 2000 The 2000 Distinguished Lecturer, The University of Western Ontario, Canada
- 2000 Doctor Honorary Degree, University Coruña, Spain
- 2000 Honorary Member Real Academy of Medicine, Valencia, Spain
- 2000 Magistral Lecture, National Congress of Hematology & Thrombosis, Bilbao, Spain
- 2000 Keynote Address, Plaque Stability Symposium, Johns Hopkins, Baltimore, MD
- 2000 Honorary Speaker, Uruguay Society of Cardiology, Montevideo, Uruguay
- 2000 The 2000 Honorary Speaker Ramón y Cajal Foundation & Hospital, Madrid, Spain
- 2000 Keynote Speaker, American University of Beirut, Beirut, Lebanon
- 2001 Keynote Speaker, New York Medical College Medical Student Research Forum, Valhalla, NY
- 2001 Sujoy B. Roy Oration at AIMS, New Delhi, India
- 2001 Keynote Speaker International Summit on Coronary Artery Disease, Mumbai, India
- 2001 Keynote Speaker, Congress of the Latin American Society of Interventionalist Cardiology, Mexico City, Mexico
- 2001 Keynote Speaker, First Annual Louis Albright Symposium, NJ
- 2001 Dean's Lectureship, Philadelphia, PA
- 2001 George C.Griffith Lecture, Los Angeles, CA
- 2001 Mount Sinai School of Medicine Dean's Lecture, New York, NY
- 2001 Grande Memorial Lecture, Barcelona, Spain
- 2001 Michaelides Lecture, Athens, Greece
- 2001 Keynote Speaker, Sociedad Espanola de Cardiologia, Barcelona, Spain
- 2001 Ethica Award Lecture
- 2002 Chapman Lecture, Baylor in Houston, TX
- 2002 Pfizer Visiting Professor, Richmond VA
- 2002 30<sup>th</sup> Annual Master Lecture, Orlando, FL
- 2002 Dr. Nicholson Lecture, Boston, MA
- 2002 4<sup>th</sup> Annual Jay N. Cohn Lecture, Minneapolis, MN
- 2002 Dr. Roman de Sanctis Lecture, Toledo, Spain
- 2002 James T. Willerson Visiting Professor Lecture, Houston, TX
- 2003 Hatter Lecture, Capetown, South Africa
- 2003 Chairman, NHLBI SPARK II Meeting, Bethesda, MD
- 2003 The Henry Barcroft Lecture, Belfast, No. Ireland
- 2003 Hildner Lecture, Boston, MA
- 2003 World Heart Federation Lecture, Toronto, Canada
- 2003 The Neufield Lecture, ISCP Congress, Barcelona, Spain
- 2003 Pfizer Visiting Professor, Stanford, CA
- 2003 KROC Lecture, Charleston, SC
- 2003 Keynote Speaker, 4<sup>th</sup> Congress of CIS Assoc. of Cardiology, St. Petersburg, Russia
- 2003 Johns Hopkins Cardiology Grand Rounds, Speaker, Baltimore, MD
- 2004 Thomas W. Smith, MD Memorial Lecture, Keynote Speaker, Boston, MA
- 2004 Mayo Clinic lecture on Valvular Heart Disease, Keynote Speaker, Rochester
- 2004 Beth Israel Cardiology Grand Rounds, Keynote speaker, New York City
- 2004 Beaumont Heart Center, Grand Rounds speaker, Detroit, MI
- 2004 Stanford University Symposium, The Evolving Paradigm for CAD, Keynote Speaker, Stanford, CA
- 2004 Antithrombotic Therapies, Keynote Speaker, Amsterdam, Netherlands
- 2004 SCMR Scientific Sessions/EURO CMR 2004, Keynote Speaker, Spain
- 2004 World Congress, Human Movements and Immigration, Keynote Speaker, Barcelona, Spain

2004 St. Barnabas Health Care System Hospital Symposium, New Jersey  
 2005 Keynote Speaker, The Eighth International Kawasaki Disease Symposium  
 2005 Foro de Marcas Renombradas Espanolas, Madrid, Spain  
 2005 First International Symposium on Prevention of Cardiovascular Diseases Krakow, Poland  
 2005 Cardiovascular Revascularization Therapy, Washington D.C.  
 2005 25<sup>th</sup> Anniversary of the Principe de Asturias  
 2005 Mario R. Garcia-Palmieri Lecture, San Juan, Puerto Rico  
 2005 Dr. E. Torrado Memorial Lecture, Malaga, Spain  
 2005 State of the Art Lecture, AHA-NASCI, Amelia Island, FL  
 2005 Closing Lecture, International Symposium of Cardiology, Barcelona, Spain  
 2005 Opening Lecture, Catalan Society of Biology, Barcelona, Spain  
 2005 Honorary Lecture, SEMERGEN, Bilbao, Spain  
 2005 Distinguished Opening Favaloro Lecture, Buenos Aires, Argentina  
 2005 Rose Weiss Lecture, Lahey Clinic, Burlington, MA  
 2005 American Heart Association Distinguished Scientist Keynote Speaker, Dallas, TX  
 2005 Paul Lichtlen Lecture, Davos, Switzerland  
 2005 Philippe Coumel Memorial Lecture, Madrid, Spain  
 2005 Keynote Opening Lecture, International Congress Coronary Intervention, Lausanne, Switzerland  
 2005 State of the Art Lecture, International Conference on Secondary Care, London, England  
 2005 Opening Keynote Lecture, International Symposium on Biomarkers, Lugano, Switzerland  
 2005 State of the Art Lecture, International Symposium on Atherothrombosis, Madrid, Spain  
 2005 Opening Lecture, Biomedical Institute "Alberto Solis" Scientific Sessions, Madrid, Spain  
 2005 Keynote Lecture, AHA Nurses Education Meeting, Melville, NY  
 2005 Dr. Tresch Memorial Lecture, Milwaukee, WI  
 2005 Keynote Lecture, International Meeting, Modena, Italy  
 2005 Keynote Lecture, Morristown Cardiovascular Symposium, Morristown, NJ  
 2005 Keynote Lecture, International Symposium, New Delhi, India  
 2005 Opening Lecture, International Symposium on Complex Coronary Intervention, New York  
 2005 Opening Lecture, European Atherosclerosis Society, Prague, Czech Republic  
 2005 Peter F. Cohn Lecture, Stony Brook, NY  
 2005 Opening Conference, International Conference on Gene and Stem Cell Therapy, Valladolid, Spain  
 2006 Opening State of the Art Lecture, International Symposium on Complex Coronary Intervention, New York  
 2006 Anne & Harry Baron Lecture, UCLA, Los Angeles, CA  
 2006 State of the Art Lecture, International Symposium on Heart Failure, Madrid, Spain  
 2006 La Caixa, Honorary Lecture, Madrid, Spain  
 2006 Professor Cirilo Rozman Lecture, Madrid, Spain  
 2006 State of the Art Lecture, MRI/CT International Symposium, Madrid, Spain  
 2006 Roman de Sanctis Lecture, Toledo, Spain  
 2006 State of the Art Lecture, Ultima Hora Club, Mallorca, Spain  
 2006 Keynote Address – American Heart Association / American Diabetes Association, San Francisco, CA  
 2006 Keynote Lecture - Southbury Symposium, Sothbury CT  
 2006 Keynote Lecture, Global Conference on Heart Health and Disease, Winnipeg, Canada  
 2006 Honorary Lecture, Mora International Bank, Andorra, Spain  
 2006 Centennial Honorary Lecture and Hospital, Hospital Clinico, Barcelona, Spain

2006 Ramon y Cajal Lecture, Barcelona, Spain  
 2006 State of the Art Lecture, MRI International Symposium, Berlin, Germany  
 2006 State of the Art Lecture, Cedars Sinai Symposium, Los Angeles, CA  
 2006 Mario Garcia Palmieri (InterAmerican Society of Cardiology) Lecture, Cancun, Mexico  
 2006 State of the Art Lecture, MRI/CT Symposium, Cannes, France  
 2006 "WHO-WHF" Expert Presentation, Geneva, Switzerland  
 2006 State of the Art lecture, Krakow International Symposium, Krakow, Poland  
 2006 Masterclass Lecture – International Symposium, London, England  
 2006 Honorary Lecture, CEDE, Mancina, Spain  
 2007 State of the Art Lecture, Spanish Society of Hypertension, Barcelona, Spain  
 2007 Keynote Address, Association of Pakistan Cardiologists, New Orleans, LA  
 2007 Distinguished Opening Lecture, International Meeting on Biomarkers, Berlin, Germany  
 2007 State of the Art Lecture, SOLACI, Buenos Aires, Argentina  
 2007 World Heart Federation State of the Art, InterAmerican Society of Cardiology Meeting, Lima, Peru  
 2007 State of the Art and Closing Lecture, CIEMET, Madrid, Spain  
 2007 State of the Art Lecture, ESC-EuroPrevent, Madrid, Spain  
 2007 State of the Art Lecture, IEF, Madrid, Spain  
 2007 State of the Art Lecturer, Symposium on Atrial Fibrillation, Madrid, Spain  
 2007 Keynote Lecture, AHA Parsippany Summit, New Jersey  
 2007 Mayo Clinic 1<sup>st</sup> Annual Gerald T. Gau Lecture, Rochester, Minnesota  
 2007 30<sup>th</sup> Anniversary Andreas Gruntzig Lecture (Zurich, Switzerland)  
 2007 Keynote Lecture, 2007 Cardiometabolic Health Congress, Boston, MA  
 2007 Berman Lecture, Cleveland, OH  
 2007 Speaker, Medical Innovation Summit @ Cleveland Clinic, Cleveland, OH  
 2007 The Weiden-Perlman Lecture in New York, NY  
 2007 Lecture, XVI International Symposium at DALM, New York, NY  
 2007 Keynote Lecture, 30<sup>th</sup> Anniversary Shaio, Bogota, Colombia  
 2007 Keynote Speaker, 7<sup>th</sup> Annual CV Research Symposium at UT Southwestern Medical Center, Dallas, TX  
 2008 Keynote Speaker, Rome Cardiology Forum  
 2008 Keynote Speaker, University of Arizona/Sarver Heart Center, Tuscon, AZ  
 2008 Keynote Speaker, St. Francis Hospital, Topeka, KS  
 2008 Keynote Speaker, European Academy of Sciences & Arts/Polzer Award, Zurs, Austria  
 2008 Keynote Speaker, NY Chapter of American College of Physicians Downstate Scientific Meeting, Rye Brook, NY  
 2008 Keynote Speaker, University of Pennsylvania, Philadelphia, PA  
 2008 Keynote Speaker, Orbita Symposium, Brussels, Belgium  
 2008 Keynote Speaker, 30<sup>th</sup> Current CV Modalities Conference, Melville, NY  
 2008 Keynote Speaker, Israel Heart Society, Tel Aviv, Israel  
 2008 Keynote Speaker, CV Cell & Gene Therapy Conference IV, New York, NY  
 2008 Keynote Speaker, Friesinger Society Meeting/Vanderbilt University, Nashville, TN  
 2008 Keynote Speaker, Biomechanics in CV Disease, Rotterdam, Netherlands  
 2008 Keynote Speaker, 77<sup>th</sup> Eur. Athero. Soc. Congress, Istanbul, Turkey  
 2008 Keynote Speaker, 4<sup>th</sup> Annual Chapman lecture, Baylor University, Houston, Texas  
 2008 Keynote Speaker, New Frontiers, University of Pennsylvania/Penn Hospital, Philadelphia, PA  
 2008 Keynote Speaker, CIHR-YI Forum, Montreal, Canada

- 2008 Honorary Government Visit, Montevideo, Uruguay
- 2008 Keynote Speaker, University of Michigan, Ann Arbor, MI
- 2008 Special Keynote Speaker, University of Alberta, Edmonton, Canada
- 2008 Keynote Speaker, Miller School of Medicine/University of Miami, FL
- 2008 Keynote Speaker, Arrhythmia Symposium/Morristown Memorial Hospital, Morristown, NJ
- 2009 Keynote Speaker, 57<sup>th</sup> Scientific Sessions Japanese College of Cardiology, Sapporo, Japan
- 2011 Honorary Award Lecture, German Cardiac Society, Mannheim, Germany
- 2011 Opening Lecture, National Congress of Cardiology Argentina, Cordoba, Argentina
- 2011 Opening Lecture Brazilian Society of Cardiology
- 2012 Nahum J. Winer Lecture, New York Academy of Medicine, New York, NY
- 2012 Opening Lecture, French Society of Cardiology, Paris, France
- 2012 Opening Lecture, Mexican Society of Cardiology, Guadalajara, Mexico
- 2012 Opening Lecture, Chilean Society of Cardiology, Santiago, Chile
- 2013 Simon Dack Lecture, ACC Scientific Sessions, San Francisco, CA
- 2013 Leahey Lecture, Columbia University, New York, NY
- 2013 Opening Lecture, XXXIX Congress of Cardiology, Buenos Aires, Argentine
- 2014 Closing Adresss Lecture, Annual CADECI Congress, Guadalajara, Mexico
- 2014 Opening Lecture, American Heart Association –Life Science Innovation Forum, New York
- 2014 Special Keynote Speaker, IESE Business School 2<sup>nd</sup> Sports Management Summit, New York, NY
- 2014 Keynote Speaker, Stony Brook Heart Institute's CME Symposium, Stony Brook, NY
- 2014 Keynote Speaker, Global Health ABC 40<sup>th</sup> Anniversary Scientific Sessions Lecture, Howard University College of Medicine, Washington DC
- 2014 Keynote Speaker, Chest World Congress, Madrid Spain
- 2014 State-of-the-Art Lecture, Case Studies from the Heart of Manhattan, Mayo Clinic, Rochester, MN
- 2014 Keynote Speaker, Twelfth Annual Cardiovascular Disease Prevention International Symposium, Baptist Health South Florida, Miami FL
- 2014 Keynote Speaker, Lecture, Sesion Clinica General del Servicio de Cardiologia, Hospital Uiversitari Vall d'Hebron, Spain
- 2014 Keynote Speaker, Lecture, The Lancet, At the Limits: Cardiology, Diabetes & Nephrology, Royal College of Physicians, London, UK
- 2014 Keynote Speaker, 2014 Preventive Cardiovascular Nurses Association Annual Sumposium, Atlanta, GA
- 2014 Opening Lecture, American Association of Clinical Endocrinologist 23<sup>rd</sup> Annual Scientific and Clinical Congress, Las Vegas, NV
- 2014 Opening Lecture, International Weinstein Conference on Cardiovascular Development, Spain
- 2015 Opening Keynote Lecture for the 2015 Society of Cardiovascular Magnetic Resonance/European Cardiovascular Magnetic Resonance Joint Scientific Sessions
- 2015 Keynote Lecture at Emory University's 2015 Atlanta Clinical Cardiology
- 2015 Keynote Lecture at Lehigh Valley Health Network's "Update in Cardiology 2015"

**Memberships in Professional Societies:**

- 1972 Society of the Sigma XI
- 1973 International Society on Thrombosis and Haemostasis
- 1973 Member of the Subcommittee on Platelet Nomenclature of the International

Committee on Haemostasis and Thrombosis  
 1974 European Society for Clinical Investigation  
 1976 American Heart Association, Council on Thrombosis,  
 1977 American College of Cardiology, Fellow,  
 1978 Member of the Central Society for Clinical Research  
 1978 American Heart Association, Council on Circulation  
 1981 Research Committee, Minnesota Heart Association  
 1981 Chairman, Cardiovascular Society, Mayo Clinic  
 1982 Medical Committee, Heart Research Foundation, New York  
 1982 American Heart Association, Member of the Executive Committee, Council on Thrombosis,  
 1983-1996 Corresponding Member of the British Cardiac Society  
 1983 Advisory Board, VA Study on Coronary Artery Bypass Surgery and Platelet Inhibitors  
 1983 Educational Committee, New York Heart Association  
 1984 Board of Directors, New York Cardiological Society  
 1984 American College of Cardiology, Residency Review Committee for Subspecialty of  
 Cardiology (Accreditations Council for Graduate Medical Education)  
 1985 American College of Cardiology, Library Committee,  
 1985 National Institute of Health, Monitoring Committee, TIMI Trial  
 1985 Committee Member of the National Conference on Antithrombotic Therapy (American  
 College of Chest Physicians)  
 1986 Member of the Research Council American Heart Association (New York Affiliate)  
 1986 American Society for Clinical Investigation (“Young Turks”)  
 1986 Member of the National Cholesterol Education Committee, National Institute of Health  
 1987 Committee Member of the Subspecialty Board of Cardiovascular Diseases  
 1987 Member of the Board of Directors, New York Heart Association  
 1987 Member of the Subcommittee on von Willebrand Factor of the International Committee on  
 Haemostasis and Thrombosis  
 1987 ACC/AHA, Member of the Committee for Guidelines on Management of Acute Myocardial  
 Infarction  
 1987 Consultant, New York State Advisory Committee on Cardiovascular Diseases  
 1987 Board of Directors, New York Heart Association  
 1988 National Institutes of Health, Monitoring Committee, Saphenous Vein Bypass Graft Disease  
 Prevention  
 1988 American College of Cardiology - Chairman, Library Committee,  
 1988 American College of Cardiology - Member, Educational Program Committee  
 1989 Faculty Member, Lambda Chapter of Alpha Omega Alpha  
 1989 American College of Cardiology - Member, Task Force on Self-Assessment  
 1989 American Heart Association (New York Affiliate) - Chairman, Professional Education  
 Committee  
 1989 Member, Alpha Omega Alpha Honor Medical Society  
 1989 Member, Executive Committee, New York Heart Association  
 1989 Member, Association of Professors of Cardiology  
 1990 Member, Int. Soc. of Cardiovascular Pharmacotherapy  
 1990 Member, European Society of Cardiology  
 1990 Member, Committee on Inter-American Society of Cardiology  
 1991 American College of Cardiology - Member, Credentials Committee  
 1991-2003 American College of Cardiology – ACCEL, Associate Editor  
 1991 Fellow, American College of Chest Physicians

1991 American Heart Association, Member of the Scientific Publishing Committee  
 1991 NHLBI - Chairman, Data Safety and Monitoring Board of Left Ventricular Assist Systems  
 1991 NHLBI - Member, Cardiovascular Advisory Committee  
 1992 Advisory Board, United Patient's Association for Pulmonary Hypertension  
 1992 Trustee, College of the Atlantic (Bar Harbor, Maine)  
 1992 Councilor of the Association of University Cardiologists  
 1992 American Heart Association - Member of the Vascular Lesions Committee  
 1992 Harvard Medical School, Committee to Develop a Clinician-Teacher Ladder  
 1992 Member, Committee on Training Cardiovascular Specialists, Association of Professors of Cardiology  
 1992 Member, Steering Committee of the ECLA2/RAPT Study, Janssen Research Foundation  
 1992 AHCPR - NHLBI Member, Expert Panel to Set National Guidelines for the Management of Unstable Angina  
 1992 Member, Executive Committee of the MGH Laser Center  
 1992 Member, The Massachusetts Medical Society  
 1993 President, Board of Directors, Vila Medieval of Cardona Foundation (Spain)  
 1993-1998 American College of Cardiology - Board of Trustees  
 1993 American College of Cardiology-Co-Chairman, 42<sup>nd</sup> Annual Scientific Session  
 1993 American College of Cardiology - Chairman, Credentials Committee  
 1993 Fellow of the Royal College of Physicians, Edinburgh  
 1993 Member, Thrombosis and Haemostasis Council of the International Society and Federation of Cardiology  
 1993 American College of Cardiology - Ad Hoc Task Force to Examine a Cardiovascular Policy Institute  
 1993 American College of Cardiology - Annual Scientific Session Program Committee  
 1993 American Heart Association - Vice Chairperson, Scientific Publishing Committee  
 1993 Founding Member, Society for Adult Congenital Cardiac Disease  
 1993 Association of Professors of Cardiology - Chairman Cardiology-Medicine Relationships  
 1994 American College of Cardiology, Board of Directors - Institute for the Study of Cardiovascular Medicine  
 1994-1995 American Heart Association – Fellowship Subgroup D  
 1994 American Heart Association - Conflict of Interest Review Committee  
 1994 American Heart Association - Chairman, Scientific Publishing Committee  
 1994 American Heart Association - Board of Directors  
 1994 American Heart Association - Chairman of the Committee on Vascular Lesions  
 1994-2000 American Heart Association, New York City Affiliate, Board of Directors  
 1994 American Heart Association, Council on Arteriosclerosis Executive Committee, Member  
 1994 North American Vascular Biology Organization - Founding Member  
 1994 The Cardiac Society of Australia and New Zealand, Corresponding Member  
 1994 President, Spanish Cultural Association, Boston, Massachusetts  
 1995 American College of Cardiology, Co-Chairman 27<sup>th</sup> Bethesda Conference  
 1995 American Heart Association, Commission of Science Advisory Committee  
 1995 Association of Professors of Cardiology, Task Force on Cardiology Work Force and Fellowship Training  
 1995 NHLBI Hypertrophy and Vascular Reactivity in Blacks (SCOR Application), External Advising and Review Committee  
 1995-1997 American Heart Association (NY City Affiliate) – Chairman's Round Table  
 1995-1997 American Heart Association (NY City Affiliate) - Nominating Committee

1996-1998 American Heart Association – Council Affairs Committee  
 1996 Medical Advisory Board, Med Help International, Inc.  
 1996 Trustee, The Spanish Institute, New York, New York  
 1996 Academic Advisory Committee Member, Pfizer Visiting Professorship Program in Cardiovascular Medicine  
 1996 Founding Member, Society for Cardiovascular Magnetic Resonance  
 1996-2000 NHLBI Member, Advisory Council  
 1996 NHLBI Chairman, Review of SCOR on Molecular Medicine and Atherosclerosis  
 1997 Member, CardioFellows Foundation Advisory Board  
 1997 Member, Fundacion Independiente, Madrid, Spain  
 1997 Member, ACC/AHA Joint Officers Committee  
 1997 Member, Subcommittee for the Commemoration of the American College of Cardiology 50<sup>th</sup> Anniversary  
 1997 Member, FPA Advisory Council, Mount Sinai Medical Center  
 1997-1998 American Heart Association - President-Elect  
 1997-1998 American Heart Association -Vice Chairman, Science Advisory and Coordinating Committee  
 1997-1998 American Heart Association - Ex officio Member, Public Affairs Policy Committee  
 1997-1998 American Heart Association - Member, Scientific Sessions Programs Committee  
 1997-1998 American Heart Association - Vice Chairman, Field Operations Coordinating Committee  
 1997-1998 American Heart Association - Member, Nominating & Awards Committee  
 1997-1998 American Heart Association – CVR Executive Committee  
 1997-1998 American Heart Association - Pharmaceutical Roundtable Medical Advisors  
 1997-1998 American Heart Association – Science Advisory and Coordinating Committee  
 1997-1998 American Heart Association – Stroke Executive Committee  
 1997-1998 American Heart Association – CTVS Executive Committee  
 1997-1998 American Heart Association – ATVB Executive Committee AHA President Elect  
 1997-1998 American Heart Association – Basic Science Executive Committee AHA President Elect  
 1997-1998 American Heart Association – CCC Executive Committee AHA President Elect  
 1997-1998 American Heart Association – CVN Executive Committee AHA President Elect  
 1997-1998 American Heart Association – Circulation Executive Committee AHA President Elect  
 1997-1998 American Heart Association – KCVD Executive Committee AHA President Elect  
 1997-2003 American College of Cardiology - Chair of the Training Directors  
 1997-1999 American Heart Association – CVDY Executive Committee AHA President  
 1997-1999 American College of Cardiology - Ex Officio Member of the Physician Workforce Advisory Committee  
 1997-2000 American Heart Association – EPI Executive Committee AHA Immediate Past President  
 1997-2001 American Heart Association – Council on Clinical Cardiology  
 1998-1999 American Heart Association - President  
 1998-1999 American Heart Association – HBP Executive Committee AHA President  
 1998-2000 American Heart Association – Executive Committee AHA Immediate Past President  
 1998 American Heart Association – Science Advisory and Coordinating Committee President  
 1998-1999 American Heart Association – Budget Committee  
 1998-2000 American Heart Association – Executive Committee AHA President  
 1998-1999 American Heart Association – Council Affairs Committee AHA President  
 1998-2000 American Heart Association – Council on Circulation  
 1998 Member, Lipid Nurse Task Force  
 1998 Honorary Member, Sociedad Medica Hispanoamericana de Nueva York

Member, Association of American Physicians

1998-2002 President, Paul Dudley White Society, Massachusetts General Hospital

1999-2000 American Heart Association – Committee on Scientific Councils AHA Immediate Past President

1999-2000 American Heart Association – Executive Committee AHA Immediate Past President

1999-2000 American Heart Association – Science Advisory and Coordinating Committee Immediate Past President

1999-2001 American Heart Association – Task Force on Scientific Sessions in 21<sup>st</sup> Century

1999-2000 American Heart Association – Basic Cardiovascular Sciences Executive Committee AHA Immediate Past President

1999 National Foundation for Advanced Cardiac Surgery, Scientific Board

1999-2004 Joint ACC/AHA Committee on Practice Guidelines - AHA Representative

1999 NIH National Cholesterol Education Program Clinical Guidelines, Member

1999 Advisory Committee Member, The White Book

1999 International Advisory Board Member, XVIII Congress, ISTH

2000 Member, Institute of Medicine, National Academy of Science

2000 The New York Academy of Medicine, Chair Selection Committee

2000-2003 American College of Cardiology – Chair, Cardiology Training and Workforce Committee

2000-2004 Stanley J. Sarnoff Endowment for Cardiovascular Science, Inc., Board of Directors

2000-2003 American College of Cardiology – Task Force on Workforce, AHA Representative

2001-2004 American Heart Association (NY City Affiliate) – Member of the Board of Directors

2001 European Society of Cardiology – U.S. Board of Directors and Industry

2001 Association of Professors of Cardiology

2001 Association of University Cardiologists

2001 Co-Chair, XVIII Congress on the International Society of Thrombosis and Haemostasis

2001 Chairman, ACC/AHA/ESC Atrial Fibrillation 1<sup>st</sup> guidelines by the three organizations

2002 Chairman, GlaxoSmithKline Foundation for Young Investigators

2002 American Heart Association – Strategically Focused Research Task Force

2002-2004 Stanley J. Sarnoff Endowment for Cardiovascular Science, Inc., Strategic Planning Committee

2002–2003 American College of Cardiology – Task Force to develop a Consensus Conference on Workforce: Working Group on Developing a Uniform System of Designating Cardiologists

2003 American College of Cardiology – Development Committee

2003 American Heart Association, New York City Board of Directors, President

2003 Spanish American Medical Dental Society, New York, NY - Honorary Member

2003 Honorary Member, World Innovation Foundation

2003-2004 World Heart Federation - President-Elect

2003-2004 American Heart Association New York – President

2004 Sarnoff Foundation, Board of Directors

2005 Leducq Foundation, Committee Member

2005-2006 World Heart Federation – President

2006 Ad Hoc-ACC International Committee

2006 Chairman, ACC/AHA/ESC Atrial Fibrillation 2<sup>nd</sup> guidelines by the three organizations

2009 World Heart Federation – Immediate Past President

2007 Private Foundation Gaspar de Portola, Honorary President

2007 Thao, Childhood Health, Honorary President

2007 Castle Connelly Medical Media, Advisory Board

2008 Member, Institute of Medicine’s (IOM) Board on Global Health



2008	American College of Cardiology, Fellowship Education Redesign Task Force
2009	Chair, IOM Committee on Preventing the Global Epidemic of Cardiovascular Disease
2009	Honorary Member, British Cardiovascular Society, London, United Kingdom
2009	Honorary Member, National Academy of Medicine of Mexico
2010	Honorary Member, Japanese Society of Cardiology

**Editorial Boards: (selected)**

1982-1990	American Journal of Cardiology
1987	Journal of the American College of Cardiology
1988	Circulation
1991	Arteriosclerosis, Thrombosis and Vascular Biology
1992-2004	Consulting Editor, Circulation
1994	Journal of Thrombosis and Thrombolysis
1997-2002	Consulting Editor, Circulation Research
1998	Journal of Cardiovascular Magnetic Resonance
2003	European Heart Journal
2004	Editor-in-Chief, Nature Cardiovascular Medicine Journal
2008	Consulting Editor, Journal of the American College of Cardiology Cardiovascular Imaging
2009-2010	Editor-in-Chief, Nature Reviews Cardiology
2009-2012	Board of Editors, Mount Sinai Journal of Medicine
2009	Board of Editors, Journal of Cardiovascular Pharmacology and Therapeutics
2014	Journal American College of Cardiology, Editor-in-Chief

**Present Research Support - NIH: (NIH funding since 1975)**

**Active**

Project: NIH/NHLBI-02-0163 (PI)  
 Title: Coronary Revascularization in Diabetic Patients  
 Dates Approved: 1/1/14 – 12/31/14

**Active**

Project: The Louis B. Meyer Foundation – GCC# 07-0479-0001-02 ME X (PI)  
 Title: Grenada Heart Project  
 Dates Aproved: 6/07 – 12/14

**Active**

Project: NHLBI-BAA-10-08 (Co-Project Director of Project #3)  
 Title: Nano Particle with Plaque Targeting  
 Dates Approved: 6/15/10 – 06/14/15

**Active**

Project: 5U01HL114200-02 (PI)  
 Title: Optimizing Linkage and Retention to Hypertension Care in Rural Kenya  
 Dates Approved: 04/01/13 – 03/31/17

**Completed Research Support**

Project: U01 HL-071988-01A1 (PI)  
Title: Coronary Revascularization in Diabetic Patients  
Dates Approved: 4/15/04 – 6/30/13

Project: NIH/NHLBI-R01 HL 09289 Farkouh (M)  
Title: Novel Imaging to Predict Cardiovascular Events in Diabetes  
Dates Approved: 7/15/09 – 6/30/13

## **Bibliography**

### **Refereed Articles**

1. Clarkson AR, MacDonald MK, Fuster V, Cash JD, Robbison JS. Glomerular coagulation in acute ischemic renal failure. *Quart J Med* 1970; 39:585-599.
2. Wright N, Clarkson AR, Brown SS, Fuster V. Effect of poisoning on serum enzyme activities, coagulation and fibrinolysis. *Br Med J* 1971; 3:347-350.
3. Cash JD, Fuster V, Clarkson AR. Preliminary studies on the protamine sulphate precipitation of plasma and serum. *Scand J Haematol* 1971; 13(Suppl):179-181.
4. Bowie EJW, Cooper HA, Fuster V, Kazmier FJ, Owen CA Jr. The diagnoses of intravascular coagulation. *Thromb Diath Haemorrh* 1973; 56:137-143.
5. Fuster V, Kazmier FJ, Cash JD, Bowie EJW, Owen CA Jr. Assay of platelet factor 4 in plasma. *Mayo Clinic Proc* 1973; 48:103-106.
6. Fuster V. Platelet kinetics and effect of aspirin in chronically induced intravascular coagulation in dogs. *Thromb Diath Haemorrh* 1974; 60(Suppl):371-376.
7. Didisheim P, Kazmier FJ, Fuster V. Platelet inhibition in the management of thrombosis. *Thromb Diath Haemorrh* 1974; 32:21-34.
8. Fuster V, Bowie EJW, Kazmier FJ, Owen CA Jr. Plasma platelet factor IV-like activity reflecting rate of platelet consumption in chronically induced intravascular coagulation in dogs. *Thromb Res* 1974; 4:247-260.
9. Fuster V, Connolly DC, Frye RL, Danielson MA, Elveback LR, Kurland LT. Arteriographic patterns early in the onset of the coronary syndromes. *Br Heart J* 1975; 37(12):1250-1255.
10. Lewis JC, Fuster V, Kottke BA. Thrombocytes in the atherosclerosis-resistant and atherosclerosis-susceptible breeds of pigeon: A comparative ultrastructural study. *Exper and Mol Pathol* 1976; 25:332-343.
11. Didisheim P, Fuster V. Hematological and vascular concepts in relation to stroke. *Clin Neurosurg* 1976; 23:125-139.
12. Fuster V, Danielson MA, Robb RA, Broadbent JC, Brown AL. Quantitation of left ventricular myocardial fiber hypertrophy and of interstitial tissue in human hearts with pressure and volume overload. *Circulation* 1977; 55:504-508.
13. Fuster V, Kottke BA, Bowie EJW, Ruiz CE, Lewis JC. Increase in platelet factor 4-like activity in the initial stages of atherosclerosis in pigeons. *Adv in Exp Med Biol* 1977; 82:225-227.
14. Fuster V, Lewis JC, Kottke BA, Ruiz CE, Bowie EJW. Platelet factor 4-like activity in the initial stages of atherosclerosis in pigeons. *Thromb Res* 1977; 10:169-172.
15. Fuster V, Bowie EJW, Brown AL. Spontaneous arterial lesions in normal pigs and pigs with von Willebrand's disease. *Adv in Exp Med Biol* 1977; 82:315-317.
16. Lewis JC, Fuster V, Kottke BA. Spontaneous endothelial cell injury in the intimal sections of atherosclerotic pigeons. *Prog Biochem Pharmacol* 1977; 14:220-224.
17. Fuster V, Bowie EJW, Lewis JC, Fass DN, Owen CA Jr, Brown AL. Resistance to arteriosclerosis in pigs with von Willebrand's disease: Spontaneous and high cholesterol diet induced arteriosclerosis. *J Clin*

- Invest 1978; 61:722-730.
18. Didisheim P, Fuster V. The actions and clinical status of platelet suppressive agents. *Seminars in Hematol Today* 1978; 15(i):55-72.
  19. Fuster V, Bowie EJW, Lewis JC. The von Willebrand pig as a model for atherosclerosis research. *Thromb and Haemostas* 1978; 39:322-327.
  20. Dewanjee MK, Fuster V, Kaye MP, Josa M. Imaging platelet deposition with III Indium- labeled platelets in coronary artery bypass grafts in dogs. *Mayo Clin Proc* 1978; 53:327-331.
  21. Linos A, Worthington JW, O'Fallon W, Fuster V, Whisnant JP, Kurland LT. Effect of aspirin on prevention of coronary and cerebrovascular disease in patients with rheumatoid arthritis. A long-term follow-up study. *Mayo Clin Proc* 1978; 53(9):581- 586.
  22. Fuster V, Bowie EJW. Interaction of platelets with the endothelium in normal and von Willebrand pigs. *Adv Exp Med and Biol* 1978; 102:187-196.
  23. Fuster V. Long-term results of total correction for Tetralogy of Fallot. *Excerpta Medica Int Congress Series* 1978; 470:780-783.
  24. Guiliani ER, Fuster V, Brandenburg RO, Mair DD. The clinical features and natural history of Ebstein's anomaly of the tricuspid valve. *Mayo Clin Proc* 1979; 54:163-173.
  25. Fuster V, Frye RL, Kennedy MA, Connolly DC, Makin HT. The role of collateral circulation in the various coronary syndromes. *Circulation* 1979; 59:1137-1144.
  26. Metke MP, Lie JT, Fuster V, Kaye MP, Josa M. Reduction of intimal thickening in canine coronary bypass vein grafts with dipyridamole and aspirin. *Am J Cardiol* 1979; 43:1144- 1148.
  27. Fuster V, Dewanjee NK, Kaye MP, Josa M, Metke MP, Chesebro JH. Noninvasive radioisotopic technique for detection of platelet deposition in coronary artery bypass grafts in dogs and its reduction with platelet inhibitors. *Circulation* 1979; 60:1508- 1512.
  28. Tyce GM, Fuster V, Owen CA Jr, Winkelman LA. Dipyridamole levels in plasma of man and other species. *Res Commun Chem Pathol Pharmacol* 1979; 26:295-508.
  29. Dewanjee MK, Kaye MP, Fuster V, Rao SA. Noninvasive radioisotopic technique for detection of platelet deposition in mitral valve prosthesis and renal microembolism in dogs. *Trans Am Soc Artif Intern Organs* 1980; 26:475-479.
  30. Cunha CLP, Giuliani ER, Fuster V, Seward JB, Brandenburg RO, McGoon DC. Preoperative M-mode echocardiography as a predictor of surgical results in chronic aortic insufficiency. *J Thorac Cardiovasc Surg* 1980; 79(2):256-265.
  31. Fuster V, McGoon DECC, Kennedy MA, Ritter DG, Kirklin JW. Long-term evaluation (12 to 22 years) of open heart surgery for Tetralogy of Fallot. *Am J Cardiol* 1980; 46:635- 642.
  32. Bowie EJW, Fuster V. Resistance to atherosclerosis in pigs with von Willebrand's disease. *Acta Med Scand* 1980; 642(Suppl):121-130.
  33. Fuster V, Chesebro JH, Frye RL, Elveback LR. Platelet survival and the development of coronary artery disease in the young: The effects of cigarette smoking, strong family history, and medical therapy. *Circulation* 1981; 63:546-551.
  34. Fuster V, Chesebro JH. Coronary atherosclerotic disease. The role of platelets and of platelet inhibitor drugs. *Scand J Haematol* 1981; 27(Suppl 38):1-37.
  35. Fuster V, Chesebro JH. Current concepts of thrombogenesis. Role of platelets. *Mayo Clin Proc* 1981; 56:102-112.
  36. Fuster V, Chesebro JH. Pharmacologic effect of platelet inhibitor drugs. *Mayo Clin Proc* 1981; 56:185-195.
  37. Fuster V, Chesebro JH. Platelet-inhibitor drugs in management of arterial thromboembolic and atherosclerotic disease. Present recommendations. (Part III) *Mayo Clin Proc* 1981; 56:265-273.
  38. Robertson JS, Dewanjee MK, Brown ML, Fuster V, Chesebro JH. Distribution and dosimetry of 111-Indium labeled platelets. *Radiology* 1981; 140(1):169-176.

39. Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. *Am J Cardiol* 1981; 47:525-531.
40. Holmes DR Jr, Hartzler GO, Smith HC, Fuster V. Coronary artery thrombosis in patients with unstable angina. *Br Heart J* 1981; 45:411-416.
41. Bowie EJW, Fuster V, Fass DN, Owen CA Jr. The role of von Willebrand factor in platelet-blood vessel interaction, including a discussion of resistance to atherosclerosis in pigs with von Willebrand's disease. *Phil Trans R Soc London B* 1981; 294:267-279.
42. Harker LA, Edmunds H, Fuster V. Antithrombotic therapy of artificial organs. *Trans Am Soc Artif Intern Org* 1981; 27:663.
43. Chesebro JH, Fuster V, Elevback LR, Frye RL. Strong family history and cigarette smoking as risk factors of coronary artery disease in young adults. *Br Heart J* 1982; 47(1):78-83.
44. Agarwal K, Wahner HW, Dewanjee MK, Fuster V, Puga FJ, Danielson GK, Chesebro JH, Feldt RH. Imaging of platelets in right-sided extracardiac conduits in humans. *J Nucl Med* 1982; 23(4):342-347.
45. Fuster V, Pumphrey CW, McGoon MD, Chesebro JH, Pluth JR, McGoon DC. Systemic thromboembolism in mitral and aortic Starr-Edwards prosthesis: A long-term follow-up (10-19 years). *Circulation* 1982; 66(Suppl I):157-161.
46. Hynes JK, Tajik AJ, Seward JB, Fuster V, Ritter DG, Brandenburg RO, Puga FJ, Danielson GK, McGoon DC. Partial atrioventricular canal defect in adults. *Circulation* 1982; 66(2):284-287.
47. Vollertsen RS, Fuster V, Conn DL, Luthra HS, McDuffie FC, Bowie EJW, Ilstrup DM. In vivo platelet survival in rheumatoid arthritis. *Mayo Clin Proc* 1982; 57:620-628.
48. Danielson GK, Fuster V. Surgical correction of Ebstein's anomaly. *Ann Surg* 1982; 196:499-504.
49. Beard CM, Fuster V, Elveback LR. Daily and seasonal variation in sudden cardiac death, Rochester Minnesota, 1950-1975. *Mayo Clin Proc* 1982; 57:704-706.
50. Pumphrey CW, Fuster V, Dewanjee MK, Murphy KP, Vlietstra RE, Kaye MP. A new in vivo model of arterial thrombosis: The effect of administration of Ticlopidine and Verapamil in dogs. *Thromb Res* 1982; 28(5):663-675.
51. Fuster V, Fass DN, Kaye MP, Josa M, Zinsmeister AR, Bowie EJW. Arteriosclerosis in normal and von Willebrand pigs: Long-term prospective study and aortic transplantation study. *Circ Res* 1982; 51(v):587-593.
52. Chesebro JH, Clements IP, Fuster V, Elveback LR, Smith HC, Bardsley WT, Frye RL, Holmes DR Jr, Vlietstra RE, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Schaff HV, Danielson GK. Platelet inhibitor drug trial in coronary artery bypass operation: Benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein graft patency. *N Engl J Med* 1982; 307:73-78.
53. Badimon L, Fuster V, Dewanjee MK, Romero JC. A sensitive new method of "ex vivo" platelet deposition. *Thromb Res* 1982; 28:237-250.
54. Chesebro JH, Fuster V. Drug trials in prevention of occlusion of aorta-coronary artery vein grafts. *J Thorac Cardiovasc Surg* 1982; 83:90-93.
55. Dewanjee MK, Tago M, Fuster V, Kaye MP. Platelet turnover in aortocoronary femoral vein bypass graft in control and aspirin-dipyridamole-treated dogs: Prevention of early thrombotic occlusion of bypass graft. *Nucl Med & Biol* 1982; 1:898-901.
56. Pumphrey CW, Dewanjee MK, Chesebro JH, Fuster V, Wahner HW. a new method for quantifying human platelet-vascular graft interaction and the effect of platelet inhibitor therapy. *Nucl Med & Biol* 1982; 1:895-897.
57. Dewanjee MK, Pumphrey CW, Murphy KP, Fuster V, Kaye MP, Rosemark JA, Chesebro JH. Evaluation of platelet-inhibitor drugs in a canine bilateral femoral graft implant model. *Trans Am Soc Artif Intern Org* 1982; 28:504-509.
58. Chesebro JH, Fuster V. Platelet inhibitors in coronary artery bypass operations. *N Engl J Med* 1982; 307(23):1453-1454.

59. Pumphrey CW, Fuster V, Dewanjee MK, Chesebro JH, Vliestra RE, Kaye MP. Comparison of the antithrombotic action of calcium antagonist drugs with dipyridamole in dogs. *Am J Cardiol* 1983; 51:591-595.
60. Chesebro JH, Fuster V. Platelets and platelet inhibitor drugs in aortocoronary vein bypass operations. *Intern J Cardiol* 1983; 2:511-516.
61. Pumphrey CW, Chesebro JH, Dewanjee MK, Wahner HW, Hollier LJ, Pairolero PC, Fuster V. In vivo quantitation of platelet deposition on human peripheral arterial bypass grafts using Indium-111-labeled platelets: Effect of dipyridamole and aspirin. *Am J Cardiol* 1983; 51:796-801.
62. Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, Wallace RB, Danielson GK, Orszulak TA, Piehler JM, Schaff HV. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole. *Am J Cardiol* 1983; 51(9):1537-1541.
63. Dewanjee MK, Fuster V, Rao SA, Forsham PL, Kaye MP. Noninvasive radioisotopic technique for the detection of platelet deposition in mitral valve prostheses and quantitation of visceral microembolism in dogs. *Mayo Clin Proc* 1983; 58:307-314.
64. Badimon L, Fuster V, Chesebro JH, Dewanjee MK. New "ex vivo" radioisotopic method of quantitation of platelet deposition: Studies in four animal species. *Thromb and Haemost* 1983; 50(3):639-644.
65. Ambrose JA, Fuster V. Coronary collateral vessels and myocardial protection. *Int J Cardiol* 1983; 3:417-420.
66. Nishimura RA, Fuster V, Burgert SL, Puga FJ. Clinical features and long-term natural history of the postpericardiotomy syndrome. *Int J Cardiol* 1983; 1:918-921.
67. Wahner HW, Dunn WL, Dewanjee MK, Fuster V. Survival time and organ distribution of 111In-Oxine-labeled human platelets in normal subjects. *Nucl Med and Biol* 1983; 1:918- 921.
68. Cohen M, Fuster V. What do we gain from the analysis of right ventricular function? *J Am Coll Cardiol* 1984; 3(4):1082-1084.
69. Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR, Bardsley WT, Pluth JR, Wallace RB, Puga FJ, Orszulak TA, Piehler JM, Danielson GK, Scchaff HV, Frye RL. Effect of dipyridamole and aspirin on late vein graft patency after coronary bypass operation. *N Engl J Med* 1984; 310:209-214.
70. McGoon MD, Fuster V, McGoon DC, Pumphrey CW, Pluth JR, Elveback LR. Aortic and mitral valve incompetence: Long-term follow-up (10-19 years of patients treated with the Starr-Edwards prosthesis. *J Am Coll Cardiol* 1984; 3(4):930-938.
71. Dewanjee MK, Tago M, Josa M, Fuster V, Kaye MP. Quantification of platelet retention in aortocoronary femoral vein bypass graft in dogs treated with dipyridamole and aspirin. *Circulation* 1984; 69(2):350-356.
72. Donadio JV Jr, Anderson CF, Mitchell JC III, Holley KE, Ilstrup DM, Fuster V, Chesebro JH. Membranoproliferative glomerulonephritis: A prospective clinical trail of platelet-inhibitor therapy. *N Engl J Med* 1984; 310(32):1421-1426.
73. Beard CM, Fuster V, Annegers JF. Reproductive history in women with coronary heart disease: A case-control study. *Am J Epidemiology* 1984; 120(1):108-114.
74. Beckett VL, Conn DL, Osmundson PJ, Strong CG, Chao EYS, Chesebro JH, O'Fallon WM, Fuster V. Trial of platelet-inhibiting drug in scleroderma. A double-blind study with dipyridamole and aspirin. *Arthritis and Rheumatism* 1984; 27(10):1137-1143.
75. Fuster V, Steel PM, Edwards WD, Gersh BI, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. *Circulation* 1984; 70(4):580-587.
76. Squire A, Goldman ME, Kupersmith J, Stern EH, Fuster V, Schweitzer P. Long-term antiarrhythmic therapy: Problem of low drug levels and patients' non-compliance. *Am J Med* 1984; 77:1035-1038.
77. Goldman ME, Mindich BP, Teichholz LE, Burgess N, Staville K, Fuster V. Intraoperative contrast echocardiography to evaluate mitral valve operations. *J Am Coll Cardiol* 1984; 4(5):1035-1040.

78. Fuster V, Lie JT, Badimon L, Rosemark JA, Badimon JJ, Bowie EJW. Spontaneous and diet induced coronary atherosclerosis in normal swine and swine with von Willebrand's disease. *Arteriosclerosis* 1985; 5:67-73.
79. Cortina A, Ambrose JA, Prieto-Granda J, Moris C, Simarro E, Holt J, Fuster V. Left ventricular function after myocardial infarction. Clinical and angiographic correlations. *J Am Coll Cardiol* 1985; 5(3):619-624.
80. Ambrose JA, Winters SL, Stern A, Eng A, Teichholz LE, Gorlin R, Fuster V. Angiographic morphology and the pathogenesis of unstable angina pectoris. *J Am Coll Cardiol* 1985; 5(3):609-616.
81. Hu DCK, Seward JB, Puga FJ, Fuster V, Tajik AJ. Total correction of Tetralogy of Fallot at age 40 years and older: Long-term follow-up. *J Am Coll Cardiol* 1985; 5(1):40-44.
82. Fuster V, Steele PM, Chesebro JH. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. *J Am Coll Cardiol* 1985; 5(6):175B-184B.
83. Steele PM, Chesebro JH, Stanson AW, Holmes DR Jr, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty: Natural history of the pathophysiologic response to injury in a pig model. *Circ Res* 1985; 57(1):105-112.
84. Cohen M, Horowitz SF, Machac J, Mindich BP, Fuster V. Response of the right ventricle to exercise in isolated mitral stenosis. *Am J Cardiol* 1985; 55:1054-1058.
85. Verstraete M, Dejana E, Fuster V, Lapetina E, Moncada JF, Mustard JF, Tans G, Vargaftig BB. An overview of antiplatelet and antithrombotic drugs. *Haemostasis* 1985; 15:89-99.
86. Riegel N, Ambrose JA, Mindich BP, Fuster V. Isolated aortic stenosis with severe pulmonary hypertension. *Cath Cardiovasc Diag* 1985; 11:181-185.
87. Mindich BP, Goldman ME, Fuster V, Burgess N, Litwak R. Improved intraoperative evaluation of mitral valve operation utilizing two-dimensional contrast echocardiography. *J Thorac Cardiovasc Surg* 1985; 90:112-118.
88. Badimon L, Steele P, Badimon JJ, Bowie EJW, Fuster V. Aortic atherosclerosis in pigs with heterozygous von Willebrand's disease: Comparison with homozygous von Willebrand and normal pigs. *Arteriosclerosis* 1985; 5(4):366-370.
89. Lapeyre AC III, Steele PM, Kazmier FJ, Chesebro JH, Vlietstra RE, Fuster V. Systemic embolism in chronic left ventricular aneurysm: Incidence and the role of anticoagulation. *J Am Coll Cardiol* 1985; 6:1233-1238.
90. Fuster V, Chesebro JH. Aortocoronary artery vein-graft disease. Experimental and clinical approach for the understanding of the role of platelets and platelet inhibitors. *Circulation* 1985; 72(Suppl V):65-70.
91. Ambrose JA, Winters SL, Arora RR, Haft JI, Goldstein J, Rentrop KP, Gorlin R, Fuster V: Coronary angiographic morphology in myocardial infarction. A link between the pathogenesis of unstable angina and myocardial infarction. *J Am Coll Cardiol* 1985; 6:1233-1238.
92. Cohen M, Edwards WD, Fuster V. Regression in thromboembolic type of primary pulmonary hypertension during 2 1/2 years of antithrombotic therapy. *J Am Coll Cardiol* 1986; 7:172-175.
93. Ambrose JA, Winters SL, Arora RR, Eng A, Riccio A, Gorlin R, Fuster V. Angiographic evolution of coronary artery morphology in unstable angina. *J Am Coll Cardiol* 1986; 7:472-478.
94. Fuster V, Chesebro JH. Role of platelets and platelet inhibitors in aortocoronary artery vein graft disease. *Circulation* 1986; 73(2):227-232.
95. Hirsh J, Fuster V, Salzman E. Dose antiplatelet agents: The relationship among side effects, and antithrombotic effectiveness. *Chest* 1986; 89(2):4S-10S.
96. Dewanjee MK, Wahner HW, Dunn WL, Robertson JS, Offord K, Fuster V, Chesebro JH. Comparison of three platelet markers for measurement of survival time in healthy volunteers. *Mayo Clin Proc* 1986; 61:327-336.
97. Meltzer RS, Teichholz LE, Visser CA, Fuster V. Intracardiac thrombi and systemic embolization: The role of two-dimensional echocardiography. *Ann Int Med* 1986; 104:689-698.
98. Badimon L, Badimon JJ, Galvez A, Chesebro JH, Fuster V. Influence of arterial damage and wall shear

- rate on platelet deposition. Ex vivo study in a swine model. *Arteriosclerosis* 1986; 6(3):312-320.
99. Gorlin R, Fuster V, Ambrose JA. Anatomic-physiologic links between acute coronary syndromes. *Circulation* 1986; 74(1):6-9.
  100. Frye RL, Parmley WW, Brundage B, Fortuin N, Fowler NO, Fuster V, Harvery WP, Hurst JW, Joyce JW, Rackley CE, Rapaport E, Reitemeier RJ, Russell RO Jr, Ryan TJ, Saunders DE. Task Force I: Training in clinical cardiology. *J Am Coll Cardiol* 1986; 7(6):1196-1200.
  101. Chesebro JH, Fuster V. Antithrombotic therapy for acute myocardial infarction: Mechanisms and prevention of deep venous, left ventricular, and coronary artery thromboembolism. *Circulation* 1986; 74(Suppl III):1-10.
  102. Chesebro JH, Fuster V. The pathogenesis and prevention of aortocoronary bypass graft occlusion and restenosis after arterial angioplasty: Role of vascular injury and platelet thrombus deposition. *J Am Coll Cardiol* 1986;8:57B-66B.
  103. Goldman M, Fuster V, Guarino T, Mindich B. Intraoperative echocardiography for the evaluation of valvular regurgitation: Experience in 263 patients. *Circulation* 1986; 74(Suppl I):143-149.
  104. Farhi JI, Cohen M, Fuster V. The broad spectrum of unstable angina pectoris and its implications for future controlled trials. *Am J Cardiol* 1986; 58:547-550.
  105. Lam JYT, Chesebro JH, Steele PM, Dewanjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty: Relation to a positive Indium-111 labeled platelet scintigram, quantitative platelet deposition, and mural thrombosis. *J Am Coll Cardiol* 1986; 8(6):1380-1386.
  106. Hjemdahl-Monsen CE, Lewis HD, Cairns J, Chesebro JH, Fuster V. The role of anti- thrombotic therapy in unstable angina, myocardial infarction, and sudden death. *J Am Coll Cardiol* 1986; 8(6):67B-75B.
  107. Vallabhajosula S, Machac J, Goldsmith SJ, Lipszyc H, Badimon L, Rand J, Fuster V. Indium-111 platelet kinetics in normal human subjects: Tropolone versus oxine methods. *J Nucl Med* 1986; 27:1669-1674.
  108. Vermylen J, Verstraete M, Fuster V. Role of platelet activation and fibrin formation in thrombogenesis. *J Am Coll Cardiol* 1986; 8(6):2B-9B.
  109. Harker LA, Fuster V. Pharmacology of platelet inhibitors. *J Am Coll Cardiol* 1986; 8(6):21B-32B.
  110. Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. *J Am Coll Cardiol* 1986; 8(6):41B-56B.
  111. Adams PC, Cohen M, Chesebro JH, Fuster V. Thrombosis and embolism from cardiac chambers and infected valves. *J Am Coll Cardiol* 1986; 8(6):76B-87B.
  112. Fuster V, Chesebro JH. Mechanisms of unstable angina. *N Engl J Med* 1986; 315(16):1023-1025.
  113. Fuster V, Griggs TR. Porcine von Willebrand's disease. Implications for the pathophysiology of atherosclerosis and thrombosis. *Prog Hemostas and Throm* 1986; 159- 183.
  114. Galvez A, Badimon L, Badimon JJ, Fuster V. Electrical aggregometry in whole blood from human, pig and rabbit. *Thromb and Haemostas* 1986; 56(2):128-132.
  115. Cohen M, Fuster V. Unstable angina: Is it time for more aggressive therapy? *Eur J Cardiol* 1986; 7(12):1014-1015.
  116. Adams PC, Lam JYT, Badimon L, Chesebro JH, Fuster V. Interactions of platelets and vessel wall in the development of restenosis after coronary angioplasty. In: *Blood in Contact with Natural and Artificial Surfaces*. (Eds: Leonard EF, Turitto VT, Vroman). *Annals of the NY Academy of Sciences*, New York, NY, 1987, Volume 516, pp 605-620.
  117. Lam JYT, Chesebro JH, Steele PM, Fuster V. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. *Circulation* 1987; 75(1):243-248.
  118. Ambrose JA, Hjemdahl-Monsen CE, Borrico S, Sherman WS, Cohen M, Gorlin M, Gorlin R, Fuster V. Quantitative and qualitative effects of intracoronary streptokinase in unstable angina and non Q wave infarction. *J Am Coll Cardiol* 1987; 9(5):1156-1165.
  119. Rand JH, Badimon L, Gordon RE, Fuster V. Distribution of von Willebrand factor in porcine intima varies with blood vessel type and location. *Arteriosclerosis* 1987; 7(3):287-291.

120. Cohen M, Monsen C, Francis X, Sherman W, Ambrose JA, Teichholz LE, Fuster V. Comparison of single plane videodensitometry-based right ventricular ejection fraction in right and left anterior oblique views to biplane geometry-based right ventricular ejection fraction. *J Am Coll Cardiol* 1987; 10:150-155.
121. Goldman ME, Mora F, Guarino T, Fuster V, Mindich BP. Mitral valvuloplasty is superior to valve replacement for preservation of left ventricular function: An intraoperative two-dimensional echocardiographic study. *J Am Coll Cardiol* 1987; 10:567-575.
122. Goldman ME, Guarino T, Fuster V, Mindich B. The necessity for tricuspid valve repair can be determined intraoperatively by two-dimensional echocardiography. *J Thorac Cardiovasc Surg* 1987; 94:542-550.
123. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease: Long-term follow-up and prediction of outcome after surgical correction. *Circulation* 1987; 76:1037-1042.
124. Badimon L, Badimon JJ, Rand R, Turitto VT, Fuster V. Platelet deposition on von Willebrand factor deficient vessels: Extracorporeal perfusion studies in von Willebrand's disease swine utilizing native and heparinized blood. *J Lab Clin Med* 1987; 110:634-647.
125. Chesebro JH, Fuster V. The therapeutic challenge of plaque rupture: Value of biochemical markers. *J Am Coll Cardiol* 1987; 10:1005-1006.
126. Adams PC, Fuster V, Badimon L, Badimon JJ, Chesebro JH. Platelet-vessel wall interactions, rheologic factors and thrombogenic substrate in acute coronary syndromes: Preventive strategies. *Am J Cardiol* 1987; 60:9G-16G.
127. Badimon L, Badimon JJ, Turitto VT, Fuster V. Thrombosis: Studies under flow conditions. In: *Blood in Contact with Natural and Artificial Surfaces*. (Eds: Leonard EF, Turitto VT, Vroman). Annals of the NY Academy of Sciences, New York, NY, 1987, Volume 516, pp 527-540.
128. Turitto VT, Weiss HJ, Baumgartner HR, Badimon L, Fuster V. Cells and aggregates at surfaces. In: *Blood in Contact with Natural and Artificial Surfaces*. (Eds: Leonard EF, Turitto VT, Vroman). Annals of the NY Academy of Sciences, New York, NY, 1987, Volume 516, pp 453-467.
129. Badimon L, Turitto V, Rosemark JA, Badimon JJ, Fuster V. Characterization of a tubular flow chamber for studying platelet interaction with biological and prosthetic materials. Deposition of 111Indium-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene. *J Lab Clin Med* 1987; 110:706-718.
130. Badimon L, Badimon JJ, Turitto VT, Fuster V. Role of von Willebrand factor in platelet interaction with an expanded PTFE surface. *Trans Am Soc Artif Intern Organ* 1987; 10:621-625.
131. Chesebro JH, Lam JYT, Badimon L, Fuster V. Restenosis after arterial angioplasty: A hemorrheologic response to injury. *Am J Cardiol* 1987; 60:10B-16B.
132. Badimon L, Badimon JJ, Fuster V. Pared arterial y arteriosclerosis. *Rev Esp Geriatr y Gerontol* 1987;22:39-49.
133. Badimon JJ, Badimon L, Galvez A, Fuster V. HDL, prostaciclina y arteriosclerosis. *Sangre* 1987; 24:80-83.
134. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Prevention of thromboembolism induced by prosthetic heart valves. *Seminars in Thrombosis and Hemostasis* 1988; 14:50-58.
135. Charney R, Leddomado E, Rose DN, Fuster V. Anticoagulation clinics and the monitoring of anticoagulant therapy. *Intern J Cardiol* 1988; 18:197-207.
136. The Expert Panel: Report of the National Education Program: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. *Arch Intern Med* 1988; 148:36-69.
137. Fuster V, Cohen M, Chesebro JH. Usefulness of aspirin for coronary artery disease. *Am J Cardiol* 1988; 61:637-640.
138. Fuster V, Badimon L, Cohen M, Ambrose J, Badimon JJ, Chesebro JH. Insights into the pathogenesis of acute ischemic syndromes. *Circulation* 1988; 77:1213-1220.
139. Gorlin R, Fuster V, Ambrose JA. Anatomic-physiologic links between acute coronary syndromes. *Current Views from Circulation: Preludes and Progress/Editorials and Perspectives*. July 1986 - June 1988, pp 2-5.



140. Fuster V, Badimon L, Cohen M, Ambrose JA, Badimon JJ, Chesebro JH. Insights into the pathogenesis of acute ischemic syndromes. Current Views from Circulation: Preludes and Progress/Editorials and Perspectives. July 1986 - June 1988, pp 15-24.
141. Vallabhajosula S, Paidi M, Badimon JJ, Le NA, Goldsmith SJ, Fuster V, Ginsberg HN: Radiotracers for low density lipoprotein biodistribution studies in vivo: Technetium- 99m low density lipoprotein versus radioiodinated low density lipoprotein preparations. J Nucl Med 1988; 29:1237-1245.
142. Ambrose JA, Monsen C, Borrico S, Gorlin R, Fuster V. Angiographic demonstration of a common link between unstable angina pectoris and non-Q wave acute myocardial infarction. Am J Cardiol 1988; 61:244-247.
143. Ambrose JA, Tannenbaum M, Alexopoulos D, Hjemdahl-Monsen CE, Leavy J, Weiss M, Borrico S, Gorlin R, Fuster V. Angiographic progression of coronary artery disease and the development of myocardial infarction. J Am Coll Cardiol 1988; 12:56-62.
144. Heras Magda, Chesebro JH, Penny WJ, Bailey KR, Lam JYT, Holmes DR, Reeder GS, Badimon L, Fuster V. Importance of adequate heparin dosage in arterial angioplasty in a porcine model. Circulation 1988; 78:654-660.
145. Lam JYT, Chesebro JH, Fuster V. Platelets, vasoconstriction, and nitroglycerin during arterial wall injury: A new antithrombotic role for an old drug. Circulation 1988; 78:712-716.
146. Schwinger M, Cohen M, Fuster V. Usefulness of onset of the pulmonary wedge V wave in predicting mitral regurgitation. Am J Cardiol 1988; 62:646-648.
147. Cohen M, Charney R, Hershman R, Fuster V. Reversal of chronic ischemic myocardial dysfunction after transluminal coronary angioplasty. J Am Coll Cardiol 1988; 12:1193- 1198.
148. Weinberger J, Ramos L, Ambrose JA, Fuster V. Morphologic and dynamic changes of atherosclerotic plaque at the carotid artery bifurcation: Sequential imaging by real time B-mode ultrasonography. J Am Coll Cardiol 1988; 12:1515-1521.
149. Fuster V, Stein B, Badimon L, Chesebro JH. Antithrombotic therapy after myocardial reperfusion following myocardial infarction. J Am Coll Cardiol 1988; 12:78A-84A.
150. Badimon L, Badimon JJ, Turitto VT, Vallabhajosula S, Fuster V. Platelet thrombus formation on collagen type I: A model of deep vessel injury. Influence of blood rheology, von Willebrand factor and blood coagulation. Circulation 1988; 78:1431-1442.
151. The TIMI Research Group: Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. JAMA 1988; 260:2849- 2858.
152. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, Lancaster L, Emery R, Sharma G, Josa M, Pacold I, Montoya A, Parikh D, Sethi G, Holt J, Kirklin J, Shabetai R, Moores W, Aldridge J, Masud Z, DeMots H, Floten S, Haakenson C, Harker LA (Fuster V, Data Monitoring Board). Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy. Circulation 1988; 77:1324-1332.
153. Israel DH, Adams PC, Stein B, Chesebro JH, Fuster V. Antithrombotic therapy in coronary vein graft patients. Clin Cardiol 1991; 14:283-295.
154. Ip JH, Stein B, Fuster V, Badimon L. Antithrombotic therapy in cardiovascular diseases. Future directions based on pathogenesis and risk. Ann NY Acad Sci 1991; 614:289-311.
155. Fuster V, Halperin JL. Left ventricular thrombi and cerebral embolism. N Engl J Med 1989; 320:392-394.
156. Cairns JA, Collins R, Fuster V, Passamani ER. Coronary thrombosis. Chest 1989; 95:73S-87S.
157. Badimon L, Badimon JJ, Turitto VT, Rand J, Fuster V. Functional behavior of vessels from pigs with von Willebrand's disease: Values of platelet deposition are identical to those obtained on normal vessels. Arteriosclerosis 1989; 9:184-188.
158. Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 1989; 60:455-461.
159. Hirsh J, Salzman EW, Harker L, Fuster V, Dalen JE, Cairns JA, Collins R. Aspirin and other platelet active

- drugs: Relationship among dose, effectiveness, and side effects. *Chest* 1989; 95:12S-18S.
160. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. *Circulation* 1989; 79:657-665.
  161. The TIMI Study Group: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Result of the thrombolysis in myocardial infarction (TIMI) Phase II trial. *N Engl J Med* 1989; 320:618-627.
  162. Fuster V, Cohen M, Halperin JL. Aspirin in the prevention of coronary disease. *N Engl J Med* 1989; 321:183-185.
  163. Halperin JL, Fuster V. Left ventricular thrombus and stroke after myocardial infarction: Toward prevention or perplexity? *J Am Coll Cardiol* 1989; 14:912-914.
  164. Stein B, Fuster V, Israel DH, Cohen M, Badimon L, Badimon JJ, Chesebro JH. Platelet inhibitor agents in cardiovascular disease: An update. *J Am Coll Cardiol* 1989; 14:813-836.
  165. Cohen M, Fuster V, Steele PM, Driscoll D, McGoon DC. Coarctation of the aorta: Long- term follow-up and prediction of outcome after surgical correction. *Circulation* 1989; 80:840-845.
  166. Machac J, Vallabhajosula S, Goldman ME, Goldsmith SJ, Palestro C, Strashun A, Vaquer R, Phillips R, Fuster V. Value of blood pool subtraction in cardiac indium-111 labeled platelet imaging. *J Nucl Med* 1989; 30:1445-1455.
  167. Heras M, Chesebro JH, Webster M, Mruk J, Grill D, Badimon L, Fuster V. Prevention of thrombosis by recombinant hirudin during arterial angioplasty in pigs: Comparison with heparin. *J Am Coll Cardiol* 1989; 13:77A.
  168. Stein B, Fuster V, Halperin J, Chesebro JH. Antithrombotic therapy in cardiac disease: An emerging approach based on the pathogenesis and risk. *Circulation* 1989; 80:1501- 1513.
  169. Stein B, Fuster V. Antithrombotic therapy in acute myocardial infarction: Prevention of venous, left ventricular and coronary artery thromboembolism. *Am J Cardiol* 1989; 64(Suppl B):33B-40B.
  170. Badimon L, Badimon JJ, Turitto VT, Fuster V. Role of von Willebrand factor in mediating platelet-vessel wall interaction at low shear rate: The importance of perfusion conditions. *Blood* 1989; 73:961-967.
  171. Badimon L, Badimon JJ, Galvez, Turitto V, Fuster V. Platelet interaction with vessel and collagen in pigs with homozygous von Willebrand's disease associated with abnormal collagen aggregation. *Thromb Haemost* 1989; 61:57-64.
  172. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Doherty J, Read R, Chesler E, Sako Y, Lancaster L, Emery R, Sharma G, Josa M, Pacold I, Montoya A, Parikh D, Sethi G, Holt J, Kirklin J, Shabetai R, Moores W, Aldridge J, Masud Z, DeMots H, Floten S, Haakenson C, Harker LA (Fuster V, Data Monitoring Board). Saphenous vein graft patency 1 year after coronary artery bypass surgery and effects of antiplatelet therapy. *Circulation* 1989; 80:1190-1197.
  173. Chesebro JH, Fuster V, Webster MWI. Endothelial injury and coronary vasomotion. *J Am Coll Cardiol* 1989; 14:1191-1192.
  174. Gomes JG, Alexopoulos D, Winters SL, Deshmukh, Fuster V, Suh Kiung. The role of silent ischemia, the arrhythmic substrate and the short-long sequence in the genesis of sudden cardiac death. *J Am Coll Cardiol* 1989; 14:1618-1625.
  175. Fuster V, Stein B, Badimon L, Badimon JJ, Ambrose JA, Chesebro JH. Atherosclerotic plaque rupture and thrombosis: Evolving concepts. *Circulation* 1990; 82(Suppl II):47- 59.
  176. Chesebro JH, Badimon L, Fuster V. New approaches to treatment of myocardial infarction. *Am J Cardiol* 1990; 65:12C-19C.
  177. Fuster V, Stein B, Halperin JL, Chesebro JH. Antithrombotic therapy in cardiac disease: An approach based on pathogenesis and risk stratification. *Am J Cardiol* 1990; 65:38C-44C.
  178. Stroke Prevention in Atrial Fibrillation Study Group Investigators: Preliminary report of the stroke prevention in atrial fibrillation study. *N Engl J Med* 1990; 322:862-868.

179. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. *J Clin Invest* 1990; 85:1234-1241.
180. Stein B, Halperin JL, Fuster V. Prevention of left ventricular mural thrombosis and arterial embolism during and after acute myocardial infarction. *Coronary Artery Disease* 1990; 1:180-189.
181. Cohen M, Fuster V. Unstable angina: Mechanisms and treatment. *Coronary Artery Disease* 1990; 1:166-169.
182. Badimon JJ, Ip J, Badimon L, Fuster V. Thrombosis and accelerated atherosclerosis in coronary bypass surgery and restenosis after percutaneous transluminal coronary angioplasty: Implications for therapy. *Coronary Artery Disease* 1990; 1:170-179.
183. Ip JH, Fuster V, Badimon L, Cohen M, Badimon JJ, Chesebro JH. Syndromes of accelerated atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. *J Am Coll Cardiol* 1990; 15:1667-1687.
184. Rogers WJ, Baim DS, Gore JM, et al for the TIMI II-A Investigators: Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI Phase II-A Trial). *Circulation* 1990; 81:1457-1476.
185. Ryan TJ, Graham TP, Annas GJ, DeMaria AN, Fost NC, Fuster V, Harvey JC, Levinsky NG, McCullough LB, Rettig RA, Schwartz WJ, Sundwall DN, Talner NS, Wagle ED, Willman VL: Task Force III: Perspectives on the allocation of limited resources in cardiovascular medicine. *J Am Coll Cardiol* 1990; 16:17-23.
186. Gunnar RM, Bourdillon PDV, Dixon DW, Fuster V, Karp RB, Kennedy JW, Klocke FJ, Passamani ER, Pitt B, Rapaport E, Reeves TJ, Russell RO, Sobel BE, Winters WL. ACC/AHA Task Force Report: Guidelines for early management of patients with acute myocardial infarction. *J Am Coll Cardiol* 1990; 16:249-292.
187. Sanborn TA, Alexopoulos D, Marmur J, Kahn H, Badimon JJ, Badimon L, Fuster V. Coronary excimer laser angioplasty: Reduced complications, and indium-111 platelet accumulation compared to laser thermal angioplasty. *J Am Coll Cardiol* 1990; 16:502-506.
188. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penyy WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin and placebo during deep arterial injury in the pig: The in vivo role of thrombin in platelet-mediated thrombosis. *Circulation* 1990; 82:1476-1484.
189. Badimon JJ, Fuster V, Badimon L. Accelerated atherosclerosis and thrombosis in coronary bypass surgery and restenosis after PTCA: Implications for therapy. *Clin Invest Arteriosclerosis* 1990; 2:107-114.
190. Chesebro JH, Fuster V, Halperin JL. Atrial fibrillation - Risk marker for stroke. *N Engl J Med* 1990; 323:1556.
191. The Stroke Prevention in Atrial Fibrillation Investigators: Design of a multicenter randomized trial for the stroke prevention in atrial fibrillation study. *Stroke* 1990; 21:538-545.
192. Cohen M, Fuster V. Insights into the pathogenetic mechanisms of unstable angina. *Haemostasis* 1990; 20(Suppl 1):102-112.
193. Badimon L, Badimon JJ, Fuster V. Thrombogenesis and inhibition of platelet aggregation. Experimental aspects and future approaches. *Kardiologie* 1990; 79:133- 145.
194. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern K, Sethi G, Sharma G, Khuri S, Richards K, Grover F, Morrison D, Johnston M, Chesler E, Sako Y, Pacold I, Montoya A, DeMots H, Floten S, Doherty J, Read R, Scott S, Spooner T, Masud Z, Haakenson C, Harker L (Fuster V, Data Monitoring Board). *Circulation* 1990; 82(suppl IV):IV-237-IV-242.
195. Cohen M, Adams PC, Hawkins L, Bach M, Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (A pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Group. *Am J Cardiol* 1990; 66:1287-1292.
196. Fuster V, Ip JH, Badimon L, Badimon JJ, Stein B, Chesebro JH. Importance of experimental models for

- the development of clinical trials on thromboatherosclerosis. *Circulation* 1991; 83(Suppl IV):IV-15-IV-25.
197. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis after coronary angioplasty. *J Am Coll Cardiol* 1991; 17:77B-88B.
  198. Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow condition in a porcine model. Effects of hirudins, heparin and calcium chelation. *Blood* 1991; 78:423-434.
  199. Marmur JD, Sanborn TA, Kahn H, Badimon JJ, Badimon L, Fuster V. Acute biological response to excimer versus thermal laser angioplasty in experimental atherosclerosis. *J Am Coll Cardiol* 1991; 17:978-984.
  200. Badimon JJ, Badimon L, Turitto VT, Fuster V. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. Study in vivo in the rabbit model. *Arteriosclerosis & Thrombosis* 1991; 11:395-402.
  201. Chesebro JH, Fuster V. Dynamic thrombosis and thrombolysis: Role of antithrombins. *Circulation* 1991; 83:1815-1817.
  202. Cohen M, Hawkins L, Greenberg S, Fuster V. Usefulness of ST-segment changes in > 2 leads on the emergency room electrocardiogram in either unstable angina pectoris or non-Q-wave myocardial infarction in predicting outcome. *Am J Cardiol* 1991; 67:1368- 1373.
  203. Lam JYT, Chesebro JH, Steele PM, Heras M, Webster MWI, Badimon L, Fuster V. Antithrombotic therapy for deep arterial injury by angioplasty: Efficacy of common platelet inhibition compared with thrombin inhibition in pigs. *Circulation* 1991; 84:814-820.
  204. Fuster V, Badimon L, Badimon JJ, Ip JH, Chesebro JH. The porcine model for the understanding of thrombogenesis and atherogenesis. *Mayo Clin Proc* 1991; 66:818-831.
  205. Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study: Final results. *Circulation* 1991; 84:527-539.
  206. Goldman S, Copeland J, Moritz T, Henderson W, Zadina K, Ovitt T, Kern KB, Sethi G, Sharma GVRK, Khuri S, Richards K, Grover F, Morrison D, Whitman G, Chesler E, Sako Y, Pacold I, Montoya A, DeMots H, Floten S, Doherty J, Read R, Scott S, Spooner T, Masud Z, Haakenson C, Harker LA, and the Department of Veterans Affairs Cooperative Study Group (Fuster V, Data Monitoring Board). Starting aspirin therapy after operation: Effects on early graft patency. *Circulation* 1991; 84:520-526.
  207. Badimon L, Merino A, Badimon JJ, Fuster V. Trombosis arterial y activacion plaquetar. I. Fisiopatologia. *Rev Imberoamer Tromb Hemostasia* 1991; 4:73-80.
  208. Badimon L, Merino A, Badimon JJ, Fuster V. Trombosis arterial y activacion plaquetar. II. Tratamiento antitrombotico. *Rev Imberoamer Tromb Hemostasia* 1991; 4:81-88.
  209. Chesebro JH, Zoldhelyi P, Fuster V. Pathogenesis of thrombosis in unstable angina. *Am J Cardiol* 1991; 68:2B-10B.
  210. Chesebro JH, Badimon L, Fuster V. Importance of antithrombin therapy during coronary angioplasty. *J Am Coll Cardiol* 1991; 17:96B-100B.
  211. Chesebro JH, Zoldhelyi P, Fuster V. Plaque disruption and thrombosis in unstable angina pectoris. *Am J Cardiol* 1991; 68:9C-15C.
  212. Habib GB, Heibig J, Forman SA, Brown BG, Roberts R, Terrin ML, Bolli R, and the TIMI Investigators. Influence of coronary collateral Vessels on myocardial infarct size in humans: Results of Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. (Fuster V, Safety and Data Monitoring Committee). *Circulation* 1991; 83:739-746.
  213. Israel DH, Fuster V, Ip JH, Chesebro JH. Antithrombotic therapy in acute myocardial infarction. *Thromb Haemorrh Disorders* 1991; 4:33-41.
  214. Baim DS, Diver DJ, Feit F, Greenberg MA, Holmes DR, Weiner BH, Williams DO, Schweiger MJ, Brown BG, Frederick MM, Knatterud GL, Braunwald E, for the TIMI II Investigators. (Fuster V, Safety and Data Monitoring Committee). Coronary angioplasty performed within the thrombolysis in myocardial infarction

- II study. *Circulation* 1992; 85:93- 105.215.
215. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Fuster V. Antithrombotic efficacy of low-molecular-weight heparin in deep arterial injury. *Arteriosclerosis and Thrombosis* 1992; 12:250-255.
  216. Ferrell M, Fuster V, Gold HK, Chesebro JH. A dilemma for the 1990's: Choosing the appropriate experimental animal model for the prevention of restenosis. *Circulation* 1992;85:1630-31.
  217. Betriu A, Heras M, Cohen M, Fuster V. Unstable angina: Outcome according to clinical presentation. *J Am Coll Cardiol* 1992; 19:1659-63.
  218. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Coronary artery disease: Progression and acute coronary syndromes (Part 1). *N Engl J Med* 1992; 326:242-250.
  219. Fuster V, Badimon L, Badimon JJ, Chesebro JH. Coronary artery disease: Progression and acute coronary syndromes (Part 2). *N Engl J Med* 1992; 326:310-318.
  220. Kleiman NS, Terrin M, Mueller H, Chaitman B, Roberts R, Knatterud GL, Solomon R, McMahan RP, Braunwald E, and the TIMI Investigators. Mechanisms of early death despite thrombolytic therapy: Experience from the thrombolysis in myocardial infarction phase II (TIMI II) study. *J Am Coll Cardiol* 1992;19:1129-35.
  221. Mueller HS, Cohen LS, Braunwald E, Forman S, Feit F, Ross A, Schweiger M, Cabin H, Davison R, Miller D, Solomon R, Knatterud GL, for the TIMI Investigators. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the thrombolysis in myocardial infarction (TIMI) trial, phase II. *Circulation* 1992;85:1254-64.
  222. Williams DO, Braunwald E, Knatterud , Babb J, Bresnahan J, Greenberg MA, Raizner A, Wasserman A, Robertson T, Ross R, and TIMI Investigators. One-year results of the thrombolysis in myocardial infarction investigation (TIMI) phase II trial. *Circulation*1992;85:533-42.
  223. Lam JYT, Badimon JJ, Ellefson RD, Fuster V, Chesebro JH. Cod liver oil alters platelet-arterial wall response to injury in pigs. *Circ Res* 1992; 71:769-775
  224. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillations: I. Clinical features of patients at risk. *Ann Intern Med* 1992;116:1-5.
  225. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillations: II: Echocardiographic features of patients at risk. *Ann Intern Med* 1992;116:6-12.
  226. The Stroke Prevention in Atrial Fibrillation Investigators. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. *J Am Coll Cardiol* 1992; 20:527-32.
  227. Fuster V (Guest Editor). Progression-Regression of Atherogenesis: Molecular, Cellular, and Clinical Bases (Supplement to *Circulation*). *Circulation* 1992; 86(Suppl III).
  228. Fuster V, Badimon JJ, Badimon L. Clinical-pathological correlations of coronary disease progression and regression. *Circulation* 1992; 86(Suppl III):III-1-III-11.
  229. Badimon JJ, Fuster V, Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. *Circulation* 1992; 86(Suppl III):III-86-III-94.
  230. Badimon L, Badimon JJ, Gold HK, Fuster V. Coronary atherosclerosis: Morphology and characteristics to identify by evolving imaging technology. *Am J Cardiac Imag* 1992; 6:278-288.
  231. Cairns JA, Fuster V, Kennedy JW. Coronary thrombolysis. *Chest* 1992; 102:482S-507S.
  232. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs: The relationship between dose, effectiveness, and side effects. *Chest* 1992; 102:237S-336S.
  233. Merino A, Hauptman P, Badimon L, Badimon JJ, Cohen M, Fuster V, Goldman M. Echocardiographic "smoke" is produced by an interaction of erythrocytes and plasma proteins modulated by shear forces. *J Am Coll Cardiol* 1992; 20:1661-1668.
  234. Zoldhelyi P, Fuster V, Chesebro JH. Antithrombins as conjunctive therapy in arterial thrombolysis. *Coronary Artery Disease* 1992; 3:1003-1009.
  235. Jang I-K, Fuster V, Gold HK. Antiplatelets. *Coronary Artery Disease* 1992; 3:1030-1036.
  236. Sugrue DD, Rodeheffer RJ, Codd MB, Ballard DJ, Fuster V, Gersh BJ. The clinical course of idiopathic

- dilated cardiomyopathy: A population-based study. *Ann Intern Med* 1992; 117:117-23.
237. Chesebro JH, Fuster V. Thrombosis in unstable angina. *N Engl J Med* 1992;327:192-194.
  238. Lam JYT, Chesebro JH, Badimon L, Fuster V. Exogenous prostacyclin decreases vasoconstriction but not platelet thrombus deposition after arterial injury. *J Am Coll Cardiol* 1993; 21:488-492.
  239. Ridker PM, Hebert PR, Fuster V, Hennekens CH. Are both aspirin and heparin justified as adjuncts to thrombolytic therapy for acute myocardial infarction? *The Lancet* 1993; 341:1574-1577.
  240. Badimon L, Badimon JJ, Chesebro JH, Fuster V. Von Willebrand Factor and Cardiovascular Disease. *Thrombosis and Haemostasis* 1993; 70:111-118.
  241. Marmur JD, Taubman MB, Fuster V. Pathophysiology of restenosis: The role of platelets and thrombin. *J Vasc Med Biol* 1993; 4:55-63.
  242. Fuster V. Coronary thrombolysis - A perspective for the practicing physician. *N Engl J Med* 1993; 329:723-5.
  243. Murphy JG, Gersh BJ, Mair DD, Fuster V, McGoon MD, Ilstrup DM, McGoon DC, Kirklin JW, Danielson GK. Long-term outcome in patients undergoing surgical repair of Tetralogy of Fallot. *New Engl J Med* 1993;329:593-9.
  244. Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesebro JH. Recombinant hirudin in patients with chronic, stable coronary artery disease: safety, half-life, and effect on coagulation parameters. *Circulation* 1993; 88[part 1]:2015-2022.
  245. Higenbottam TW, Spiegelhalter D, Scott JP, Fuster V, Dinh-Xuan AT, Caine N, Wallwork J. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. *Br Heart J* 1993; 70:366.
  246. Cohen M, Xiong J, Parry G, Adams PC, Chamberlain D, Wieczorek I, Fox KAA, McBride R, Chesebro JH, Fuster V. Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. *J Am Coll Cardiol* 1993; 22:1338-1343.
  247. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. *Circulation* 1993; 87:659-675.
  248. Lerman A, Webster MWI, Chesebro JH, Edwards WD, Wei C-M, Fuster V, Burnett JC. Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs. *Circulation* 1993; 88:2923-2928.
  249. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary Atherosclerosis: A multifactorial disease. *Circulation* 1993; 87(Suppl II):II-3 - II-16.
  250. Jang I-K, Lassila R, Fuster V. Atherogenesis and inflammation. *Eur Heart J* 1993; 14(Suppl K):2-6.
  251. The RAPT Investigators (Fuster V, Data and Safety Monitoring Committee). Ridogrel, a combined thromboxane A2 synthase inhibitor and prostaglandin/endoperoxide receptor antagonist, vs aspirin as conjunctive therapy for thrombolysis. The Ridogrel vs Aspirin Patency Trial (RAPT). *Circulation* 1994; 89:588-595.
  252. Alexopoulos D, Sanborn TA, Marmur JD, Badimon JJ, Badimon L, Dische R, Fuster V. The acute biological response to laser balloon angioplasty in the atherosclerotic rabbit. *Lasers in Surgery and Medicine* 1994; 14:7-12.
  253. Fuster V. In memory of Dr. Simon Dack. *J Am Coll Cardiol* 1994; 23:1265.
  254. Antiplatelet Trialists' Collaboration (Fuster V, Collaborator). Collaborative overview of randomized trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *Br Med J* 1994; 308:81-106.
  255. Antiplatelet Trialists' Collaboration (Fuster V, Collaborator). Collaborative overview of randomized trials of antiplatelet therapy II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. *Br Med J* 1994; 308:159-168.
  256. Antiplatelet Trialists' Collaboration (Fuster V, Collaborator). Collaborative overview of randomized trials of antiplatelet therapy III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. *Br Med J* 1994; 308:235-246.

257. Israel DH, Sharma SK, Fuster V. Antithrombotic therapy in prosthetic heart valve replacement. *Am Heart J* 1994; 127:400-411.
258. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Chesebro JH, Strain J, Keller C, Kelly A, Lancaster G, Ali J, Kronmal R, Fuster V. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users: Primary end points analysis from the ATACS trial. *Circulation* 1994; 89:81-88.
259. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. *Circulation* 1994; 89:1449-1468.
260. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 2: Oral Anticoagulants. *Circulation* 1994; 89:1469-1480.
261. Badimon JJ, Weng D, Chesebro JH, Fuster V, Badimon L. Platelet deposition induced by severely damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity. *Thrombosis and Haemostasis* 1994; 71:1-7.
262. Fernandez-Ortiz A, Meyer BJ, Mailhac A, Falk E, Badimon L, Fallon JT, Fuster V, Chesebro JH, Badimon JJ. A new approach for local intravascular drug delivery: Iontophoretic balloon. *Circulation* 1994; 89:1518-1522.
263. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleinman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J. Recombinant hirudin for unstable angina pectoris: A multicenter, randomized angiographic trial. *Circulation* 1994; 89:1557-1566.
264. Fernandez-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, Weng D, Shah PK, Badimon L. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. *J Am Coll Cardiol* 1994; 23:1562-1569.
265. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes: Implications for plaque rupture. *Circulation* 1994; 90:775-778
266. Schechter AD, Chesebro JH, Fuster V. Refractory Prinzmetal angina treated with cyproheptadine. *Ann Intern Med* 1994; 121:113-114.
267. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction—insights from studies of vascular biology. *Circulation* 1994; 90:2126-2146.
268. Huggins G, Fuster V. Left ventricular thromboembolism after myocardial infarction. *Heart Disease and Stroke* 1994; 3:355-360.
269. Meyer BJ, Badimon JJ, Mailhac A, Fernandez-Ortiz A, Chesebro JH, Fuster V, Badimon L. Inhibition of growth of thrombus on fresh mural thrombus: Targeting optimal therapy. *Circulation* 1994; 90:2432-2438.
270. Meyer B, Fernandez-Ortiz A, Mailhac A, Falk E, Badimon L, Michael AD, Chesebro JH, Fuster V, Badimon JJ. Local delivery of r-hirudin by a double-balloon perfusion catheter prevents mural thrombosis and minimizes platelet deposition after angioplasty. *Circulation* 1994; 90:2474-2480.
271. Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. *N Engl J Med* 1994; 331:1564-1575.
272. Goodman SG, Langer A, Durica SS, Raskob GE, Comp PC, Gray RJ, Hall JH, Kelley P, Hua TA, Lee RJ, Fuster V, for the Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Safety and anticoagulation effect of a low-dose combination of warfarin and aspirin in clinically stable coronary artery disease. *Am J Cardiol* 1994; 74:657-661.
273. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. *Circulation* 1994; 90:1631-1637.
274. Alexopoulos D, Sanborn TA, Marmur JD, Badimon JJ, Badimon L, Dische R, Fuster V. Acute biological response to laser balloon angioplasty in the atherosclerotic rabbit. *Lasers in Surgery and Medicine* 1994; 14:7-12.
275. Fuster V, Halperin JL. Aortic Dissection: A medical perspective. *J Card Surg* 1994; 9:713-728.
276. King SB, Frye RL, Fuster V, Garson A, Gay WA Jr., Popp RL. 25<sup>th</sup> Bethesda Conference: Future

- Personnel Needs for Cardiovascular Health Care □ Task Force 2: Academic Health Centers. *J Am Coll Cardiol* 1994; 24:275-328.
277. Falk E, Fallon JT, Mailhac A, Fernandez-Ortiz A, Meyer B, Weng D, Shah PK, Badimon JJ, Fuster V. Muramidase: A useful monocyte/macrophage immunocytochemical marker in swine of special interest in experimental cardiovascular disease. *Cardiovascular Pathology* 1994; 3:183-189.
  278. Cohen M, Parry G, Adams PC, Xiong J, Chamberlain D, Wieczorek I, Fox KAA, Kronmal R, Fuster V, and the Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Prospective evaluation of a prostacyclin-sparing aspirin formulation and heparin/warfarin in aspirin users with unstable angina or non-Q wave myocardial infarction at rest. *Eur Heart J* 1994; 15:1196-1203.
  279. Merino A, Cohen M, Badimon JJ, Fuster V, Badimon L. Synergistic action of severe wall injury and shear forces on thrombus formation in arterial stenosis: Definition of a thrombotic shear rate threshold. *J Am Coll Cardiol* 1994; 24:1091-1094.
  280. Zoldeheli P, Bichler J, Owen WG, Grill DE, Fuster V, Mruk JS, Chesebro JH. Persistent thrombin generation in humans during specific thrombin inhibition with hirudin. *Circulation* 1994; 90:2671-2678.
  281. Pearson T, Rapaport E, Criqui M, Furgberg C, Fuster V, Hiratzka L, Little W, Ockene I, Williams G. Optimal risk factor management in the patient after coronary revascularization: A statement for healthcare professionals from an American Heart Association Writing Group. *Circulation* 1994; 90:3125-3133.
  282. Toussaint J-F, Southern JF, Fuster V, Kantor HL. <sup>13</sup>C-NMR spectroscopy of human atherosclerotic lesions: Relation between fatty acid saturation, cholesteryl ester content, and luminal obstruction. *Arterioscler. Thromb.* 1994; 14:1951-1957.
  283. Mailhac A, Badimon JJ, Fallon JT, Fernandez-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon L. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis. Relative contribution of fibrin(ogen) and platelet. *Circulation* 1994; 90:988-996.
  284. Braunwald E, Jones RH, Mark DB, Brown J, Brown L, Cheitlin MD, Concannon CA, Cowan M, Edwards C, Fuster V, Goldman L, Green LA, Grines CL, Lytle BW, McCauley KM, Mushlin AI, Rose GC, Smith EE, Swain JA, Topol EJ, Willerson JT. Diagnosing and managing unstable angina. *Circulation* 1994; 90:613-622.
  285. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, Danielson GK, Orszulak TA, Pluth JR, Puga FJ, Schaff HV, Larsonkeller JJ. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. *J Am Coll Cardiol* 1995; 25:1111-1119.
  286. Smith SC, Blair SN, Criqui MH, Fletcher GF, Fuster V, Gersh BJ, Gotto AM, Gould KL, Greenland P, Grundy SM, Hill MN, Hlatky MA, Houston-Miller N, Krauss RM, LaRosa J, Ockene IS, Oparil S, Pearson TA, Rapaport E, Starke RD. Consensus Panel Statement: Preventing heart attack and death in patients with coronary disease. *Circulation* 1995; 92:2-4.
  287. Badimon L, Chesebro JH, Badimon JJ, Fuster V. Arterial angioplasty: Thrombosis and restenosis. *J Physiol Pharmacol* 1996(In press).
  288. Fuster V, Badimon JJ. Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. *Eur Heart J* 1995; 16:6-12.
  289. Fuster V, Chesebro JH. Aspirin for primary prevention of coronary disease: An aspirin a day? *Eur Heart J* 1995; 16:16-20.
  290. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. *Am J Cardiol* 1995; 76:24C-33C.
  291. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Circulation* 1995; 92:1355-1374.
  292. Falk E, Shah PK, Fuster V. Coronary plaque disruption. *Circulation* 1995; 92:657-671.
  293. Falk E, Fuster V. Angina pectoris and disease progression. *Circulation* 1995; 92:2033-2035.



294. Sary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. *Arterioscler Thromb Vasc Biol* 1995; 15:1512-1531.
295. Chesebro JH, Badimon JJ, Hassinger NL, McBane RD, Fuster V. Acute myocardial infarction and the role of aspirin, heparin, and warfarin. *Journal of Thrombosis and Thrombolysis* 1995; 1:231:235.
296. Toussaint J-F, Southern JF, Fuster V, Kantor HL. T2-weighted contrast for NMR characterization of human atherosclerosis. *Arterioscler Thromb Vasc Biol* 1995; 15:1533-1542.
297. Fernandez-Ortiz A, Meyer B, Chesebro JH, Fuster V, Badimon JJ. Potential applications of iontophoresis for local drug delivery of vascular diseases. *J Interven Cardiol* 1995; 8:420.
298. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. *Circulation* 1995; 92:1565.
299. Vorchheimer DA, Fuster V. Coumadin Aspirin Reinfarction Study: Rationale and Design of the CARS Study. *J Thrombos & Thrombolysis* 1995; 2:171-176.
300. Cairns JA, Fuster V, Gore J, Kennedy JW. Coronary thrombolysis. *Chest* 1995; 108 (Suppl Oct):401S-423S.
301. Hirsh J, Dalen JE, Fuster V, Harker L, Patrono C, Roth GJ. Aspirin and other platelet-active drugs: The relationship between dose, effectiveness, and side effects. *Chest* 1995; 108(Suppl Oct):247S.
302. Fuster V, Falk E, Fallon JT, Badimon L, Chesebro JH, Badimon JJ. The three processes leading to post PTCA restenosis: Dependence on the lesion substrate. *Thrombosis and Haemostasis* 1995; 74:552-559.
303. Badimon L, Alfon J, Royo T, Berrozpe M, Martinez-Gonzalez J, Vidal F, Chesebro JH, Fuster V, Badimon JJ. Cell biology of restenosis post-angioplasty. *Z Kardiol* 1995; 84(Suppl 4):145-149.
304. Goldman ME, Fisher EA, Winters S, Reichstein R, Stavile K, Gorlin R, Fuster V. Early identification of patients with native valve infectious endocarditis at risk for major complications by initial clinical presentation and baseline echocardiography. *International Journal of Cardiology* 1995; 52:257-264.
305. Langer A, Fisher M, Califf RM, Goodman S, O'Connor CM, Harrington RA, Fuster V. for the CARS Investigators. Higher rates of Coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. *Can J Cardiol* 1999;15:1095-1102.
306. Mruk JS, Zoldhelyi P, Webster MWI, Heras M, Grill DE, Holmes DR, Fuster V, Chesebro JH. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of r-hirudin, heparin or aspirin. *Circulation* 1996; 93:792-799.
307. Toussaint JF, LaMuraglia GM, Southern JF, Fuster V, Kantor HL. Magnetic resonance images lipid, fibrous, calcified, hemorrhagic, and thrombotic components of human atherosclerosis in vivo. *Circulation* 1996; 94:932-938.
308. Prystowsky EN, Benson DW, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse G. Special report: Management of patients with atrial fibrillation: A report for health professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. *Circulation* 1996; 93:1262-1277.
309. Fuster V, Pearson TA (Co-Chairs). 27<sup>th</sup> Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. *J Am Coll Cardiol* 1996;27:957-1047.
310. Fuster V, Gotto AM, Libby P, Loscalzo J, McGill H. Task Force 1. Pathogenesis of coronary disease: The biologic role of risk factors. *J Am Coll Cardiol* 1996; 7(5):964-975.
311. Pearson TA, Fuster V. Executive Summary. 27<sup>th</sup> Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. *J Am Coll Cardiol* 1996;27(5):961-963.
312. Smith AJC, Holt RE, Fitzpatrick K, Palacios IF, Gold HK, Werner W, Bovill EG, Fuster V, Jank IK.

- Transient thrombotic state after abrupt discontinuation of heparin in percutaneous coronary angioplasty. *Am Heart J* 1996;131:434-439.
313. Dangas G, Fuster V. Management of restenosis after coronary intervention. *Am Heart J* 1996; 132(2):428-436.
  314. Wexler L, Brundage B, Crouse J, Detrano R, Fuster V, Maddahi J, Rumberger J, Stanford W, White R, Taubert K. Coronary artery calcification: Pathophysiology, epidemiology, imaging methods and clinical implications. *Circulation* 1996;94:1175-1192.
  315. Rao AK, Sun L, Chesebro JH, Fuster V, Harrington RA, Schwartz D, Gallo P, Matos D, Topol EJ. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial. *Circulation* 1996; 94:2389-2395.
  316. Moreno PR, Bernardi VH, Lopez-Cuellar J, Murcia AM, Palacios IF, Gold HK, Mehran R, Sharma SK, Nemerson Y, Fuster V, Fallon JT. Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombogenicity in acute coronary syndromes. *Circulation* 1996;94:3090-3097.
  317. Moreno PR, Bernardi VH, Lopez-Cuellar J, Newell JB, McMellon C, Gold HK, Palacios IF, Fuster V, Fallon JT. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. *Circulation* 1996; 94:3098-3102.
  318. Chesebro JH, Fuster V. Optimal antithrombotic therapy for mechanical prosthetic heart valves. *Circulation* 1996;94:2055-2056.
  319. Cohen M, Adams PC, McBride R, Fuster V. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Prospective comparison of patient characteristics and outcome of non-prior aspirin users versus aspirin users with unstable angina or non-Q-wave myocardial infarction treated with combination antithrombotic therapy. *J Thrombosis and Thrombolysis* 1997;4:275-280.
  320. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. *Circulation* 1997;95:594-599.
  321. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) I  $\square$  b Investigators (Fuster V, Investigator). A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. *N Engl J Med* 1996;335:775-782.
  322. Fuster V, Fallon JT, Nemerson Y. Coronary thrombosis. *Lancet* 1996;348 (Suppl D):s7-s10.
  323. Caprie Steering Committee (Fuster V, Study Chairman). A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). *Lancet* 1996; 348:1329-1339.
  324. Fuster V, Vorchheimer DA. Prevention of atherosclerosis in coronary artery bypass grafts. *N Engl J Med* 1997;336(3):212-213.
  325. Ambrose JA, Fuster V. Editorial. Can we predict future acute coronary events in patients with stable coronary artery disease? *JAMA* 1997;277:343-344.
  326. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. *N Engl J Med* 1997;336:267-276.
  327. The Post Coronary Artery Bypass Graft Trial Investigators (Fuster V, Investigator). The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. *N Engl J M* 1997;336:153-162.
  328. Nash IS, Nash DB, Fuster V. Do cardiologists do it better? *J Am Coll Cardiol* 1997;29:475-478.
  329. Chilian WM, NHLI Workshop Participants (Fuster V, Participant). Coronary microcirculation in health and disease. *Circulation* 1997;95:522-528.
  330. Toussaint JF, Southern JF, Fuster V, Kantor HL. Water diffusion properties of human atherosclerosis and thrombosis measured by pulse field gradient nuclear magnetic resonance. *Arterioscler Thromb Vasc Biol* 1997;17:542-546.
  331. Fuster V, Fallon JT, Badimon JJ, Nemerson Y. The unstable atherosclerotic plaque: Clinical significance and therapeutic intervention. *Thrombosis and Haemostasis* 1997;78(1):247-255.

332. Lengyel M, Fuster V, Keltai M, Roudaut R, Schulte HD, Seward JB, Chesebro JH, Turpie AGG. Guidelines for the management of left-sided prosthetic valve thrombosis. A role for thrombolytic therapy. *J Am Coll Cardiol* 1997;30:1521-1526.
333. Fuster V, Nash I. The generalist/cardiovascular specialist: A proposal for a new training track. *Ann Intern Med* 1997;127:630-634.
334. Mehta D, Curwin J, Gomes JA, Fuster V. Sudden death in coronary disease: Acute ischemia versus myocardial substrate. *Circulation* 1997;96:3215-3223.
335. The Mechanisms Precipitating Acute Cardiac Events Group (Fuster V, member). Mechanisms precipitating acute cardiac events: Review and recommendations of an NHLBI Workshop. *Circulation* 1997;96:3233-3239.
336. Badimon JJ, Meyer B, Feigen LP, Baron DA, Chesebro JH, Fuster V, Badimon L. Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein I $\square$ b/IIIa antagonist. *Eur J Clin Inv* 1997;27:568-574.
337. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease. A statement for healthcare professionals from the American Heart Association Writing Group. *Circulation* 1997;96:2751-2753.
338. Schussheim A, Fuster V. Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. *Progress in Cardiovascular Disease* 1997;40(3):205-238.
339. Vallabhajosula S, Fuster V. Atherosclerosis: Imaging techniques and the evolving role of nuclear medicine. *J Nucl Med* 1997;38:1788-1796.
340. Fuster V Investigator: Coumadin Aspirin Reinfarction Study (CARS). Randomized Double trial of fixed low dose warfarin with aspirin after acute myocardial infarction. *Lancet* 997;350:389
341. Harnick DJ, Cohen JL, Schechter CB, Fuster V, Smith DA. Effects of practice setting on quality of lipid lowering management in patients with coronary artery disease. *Am J Cardiol* 1998;81(12):1416-20.
342. Gutstein DE, Fuster V. Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction. *Clin Cardiol* 1998;21:161-168.
343. Ambrose JA, Fuster V. Editorial. The risk of coronary occlusion is not proportional to the prior severity of coronary stenosis. *Heart* 1998;79:3-4.
344. Adams PC, Skinner JS, Cohen M, McBride R, Fuster V, The Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Acute coronary syndromes in the United States and United Kingdom: A comparison of approaches. *Clin Cardiol* 1998;21:348-352.
345. Toussaint J-F, Southern JF, Kantor HL, Jang I-K, Fuster V. Behavior of atherosclerotic plaque components after in vitro angioplasty and atherectomy studied by high field MR imaging. *Magnetic Resonance Imaging* 1998;16(2):175-183.
346. Metz BK, White HD, Granger CB, Simes RJ, Armstrong PW, Hirsh J, Fuster V, MacAulay CM, Califf RM, Topol EJ for the GUSTO Iib Investigators. Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: Results from the GUSTO Iib Trial. *J Am Coll Cardiol* 1998;31:1493-1498.
347. Vorchheimer DA, Fuster V. Oral platelet glycoprotein I $\square$ b/IIIa antagonists: The present challenge is safety. *Circulation* 1998;97:312-314.
348. Gallo R, Padurean A, Toschi V, Bichler J, Fallon JT, Chesebro JH, Fuster V, Badimon JJ. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. *Circulation* 1998;97:581-588.
349. Meyer BJ, Badimon JJ, Chesebro JH, Fallon JT, Fuster V, Badimon L. Dissolution of mural thrombus by specific thrombin inhibition with r-Hirudin. Comparison with heparin and aspirin. *Circulation* 1998;97:681-685.
350. Fuster V. Mechanisms of arterial thrombosis: Foundation for therapy. *Am Heart J* 1998;135:S361-S366.
351. Fayad Z, Fallon JT, Shinnar M, Dansky HM, Poon M, Badimon JJ, Charlton SA, Fisher EA, Breslow JL,

- Fuster V. Noninvasive in vivo high resolution magnetic resonance imaging of atherosclerotic lesions in genetically-engineered mice. *Circulation* 1998;98: 1541-1547.
352. Gertz DS, Fallon JT, Gallo R, Taubman MB, Banai S, Barry WL, Gimple LW, Nemerson Y, Thiruvikraman S, Naidu SS, Chesebro, JH, Fuster V., Sarembock IJ, Badimon JJ. Hirudin reduces tissue factor expression in Neointima after balloon injury in rabbit femoral and porcine coronary arteries. *Circulation* 1998;98: 580-587.
353. Badimon JJ, Fernandez-Ortiz A, Meyer B, Mailhac A, Fallon JT, Falk E, Badimon L, Chesebro JH, Fuster V. Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening. *Atherosclerosis* 1998;140:307-314.
354. Cairns JA, Kennedy JW, Fuster V. Coronary Thrombolysis. *Chest* 1998;634S-657S.
355. Fuster V., Fayad ZA, Badimon JJ. Acute Coronary Syndromes: Biology. *Lancet* 1999;353:SII5-SII9.
356. Gallo R, Padurean A, Jayaraman T, Marx S, Roque M, Adelman S, Chesebro J, Fallon J, Fuster V., Marks, A, Badimon JJ. Inhibition of Intimal Thickening after Balloon Angioplasty in Porcine Coronary Arteries by Targeting Regulators of the Cell Cycle. *Circulation* 1999;99:2164-2170.
359. Badimon JJ, Lettino M, Toschi V, Fuster V., Berrozpe M, Chesebro JH, Badimon L. Local Inhibition of Tissue Factor Reduces the Thrombogenicity of Disrupted Human Atherosclerotic Under Flow Conditions. *Circulation* 1999;99:1780-1787.
360. Vorchheimer DA, Badimon JJ, Fuster V. Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Cardiovascular Disease. *JAMA* 1999;281:1407-1414.
361. Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V., Fallon JT. Histopathologic Comparison of Human Coronary Intest and Post-Balloon Angioplasty Restenotic Tissue. *Amer J. Cardiol* 999;84:462-465.
362. Grundy SM, Pasternack R, Greenland P, Smith S, Fuster V. Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation* 1999;100:1481-1492.
363. Langer A, Fisher M, Claiff RM, Goodman S, O'Connor CM, Harrington RA, Fuster V. Higher Rates of Coronary Angiography and Revascularization following Myocardial Infarction may be associated with greater survival in the United States than in Canada. *Can J Cardiol* 1999;15:1095-1102.
364. Moreno PR, Fallon JT, Bernardi VH, Harrell L, Weissman NJ, Fuster V., Rodriguez A, Palacios IF. Histopathology of Coronary Lesions with early loss of minimal luminal diameter after successful percutaneous transluminal coronary angioplasty: Is thrombus a significant contributor? *Amer Heart J* 1999;136:804-811.
365. Reis ED, Roque M, Cordon-Cardo C, Fuster V., Badimon JJ. Time Course of p27 Expression after Femoral Arterial Injury in the Mouse. *Vascular Surgery* 1999;L:482-483.
366. Freudenberger R, Alexis J, Gass A, Fuster V., Badimon JJ. Antithrombotic Effect of FK506 vs Cyclosporine in Cardiac Transplant Recipients: Potential Implications in Transplant Arteriopathy. *Journal of Heart and Lung Transplant* 1999;18:1228-1231.
367. Moreno PR, Fallon JT, Murcia AM, Leon MN, Simosa H, Fuster V., Palacios IF. Tissue Characteristics of Restenosis after Percutaneous Transluminal Coronary Angioplasty in Diabetic Patients. *JACC* 1999;34:1045-1049.
368. Shinnar M, Fallon JT, Wehrli S, Levin M, Dalmacy D, Fayad ZA, Badimon JJ, Harrington M, Harrington E, Fuster V. The diagnostic accuracy of ex vivo MRI for human atherosclerotic plaque characterization. *Arterioscler Thromb Vasc Biol.* 1999 Nov;19(11):2756-61.
369. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circulation.* 1999;100:(14)81-92 and *J Am Coll Cardiol.* 1999.Oct;34(4):1348-59.
370. Fuster V., Smaha L. AHA's new strategic impact goal designed to curb epidemic of cardiovascular disease

- and stroke. *Circulation*. 1999 May 11;99(18):2360.
371. Fuster V. Epidemic of cardiovascular disease and stroke: the three main challenges. *Circulation*. 1999 Mar 9;99(9):1132-7.
  372. Roque M, Rauch U, Reis ED, Chesebro JH, Fuster V, Badimon JJ. Comparative study of antithrombotic effect of a low molecular weight heparin and unfractionated heparin in an ex vivomodel of deep arterial injury. *Thromb Res*. 2000 Jun 15;98(6):499-505.
  373. Rauch U, Crandall J, Osende JI, Fallon JT, Chesebro JH, Fuster V. Increased thrombus formation relates to ambient blood glucose and leukocyte count in diabetes mellitus type 2. *Am J Cardiol*. 2000 Jul 15;86(2):246-9.
  374. Fuster V. [Thrombus remodeling. Key factor in the progression of coronary atherosclerosis]. *Rev Esp Cardiol*. 2000;53 Suppl 1:2-7.
  375. Helft G, Osende JI, Worthley SG, Zaman AG, Rodriguez OJ, Lev EI, Farkouh ME, Fuster V, Badimon JJ, Chesebro JH. Acute antithrombotic effect of a front-loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. *Arterioscler Thromb Vasc Biol*. 2000 Oct;20(10):2316-21.
  376. Reis, ED, Roque M, Cordon-Cardo C, Drobnjak M, Fuster V, Badimon JJ. Apoptosis, proliferation, and p27 expression during vessel wall healing: time course study in a mouse model of transluminal femoral artery injury. *J Vasc Surg*. 2000 Nov;32(5):1022-9.
  377. Fuster V, Gotto AM. Risk Reduction. *Circulation*. 2000 Nov 14;102(20 Suppl 4):IV94-IV102.
  378. Worthley SG, Helft G, Fuster V, Zaman AG, Fayad ZA, Fallon JT, Badimon JJ. Serial In vivo MRI documents arterial remodeling in experimental atherosclerosis. *Circ*. 2000;101:586-589.
  379. Greenland P, Abrams J, Aurigemma GP, Bond MG, Clark LT, Criqui MH, Crouse JR, Friedman L, Fuster V, Herrington DM, Kuller LH, Ridker PM, Roberts WC, Stanford W, Stone N, Swan, HJ, Taubert KA, Wexler L. Prevention Conference V. Beyond Secondary Prevention: Identifying the high-risk patient for primary prevention: Non invasive tests of atherosclerotic burden. *Circ* 2000;101:e16-e22.
  380. Fayad ZA and Fuster V. Characterization of atherosclerotic plaques by magnetic resonance imaging. *Annals New York Academy of Sciences*. 2000 Characterization of atherosclerotic plaques by magnetic resonance imaging. *Ann N Y Acad Sci*. 2000 May;902:173-86.
  381. Worthley SG, Helft G, Fuster V, Fayad ZA, Fallon JT, Osende JI, Roque M, Shinnar M, Zaman AG, Rodriguez OJ, Verhallen P, Badimon JJ. High resolution ex vivo magnetic resonance imaging of in situ coronary and aortic atherosclerotic plaque in a porcine model. *Atherosclerosis*. 2000;150:321-9.
  382. Fayad ZA, Nahar T, Fallon JT, Goldman M, Aguinaldo JG, Badimon JJ, Shinnar M, Chesebro JH, Fuster V. In Vivo MR Evaluation of Atherosclerotic Plaques in the Human Thoracic Aorta: A Comparison with TEE. *Circ*. 2000 101: 2503-2509.
  383. Fayad ZA. Fuster V, Fallon JT, Jayasundera T, Worthley SG, Helft GMD; Aguinaldo JG, Badimon JJ, Sharma Noninvasive in vivo human coronary artery lumen and wall imaging using black blood magnetic resonance. *Circ*. 2000;102:506-10.
  384. Worthley SG, Helft G, Fayad ZA, Fuster V, Zaman AG, Shinnar M, Badimon JJ. Magnetic resonance imaging and asymptomatic aortic dissection. *Circ*. 2000;101:2771.
  385. Worthley SG, Helft G, Fayad ZA, Fuster V, Rodriguez OJ, Zaman AG, Fallon JT, JJ Badimon. Noninvasive in vivo magnetic resonance imaging of experimental coronary artery lesions in a porcine model. *Circ*. 2000;101:2956-61.
  386. Rauch U, Fuster V, et al. Statins and Cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. *Atherosclerosis* 2000;1153:181-9.
  387. Roque M, Fuster V, et al. Modulation of apoptosis, proliferation and p27 expression in a porcine coronary angioplasty model. *Atherosclerosis* 2000;153:315-22.
  388. Hayes R, Chesebro JH, Fuster V, et al. Antithrombotic Effects of Abciximab, *AJC* 2000;85:1167-1172.
  389. Zaman AG, Osende JI, Chesebro JH, Fuster V, et al. In Vivo Dynamic Real-time Monitoring and Quantification of Platelet-Thrombus Formation. *ATVB* 2000;20:860-865.

390. Sharma SK, Kini A, Marmur JD, Fuster V. Cardio-protective Effect of Prior Beta-Blocker Therapy in Reducing CK-MB Elevation after Coronary Intervention. *Circulation* 2000;102:166-72.
391. Moreno PR, Murcia AM, Palacios IF, Leon MN, Bernardi VH, Fuster V, Fallon JT. Coronary Composition and Macrophage Infiltration in Atherectomy Specimens from Patients with Diabetes Mellitus. *Circ*. 2000;102:2180-4.
392. Roque M, Reis ED, Fuster V, Padurean A, Fallon JT, Taubman MB, Chesebro JH, Badimon JJ. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. *J Am Coll Cardiol*. 2000;36(7):2303-10.
393. Fonseca FA, Izar MC, Fuster V, Gallo R, Padurean A, Fallon JT, Schachter EN, Chesebro JH, Badimon JJ. Chronic endothelial dysfunction after oversized coronary balloon angioplasty in pigs: a 12-week follow-up of coronary vasoreactivity in vivo and in vitro. *Atherosclerosis*. 2001;154(1):61-9.
394. Patrono C, Collier B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-active drugs : the relationships among dose, effectiveness, and side effects. *Chest*. 2001 Jan;119(1 Suppl):39S-63S.
395. Willerson JT, Majesky MW, Fuster V. Russell Ross, PhD : Visionary Basic Scientist in Cardiovascular Medicine. *Circ*. 2001 Jan 30;103(4):478-479.
396. Fuster V, Willerson JT. Rene G. Favalaro, MD : The Passing of a Pioneer. *Circ*. 2001;103(4):480-481.
397. Gombert-Maitland, M, Baran DA, Fuster V. Treatment of Congestive Heart Failure: Guidelines for the Primary Care Physician and the Heart Failure Specialist. *Arch Intern Med*. 2001 Feb 12;161(3):342-352.
398. Rauch U, Osende JI, Fuster V, Badimon JJ, Fayad Z, Chesebro JH. Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. *Ann Intern Med*. 2001;134(3):224-38.
399. Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. *Circ*. 2001;103(11):1488-91.
400. Helft G, Worthley SG, Fuster V, Zaman AG, Schechter C, Osende JI, Rodriguez OJ, Fayad ZA, Fallon JT, Badimon JJ. Atherosclerotic aortic component quantification by noninvasive magnetic resonance imaging: an in vivo study in rabbits. *J Am Coll Cardiol*. 2001;37(4):1149-54.
401. Corti R, Osende JI, Fuster V, Fayad ZA, Fallon JT, Badimon JJ. Artery dissection and arterial thrombus aging: the role of noninvasive magnetic resonance imaging. *Circ*. 2001;103(19):2420-1.
402. Worthley SG, Osende JI, Helft G, Badimon JJ, Fuster V. Coronary artery disease: pathogenesis and acute coronary syndromes. *Mt Sinai J Med*. 2001;68(3):167-81.
403. Roque M, Reis ED, Cordon-Cardo C, Taubman MB, Fallon JT, Fuster V, Badimon JJ. Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. *Lab Invest*. 2001;81(6):895-903.
404. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. *Circ*. 2001;103(24):2994-3018 and *Arterioscler Thromb Vasc Biol*. 2001;21(7):1094-6.
405. Alexander KP, Newby LK, Hellkamp AS, Harrington RA, Peterson ED, Kopecky S, Langer A, O'Gara P, O'Connor CM, Daly RN, Califf RM, Khan S, Fuster V. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. *J Am Coll Cardiol*. 2001;38(1):1-7.
406. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to anticoagulant therapy: heparin : a statement for healthcare professionals from the American Heart Association. *Arterioscler Thromb Vasc Biol*. 2001;21(7):E9-9.
407. Corti R, Fayad ZA, Fuster V, Worthley SG, Helft G, Chesebro J, Mercuri M, Badimon JJ. Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging. *Circ*. 2001;104(3):249-52.
408. Fayad ZA, Fuster V. The human high-risk plaque and its detection by magnetic resonance imaging. *Am J Cardiol*. 2001;88(2-A):42E-45E.

409. Fayad ZA, Fuster V. Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. *Circ Res*. 2001 Aug 17;89(4):305-16.
410. O'Connor CM, Gattis WA, Hellkamp AS, Langer A, Larsen RL, Harrington RA, Berkowitz SD, O'Gara PT, Kopecky SL, Gheorghiade M, Daly R, Califf RM, Fuster V. Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). *Am J Cardiol*. 2001 Sep 88(5):541-6.
411. Smith SC Jr., Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert K. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. *Circ*. 2001;104(13):1577-9.
412. Vorchheimer DA, Fuster V. Inflammatory markers in coronary artery disease: let prevention douse the flames. *JAMA*. 2001;286(17):2154-6.
413. Donahue M, Fuster V., Califf RM. Results of Expert Meetings: Obesity and Cardiovascular Disease. Introduction: Cardiologists should target obesity. *Am Heart J*. 2001;142(6):1088-90.
414. Rao SV, Donahue M, Pi-Sunyer FX, Fuster V. Results of Expert Meetings: Obesity and Cardiovascular Disease. Obesity as a risk factor in coronary artery disease. *Am Heart J*. 2001;142(6):1102-7.
415. Fuster V, Charlton P, Boyd A. Clinical protocol. A phase IIb, randomized, multicenter, double-blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft-vein anastomosis site in dialysis patients. *Hum Gene Ther*. 2001;12(16):2025-7.
416. Fuster V, Ryden LE, Asinger RW, Cannon DS, Crijns HJ, Frye RL, Halperin, JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. *Circ*. 2001;104(17):2118-50.
417. Osende JL, Badimon JJ, Fuster V, Herson P, Rabito P, Vidhun R, Zaman A, Rodriguez OJ, Lev EI, Rauch U, Helft G, Fallon JT, Crandall JP. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. *J Am Coll Cardiol*. 2001;38(5):1307-12.
418. Worthley SG, Helft G, Fayad ZA, Fuster V, Rodriguez OJ, Zaman AG, Badimon JJ. Cardiac gated breath-hold black blood MRI of the coronary artery wall: an in vivo and ex vivo comparison. *Int J Card Imaging*. 2001;17(3):195-201.
419. Corti R, Fuster V, Badimon JJ, Hutter R, Fayad ZA. New understanding of atherosclerosis (clinically and experimentally) with evolving MRI technology in vivo. *Ann N Y Acad Sci*;947:181-95; discussion 195-8.
420. Shimbo D, Child J, Davidson K, Geer E, Osende JI, Reddy S, Dronge A, Fuster V, Badimon JJ. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. *Am J Cardiol*. 2002;89(3):331-3.
421. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, GAniats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Jacobs AK, Hiratzka LF, Russel RO, Smith SC. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. *J Heart Lung Transplant*. 2002;21(2):189-203.
422. Corti R, Osende JI, Fayad ZA, Fallon JT, Fuster V, et.al. In vivo noninvasive detection and age definition of arterial thrombus by MRI. *J Am Coll Cardiol*. 2002;39(8):1366-73.
423. Fuster V. Applied cardiological research. Challenges for the new millennium. *Rev Esp Cardiol*.

- 2002;55(4):327-32. Spanish.
424. Redberg RF, Greenland P, Fuster V, et.al. Prevention Conference VI: Diabetes and Cardiovascular Disease: risk assessment in persons with diabetes. *Circ.* 2002;105(18):e144-52.
  425. Choudhury RP, Aguinaldo JG, Rong JX, Kulak JL, Kulak AR, Reis ED, Fallon JT, Fuster V, Fisher EA, Fayad ZA. Atherosclerotic lesions in genetically modified mice quantified in vivo by non-invasive high-resolution magnetic resonance microscopy. *Atherosclerosis.* 2002;162(2):315-21.
  426. Moreno, PR, Purushothaman KR, Fuster V, O'Connor WN. Intimomedial interface damage and adventitial inflammation is increased beneath disrupted atherosclerosis in the aorta: implications for plaque vulnerability. *Circ.* 2002;105(21):2504-11.
  427. Borreguero LJ, Corti R, de Soria RF, Osende JI, Fuster V, Badimon JJ. Images in cardiovascular medicine. Diagnosis of isolated noncompaction of the myocardium by magnetic resonance imaging. *Circ.* 2002;105(21):E177-8.
  428. Halperin JL, Fuster V. Patent foramen ovale and recurrent stroke: another paradoxical twist. *Circ.* 2002;105(22):2580-2.
  429. Fuster V, Rosenbluth A. Aortic valve disease etiology and the role of vascular pathology: is the face of the disease changing? *Adv Cardiol.* 2002;39:25-38.
  430. Merz CN, Mensah GA, Fuster V, et.al. The role of cardiovascular specialists as leaders in prevention: from training to champion. 33<sup>rd</sup> Bethesda Conference. *J Am Coll Cardiol.* 2002;40(4):641-51.
  431. Strain J, Karim A, Caliendo G, Alexis J, Sandlin Lowe R, Fuster V. Cardiac drug-psychotropic drug update small star, filled. *Gen Hosp Psychiatry.* 2002;24(5):283.
  432. Corti R, Wyttenbach R, Alerci M, Badimon JJ, Fuster V, Gallino A. Images in cardiovascular medicine. Effect of percutaneous transluminal angioplasty on severely stenotic femoral lesions: in vivo demonstration by noninvasive magnetic resonance imaging. *Circ.* 2002;106(12):1570-1.
  433. Fayad ZA, Fuster V, Nikolaou K, Becker C. Computed tomography and magnetic resonance imaging for noninvasive coronary angiography and plaque imaging: current and potential future concepts. *Circ.* 2002;106(15):2026-34.
  434. Badimon JJ, Fuster V. Can we image the "active" thrombus? *Arterioscler Thromb Vasc Biol.* 2002;22(11):1753-4.
  435. Shimbo D, Osende J, Chen J, Robbins J, Shimoto Y, Kunitada S, Fuster V, Badimon JJ. Antithrombotic Effects of DX-9065a, a Direct Factor Xa Inhibitor. *Thromb Haemost.* 2002;88(5):733-8.
  436. Corti R, Fuster V, et.al. Lipid Lowering By Simvastatin Induces Regression of Human Atherosclerotic Lesions: 2 Years Follow-Up By High-Resolution Noninvasive MRI. *Circ.* 2002;106:2884-87.
  437. Fayad ZA, Fuster V. Atherothrombotic plaques and the need for imaging. *Neuroimaging Clin N Am.* 2002;12(3):351-64.
  438. Doshi SN, Kim MC, Sharma SK, Fuster V. Images in cardiovascular medicine. Right and left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. *Circ.* 2002;106(2):e3-4.
  439. Choudhury RP, Fuster V, et.al. MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. *Arterioscler Thromb Vasc Biol.* 2002;22(7):1065-74.
  440. Vorchheimer DA, Fuster V. Thrombin inhibitors in acute coronary artery disease. *Eur Heart J.* 2002;23(15):1142-4.
  441. Fuster V, Corti R, Badimon JJ. The Mikamo Lecture 2002. Therapeutic targets for the treatment of atherothrombosis in the new millennium clinical frontiers in atherosclerosis research. *Circ J.* 2002;66(9):783-9
  442. Poon M, Badimon JJ, Fuster V. Overcoming restenosis with sirolimus: from alphabet soup to clinical reality. *Lancet.* 2002;359(9306):619-22.
  443. Worthley SG, Helft G, Fuster V, et.al. A novel nonobstructive intravascular MRI coil: in vivo imaging of experimental atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2003;23(2):346-50.
  444. Rastegar R, Harnick DJ, Weidemann P, Fuster V, et.al. ME. Spontaneous echo contrast videodensity is



- flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. *J Am Coll Cardiol.* 2003;41(4):603-10.
445. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. *Circulation.* 2003;107(7):973-7.
  446. Chesebro JH, Fuster V, Pugo FJ. Aspirin and mortality from coronary bypass surgery. *N Engl J Med.* 2003 ;348(11):1057-9.
  447. Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. *J Am Coll Cardiol.* 2003 ;41(4 Suppl S):7S-14S.
  448. Hutter R, Sauter BV, Reis ED, Roque M, Vorchheimer D, Carrick FE, Fallon JT, Fuster V, Badimon JJ. Decreased reendothelialization and increased neointima formation with endostatin overexpression in a mouse model of arterial injury. *Circulation.* 2003;107(12):1658-63.
  449. Hirsh J, Fuster V, Ansell J, Halperin JL; American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. *Circulation.* 2003;107(12):1692-711 and *J Am Coll Cardiol.* 2003;41(9):1633-52.
  450. Halperin JL, Fuster V. Meeting the challenge of peripheral arterial disease. *Arch Intern Med.* 2003;163(8):877-8.
  451. Jneid H, Bhatt DL, Corti R, Badimon JJ, Fuster V, Francis GS. Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. *Arch Intern Med.* 2003;163(10):1145-53.
  452. Gomberg-Maitland M, Fuster V, Fayad ZA, Badimon JJ, Corti R. Statins and plaque stability. *J Cardiovasc Risk.* 2003;10(3):161-7.
  453. MacNeill BD, Lowe HC, Takano M, Fuster V, Jang IK. Intravascular modalities for detection of vulnerable plaque: current status. *Arterioscler Thromb Vasc Biol.* 2003;23(8):1333-42.
  454. Viles-Gonzalez JF, Fuster V, Corti R, Badimon JJ. Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. *Curr Opin Cardiol.* 2003;18(4):286-94.
  455. Bayes de Luna A, Tse TF, de Figueiredo MB, Maranhao M, Voute J, Nishtar S, Fuster V, Poole-Wilson P; World Heart Federation. World Heart Day: a World Heart Federation enterprise promoting the prevention of heart disease and stroke across the world. *Circulation.* 2003;108(9):1038-40.
  456. Bauriedel G, Jabs A, Skowasch D, Hutter R, Badimon JJ, Fuster V, Welsch U, Luderitz B. Dendritic cells in neointima formation after rat carotid balloon injury: coordinated expression with anti-apoptotic Bcl-2 and HSP47 in arterial repair. *J Am Coll Cardiol.* 2003 ;42(5):930-8.
  457. Purushothaman KR, Fuster V, et.al. Neovascularization is the most powerful independent predictor for progression to disruption in high-risk atherosclerotic plaques. *J Am Coll Cardiol.* 2003; 41;352-3.
  458. Corti R, Fuster V. New understanding, diagnosis, and prognosis of atherothrombosis and the role of imaging. *Am J Cardiol.* 2003;91(3A):17A-26A.
  459. Fuster V, Corti R, Fayad ZA, Schwitter J, Badimon JJ. Integration of vascular biology and magnetic resonance imaging in the understanding of atherothrombosis and acute coronary syndromes. *J Thromb Haemost.* 2003;1(7):1410-21.
  460. Fayad ZA, Choudhury RP, Fuster V. Magnetic resonance imaging of coronary atherosclerosis. *Curr Atheroscler Rep.* 2003;5(5):411-7.
  461. Olin JW, Fuster V. Acute aortic dissection: the need for rapid, accurate, and readily available diagnostic strategies. *Arterioscler Thromb Vasc Biol.* 2003; 23 (10): 1721-3.
  462. Maseri A, Fuster V. Is there a vulnerable plaque? *Circulation.* 2003;107(16):2068-71.
  463. Moreno P, Purushothaman K, Fuster V, et.al. Plaque Neovascularization is increased in ruptured atherosclerotic lesions of the human aorta: Implications for plaque vulnerability. *Circulation.* 2004 110(14):2032-8.
  464. Hutter, R, Valdiviezo C, Bernhard V, Sauter, Savaontaus, Chereshev I, Carrick F, Bauriedel G, Luderitz

- B, Fallon J, Fuster V, Badimon J, Caspase-3 and tissue-factor expression in lipid-rich plaque macrophages: Evidence for apoptosis as link between inflammation and atherothrombosis. *Circulation*. 2004 109(16); 2001-8.
465. Corti R, Osende J, Fallon J, Fuster V, et.al. The selective peroxisomal proliferator-activated receptor-gamma agonist has an additive effect on plaque regression in combination with Simvastatin in experimental atherosclerosis. *J Am Coll Cardiol*. 2004 43(3); 464-73
466. Osende, J, Shimbo D, Fuster V, et.al. Antithrombotic effects of S 18886, a novel orally-active thromboxane A<sub>2</sub> Receptor Antagonist, *J Thrombosis Haemost* 2004 Mar;2(3):492-8.
467. Sirol M, Itskovich V, Mani V, Aguinaldo J, Fallon J, Misselwitz B, Weinmann H, Fuster V, et.al. Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. *Circulation* 2004 Jun 15;109(23):2890-6.
468. Viles-Gonzalez J, Anand SX, Valdiviezo C, Zafar MU, Hutter R, Sanz J, Rius T, Poon M, Fuster V, Badimon JJ. Update in atherothrombosis disease. *Mt. Sinai J Med*. 2004, 71(3); 197-208.
469. Faxon D, Fuster V, et.al. Atherosclerotic vascular disease conference: Writing Group III: pathophysiology. *Circulation*. 2004 109(21);2617-25.
470. Schaar J, Muller J, Falk E, Virmani R, Fuster V, et al. Terminology for high-risk and vulnerable coronary artery plaques. *Eur Heart J*. 2004 25(12); 1077-82.
471. Hutter R, Carrick FE, Valdiviezo C, Wolinsky C, Rudge JS, Wiegand SJ, Fuster V, et al. Vascular endothelial growth factor regulates reendothelialization and neointima formation in a mouse model of arterial injury. *Circulation* 2004 110(16): 2430-5.
472. Viles-Gonzalez JF, Poon M, Sanz J, Rius T, Nikolaou K, Fayad ZA, Fuster V, Badimon JJ. In vivo 16-slice, multidetector-row computed tomography for the assessment of experimental atherosclerosis: comparison with magnetic resonance imaging and histopathology. *Circulation* 2004 110(11): 1467-72.
473. Jacobs AK, Lindsay BD, Bellande BJ, Fonarow GC, Nishimura RA, Shah PM, Annex BH, Fuster V, et al. Task force 3: Disclosure of relationships with commercial interests: policy for education activities and publications. *J Am Coll Cardiol* 2004 44(8): 1736-40.
474. Viles-Gonzalez JF, Choi BG, Fuster V, Badimon JJ. Peroxisome proliferator-activated receptor ligands in atherosclerosis. *Expert Opin Investig Drugs* 2004 13(11): 1393-403.
475. Fuster V. Oral Antithrombins and the future of antithrombotic therapy. *Rev Esp Cardiol* 2004 57(Supl. 1): 2-8.
476. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. *Nat Rev Drug Disc* 2004 3(11): 913-25.
477. Danik S, Fuster V. Anticoagulation in pregnant women with prosthetic heart valves. *Mt. Sinai J Med* 2004 71(5):322-9.
478. Sanz J, Rius T, Kuschner P, Macaluso F, Fuster V, Poon M. Images in cardiovascular medicine. Double-chambered left ventricle: complete characterization by cardiac magnetic resonance and multidetector-row computed tomography. *Circulation* 2004 110(20): e502-3.
479. Corti R, Fuster V. Should standard medical therapy for angina include a statin? *Clin Cardiol* 2004 27(10): 547-51.
480. Viles-Gonzalez JF, Gaztanaga J, Zafar UM, Fuster V, Badimon JJ. Clinical and experimental experience with factor Xa inhibitors. *Am J Cardiovasc Drugs* 2004 4(6):379-84.
481. Dayal R, Mousa A, Bernheim J, Hollenbeck S, Henderson P, Prince M, Gordon R, Badimon J, Fuster V, et al. Characterization of retrograde collateral (type II) endoleak using a new canine model. *J Vasc Surg* 2004 40(5): 985-94.
482. Moreno PR, Fuster V. The year in atherothrombosis. *J Am Coll Cardiol*. 2004 44(11): 2099-110.
483. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. *J Am Coll Cardiol*. 2004 44(12): 2293-300.
484. Viles-Gonzalez JF, Fuster V, Badimon JJ. Thrombin/inflammation paradigms: a closer look at arterial and

- venous thrombosis. *Am Heart J* 2005 149(1 Supl): S19-31.
485. Shimbo D, Davidson KW, Haas DC, Fuster V, Badimon JJ. Negative impact of depression on outcomes in patients with coronary artery disease: mechanisms, treatment considerations, and future directions. *J Thromb Haemost*. 2005. May;3(5):897-908.
486. Sulica R, Dinh HV, Dunsky K, Fuster V, Poon M. The acute hemodynamic effect of IV nitroglycerin and dipyridamole in patients with pulmonary arterial hypertension: comparison with IV epoprostenol. *Congest Heart Fail*. 2005 May-Jun;11(3):139-44.
487. Corti R, Fuster V, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. *J Am Coll Cardiol*. 2005 Jul 5;46(1):106-12.
488. Fuster V, Kim RJ. Frontiers in cardiovascular magnetic resonance. *Circulation*. 2005 Jul 5;112(1):135-44.
489. Couturier G, Voustantiok A, Weiberger J, Fuster V. Correlation between coronary artery disease and aortic arch plaque thickness measured by non-invasive B-mode ultrasonography. *Atherosclerosis*. 2005 Jul 13
490. Rhee JY, Trocciola SM, Dayal R, Lin S, Chaer R, Kumar N, Mousa A, Bernheim J, Christos P, Prince M, Marin ML, Gordon R, Badimon J, Fuster V, Kent KC, Faries PL. Treatment of type II endoleaks with a novel polyurethane thrombogenic foam: induction of endoleak thrombosis and elimination of intra-aneurysmal pressure in the canine model. *J Vasc Surg*. 2005 Aug;42(2):321-8.
491. Brandoa AP, Brandoa AA, Berenson GS, Fuster V. Metabolic syndrome in children and adolescents. *Arq Bras Cardiol*. 2005 Aug;85(2):79-81.
492. Sirol M, Aguinaldo JG, Graham PB, Weisskoff R, Lauffer R, Mizsei G, Chereshev I, Fallon JT, Reis E, Fuster V, et al. Fibrin-targeted contrast agent for improvement of in vivo acute thrombus detection with magnetic resonance imaging. *Atherosclerosis*. 2005 Sep;182(1):79-85.
493. Gehi A, Haas D, Fuster V. Primary prophylaxis with the implantable cardioverter-defibrillator: the need for improved risk stratification. *JAMA*. 2005 Aug 24;294(8):958-60.
494. Sirol M, Fuster V et al. Chronic thrombus detection with in vivo magnetic resonance imaging and a fibrin-targeted contrast agent. *Circulation*. 2005 Sep 13;112(11):1594-600.
495. Fuster V, Moreno P, Fayad Z, Corti R, Badimon JJ. Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts *J Am Coll Cardiol*. 2005 Sept 20;46(6): 937-954.
496. Fuster V, Fayad ZA, Moreno PR, Poon M, Corti R, Badimon JJ. Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. *J Am Coll Cardiol*. 2005 Oct 4;46(7):1209-18.
497. Fuster V, Voûte J. MDGs: chronic diseases are not on the agenda. *Lancet*. 2005 Oct 29-Nov 4;366(9496):1512-4.
498. Fuster V. Cardiovascular disease in the elderly: a challenge for science and clinical care. *Nat Clin Pract Cardiovasc Med*. 2005 Nov;2(11):549.
499. Sun Q, Wang A, Jin X, Natanzon A, Duquaine D, Brook RD, Aguinaldo JG, Fayad ZA, Fuster V, Lippmann M, Chen LC, Rajagopalan S. Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. *JAMA*. 2005 Dec 21;294(23):3003-10.
500. Trocciola SM, Dayal R, Chaer RA, Lin SC, DeRubertis B, Ryer EJ, Hyneccek RL, Pierce MJ, Prince M, Badimon J, Marin ML, Fuster V, Kent KC, Faries PL. The development of endotension is associated with increased transmission of pressure and serous components in porous expanded polytetrafluoroethylene stent-grafts: characterization using a canine model. *J Vasc Surg*. 2006 Jan;43(1):109-16.
501. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, Morrison DA, O'Neill WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article. *Circulation*. 2006 Jan 3;113(1):156-75.
502. Fuster V. Novel cardiovascular biomarkers and implications for clinical trials. *Nat Clin Pract Cardiovasc*

- Med. 2006 Feb;3(2):57.
503. Winslow RD, Pinney S, Fuster V. Impact of implantable-cardioverter-defibrillator trials on clinical management of patients with heart failure. *Nat Clin Pract Cardiovasc Med*. 2006 Feb;3(2):86-93.
  504. Fayad ZA, Amirbekian V, Toussaint JF, Fuster V. Identification of interleukin-2 for imaging atherosclerotic inflammation. *Eur J Nucl Med Mol Imaging*. 2006 Feb;33(2):111-6.
  505. Beller GA, Bonow RO, Fuster V. ACCF 2006 Update for Training in Adult Cardiovascular Medicine (Focused Update of the 2002 COCATS 2 Training Statement): A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training. Introduction. *J Am Coll Cardiol*. 2006 Feb 21;47(4):894-7.
  506. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, Morrison DA, O'Neil WW, Schaff HV, Whitlow PL, Williams DO, Antman EM, Adams CD, Anderson JL, Faxon DP, Fuster V, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). *Circulation*. 2006 Feb 21;113(7):e166-286.
  507. Fuster V, Sanz J, Viles-Gonzalez JF, Rajagopalan S. The utility of magnetic resonance imaging in cardiac tissue regeneration trials. *Nat Clin Pract Cardiovasc Med*. 2006 Mar;3 Suppl 1:S2-7.
  508. Couturier G, Voustantiok A, Weinberger J, Fuster V. Correlation between coronary artery disease and aortic arch plaque thickness measured by non-invasive B-mode ultrasonography. *Atherosclerosis*. 2006 Mar;185(1):159-64.
  509. Hirsch AT, Haskal ZJ, Hertzner NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). *Circulation*. 2006 Mar 21;113(11):e463-654.
  510. Fuster V. The several faces of clinical trials: from new therapies to failed preventive strategies. *Nat Clin Pract Cardiovasc Med*. 2006 Apr;3(4):173.
  511. Corti R, Osende J, Hutter R, Viles-Gonzalez JF, Zafar U, Valdivieso C, Mizsei G, Fallon JT, Fuster V, Badimon JJ. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: In vivo demonstration by high-resolution MRI. *Atherosclerosis*. 2006 Apr 4.
  512. Gibbons RJ, Fuster V. Therapy for patients with acute coronary syndromes--new opportunities. *N Engl J Med*. 2006 Apr 6;354(14):1524-7.
  513. Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V. Neovascularization in human atherosclerosis. *Circulation*. 2006 May 9;113(18):2245-52.
  514. Zhang Z, Machac J, Helft G, Worthley SG, Tang C, Zaman AG, Rodriguez OJ, Buchsbaum MS, Fuster V, Badimon JJ. Non-invasive imaging of atherosclerotic plaque macrophage in a rabbit model with F-18 FDG PET: a histopathological correlation. *BMC Nucl Med*. 2006 May 25;6:3.
  515. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy. *Circulation*. 2006 Jun 6;113(22):2662-74.
  516. Sanz J, Weeks D, Nikolaou K, Sirol M, Rius T, Rajagopalan S, Dellegrottaglie S, Strobeck J, Fuster V, Poon M. Detection of healed myocardial infarction with multidetector-row computed tomography and comparison with cardiac magnetic resonance delayed hyperenhancement. *Am J Cardiol*. 2006 Jul 15;98(2):149-55.
  517. Bonow RO, Carabello BA, Kanu C, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC Jr, Jacobs AK,

- Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. *Circulation*. 2006 Aug 1;114(5):e84-231.
518. Fuster V. Cardiovascular disease and the UN millennium development goals: a serious concern. *Nat Clin Pract Cardiovasc Med*. 2006 Aug;3(8):401.
519. Viles-Gonzalez JF, Fuster V, Badimon JJ. Links between inflammation and thrombogenicity in atherosclerosis. *Curr Mol Med*. 2006 Aug;6(5):489-99.
520. Meerarani P, Badimon JJ, Zias E, Fuster V, Moreno PR. Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications. *Curr Mol Med*. 2006 Aug;6(5):501-14.
521. Sanz J, Dellegrottaglie S, Fuster V, Rajagopalan S. Calcium scoring and contrast-enhanced CT angiography. *Curr Mol Med*. 2006 Aug;6(5):525-39.
522. Sirol M, Fuster V, Fayad ZA. Plaque imaging and characterization using magnetic resonance imaging: towards molecular assessment. *Curr Mol Med*. 2006 Aug;6(5):541-8.
523. Purushothaman KR, Sanz J, Zias E, Fuster V, Moreno PR. Atherosclerosis neovascularization and imaging. *Curr Mol Med*. 2006 Aug;6(5):549-56.
524. Moreno PR, Sanz J, Fuster V. Atherosclerosis. *Curr Mol Med*. 2006 Aug;6(5):437-8
525. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation. *Circulation*. 2006 Aug 15;114(7):e257-354.
526. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S; Guidelines for the Management of Patients with Atrial Fibrillation. *Eur Heart J*. 2006 Aug;27(16):1979-2030
527. Lipinski MJ, Amirbekian V, Frias JC, Aguinaldo JG, Mani V, Briley-Saebo KC, Fuster V, Fallon JT, Fisher EA, Fayad ZA. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. *Magn Reson Med*. 2006 Sep;56(3):601-10.
528. Smith S, Voute J, Fuster V. Principles for national and regional guidelines on cardiovascular disease prevention. *Nat Clin Pract Cardiovasc Med*. 2006 Sep;3(9):461.
529. Danik S, Fuster V. The obstetrical patient with a prosthetic heart valve. *Obstet Gynecol Clin North Am*. 2006 Sep;33(3):481-91
530. Pucci A, Sheiban I, Formato L, Celeste A, Brscic E, Moretti C, De Bernardi A, Alberti A, Bergamasco L, Trevi G, Fuster V. In vivo coronary plaque histology in patients with stable and acute coronary syndromes Relationships with hyperlipidemic status and statin treatment. *Atherosclerosis*. 2006 Sep 11.
531. Fuster V. Inoperable valve disease: should percutaneous valve replacement be an option? *Rev Esp Cardiol*. 2006 Nov;59 Suppl 3:2-9.
532. Spektor G, Gehi AK, Love B, Sharma SK, Fuster V. A case of symptomatic coronary artery fistula. *Nat Clin Pract Cardiovasc Med*. 2006 Dec;3(12):689-92.
533. Nadal-Ginard B, Fuster V. Myocardial cell therapy at the crossroads. *Nat Clin Pract Cardiovasc Med*. 2007 Jan;4(1):1.
534. Vilahur G, Choi BG, Zafar MU, Viles-Gonzalez JF, Vorchheimer DA, Fuster V, Badimon JJ. Normalization of platelet reactivity in clopidogrel-treated subjects. *J Thromb Haemost*. 2007 Jan;5(1):82-90.
535. Choi BG, Novoselsky CA, Vilahur G, Viles-Gonzalez JF, Zafar MU, Ibanez B, Fuster V, Badimon JJ. Validation study of a semi-automated program for quantification of atherosclerotic burden. *J Cardiovasc Magn Reson*. 2007;9(3):615-20.
536. Corti R, Osende J, Hutter R, Viles-Gonzalez JF, Zafar U, Valdivieso C, Mizsei G, Fallon JT, Fuster V, Badimon JJ. Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI. *Atherosclerosis*. 2007 Jan;190(1):106-13.
537. Levy AP, Levy JE, Kalet-Litman S, Miller-Lotan R, Levy NS, Asaf R, Guetta J, Yang C, Purushothaman KR, Fuster V, Moreno PR. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and

- macrophage accumulation in the atherosclerotic plaque. *Arterioscler Thromb Vasc Biol.* 2007 Jan;27(1):134-40.
538. Fuster V, Sanz J. Gene therapy and stem cell therapy for cardiovascular diseases today: a model for translational research. *Nat Clin Pract Cardiovasc Med.* 2007 Feb;4 Suppl 1:S1-8.
539. Sanz J, Moreno PR, Fuster V. Update on advances in atherothrombosis. *Nat Clin Pract Cardiovasc Med.* 2007 Feb;4(2):78-89.
540. Bansilal S, Farkouh ME, Fuster V. Role of insulin resistance and hyperglycemia in the development of atherosclerosis. *Am J Cardiol.* 2007 Feb 19;99(4A):6B-14B.
541. Zafar MU, Farkouh ME, Osende J, Shimbo D, Palencia S, Crook J, Leadley R, Fuster V, Chesebro JH. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. *Thromb Haemost.* 2007 Mar;97(3):487-92.
542. Fuster V, Voûte J. Expanding the cardiovascular mandate: from treatment to the protection of health. *Nat Clin Pract Cardiovasc Med.* 2007 Mar;4(3):117.
543. Escaned J, Rydén L, Zamorano JL, Poole-Wilson P, Fuster V, Gitt A, Fernández-Avilés F, Scholte Op Reimer W, de Teresa E, Alonso-Pulpón L, Tendra M; on behalf of the participants in the European Conference on the Future of Cardiology. Trends and contexts in European cardiology practice for the next 15 years: the Madrid Declaration: a report from the European Conference on the Future of Cardiology, Madrid, 2-3 June 2006. *Eur Heart J.* 2007 Mar;28(5):634-7.
544. Sanz J, Kuschnir P, Rius T, Salguero R, Sulica R, Einstein AJ, Dellegrottaglie S, Fuster V, Rajagopalan S, Poon M. Pulmonary arterial hypertension: noninvasive detection with phase-contrast MR imaging. *Radiology.* 2007 Apr;243(1):70-9.
545. Dellegrottaglie S, Sanz J, Poon M, Viles-Gonzalez JF, Sulica R, Goyenechea M, Macaluso F, Fuster V, Rajagopalan S. Pulmonary hypertension: accuracy of detection with left ventricular septal-to-free wall curvature ratio measured at cardiac MR. *Radiology.* 2007 Apr;243(1):63-9.
546. Fuster V, Sanz G. A polypill for secondary prevention: time to move from intellectual debate to action. *Nat Clin Pract Cardiovasc Med.* 2007 Apr;4(4):173.
547. Lipinski MJ, Abbate A, Fuster V, Vetrovec GW. Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms. *Nat Clin Pract Cardiovasc Med.* 2007 Apr;4(4):196-205.
548. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. *J Am Coll Cardiol.* 2007 Apr 24;49(16):1740-9.
549. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, Fisher EA, Fuster V, Feldman LJ, Fayad ZA. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. *Nat Med.* 2007 May;13(5):636-41.
550. Dellegrottaglie S, Einstein AJ, Sanz J, Zucker MJ, Fuster V, Rajagopalan S. Magnetic resonance imaging of a bioprosthetic mitral valve: a smiling heart. *J Cardiovasc Med (Hagerstown).* 2007 May;8(5):394-5.
551. Fuster V. Centres of excellence: a Spanish cardiovascular research initiative. Interview by Jennifer Taylor. *Circulation.* 2007 May 29;115(21):f104-6.
552. Rudd JH, Fayad ZA, Machac J, Weissberg PL, Davies JR, Warburton EA, Tawakol AA, Strauss HW, Fuster V. Atherosclerosis. 2007 Jun;192(2):453-4.
553. Farkouh ME, Greenberg JD, Jeger RV, Ramanathan K, Verheugt FW, Chesebro JH, Kirshner H, Hochman JS, Lay CL, Ruland S, Mellein B, Matchaba PT, Fuster V, Abramson SB. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. *Ann Rheum Dis.* 2007 Jun;66(6):764-70.
554. Ibanez B, Prat-González S, Speidl WS, Vilahur G, Pinero A, Cimmino G, García MJ, Fuster V, Sanz J, Badimon JJ. Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance. *Circulation.* 2007 Jun 12;115(23):2909-16.
555. Farkouh ME, Bansilal S, Fuster V. Risk profiling patients for selective use of drug-eluting stents is

- warranted. *Nat Clin Pract Cardiovasc Med*. 2007 Jul;4(7):346-7
556. Voûte J, Fuster V. Can adults at high-risk of cardiovascular disease be identified by screening their children for risk factors? *Nat Clin Pract Cardiovasc Med*. 2007 Jul;4(7):360-1.
  557. Fuster V, Farkouh ME. Faster publication isn't always better. *Nat Clin Pract Cardiovasc Med*. 2007 Jul;4(7):345.
  558. Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, Asleh R, Marsh S, Cohen O, Moestrup SK, Moller HJ, Zias EA, Benhayon D, Fuster V, Moreno PR. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. *Circ Res*. 2007 Jul 6;101(1):106-10.
  559. Wytenbach R, Corti R, Alerci M, Cozzi L, Di Valentino M, Segatto JM, Badimon JJ, Fuster V, Gallino A. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow-up by noninvasive magnetic resonance imaging. *Eur J Vasc Endovasc Surg*. 2007 Aug 2.
  560. Sanz J, Dellegrottaglie S, Kariisa M, Sulica R, Poon M, O'Donnell TP, Mehta D, Fuster V, Rajagopalan S. Prevalence and correlates of septal delayed contrast enhancement in patients with pulmonary hypertension. *Am J Cardiol*. 2007 Aug 15;100(4):731-5.
  561. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, Fuster V, Fayad ZA. Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. *J Am Coll Cardiol*. 2007 Aug 28;50(9):892-6.
  562. Pucci A, Sheiban I, Formato L, Celeste A, Brscic E, Moretti C, De Bernardi A, Alberti A, Bergamasco L, Trevi G, Fuster V. In vivo coronary plaque histology in patients with stable and acute coronary syndromes Relationships with hyperlipidemic status and statin treatment. *Atherosclerosis*. 2007 Sep;194(1):189-95.
  563. Fuster V. A new perspective on nonprescription statins: an opportunity for patient education and involvement. *Am J Cardiol*. 2007 Sep 1;100(5):907-10.
  564. Goldbarg S, Elmariah S, Miller M, Fuster V. Insights into degenerative aortic valve disease. *J Am Coll Cardiol*. 2007 Sep 25;50(13):1205-13.
  565. Ferro D, Loffredo L, Polimeni L, Fimognari F, Villari P, Pignatelli P, Fuster V, Violi F. Soluble CD40 Ligand Predicts Ischemic Stroke and Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. *Arterioscler Thromb Vasc Biol*. 2007 Sep 27.
  566. Fuster V, Voûte J, Hunn M, Smith SC. Cardiovascular and chronic diseases' low priority on the global health agenda – A cause for concern. *Circulation* 2007; 116:1966-1970.
  567. Zafar MU, Vorchheimer DA, Gaztanaga J, Velez M, Yadegar D, Moreno PR, Kunitada S, Pagan J, Fuster V, Badimon JJ. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. *Thromb Haemost*. 2007 Oct;98(4):883-8.
  568. O'Rourke RA, Fuster V. Sophisticated technology is not a substitute for cognitive cardiology. *Nat Clin Pract Cardiovasc Med*. 2007 Oct;4(10):519.
  569. Wytenbach R, Corti R, Alerci M, Cozzi L, Di Valentino M, Segatto JM, Badimon JJ, Fuster V, Gallino A. Effects of percutaneous transluminal angioplasty and endovascular brachytherapy on vascular remodeling of human femoropopliteal artery: 2 years follow-up by noninvasive magnetic resonance imaging. *Eur J Vasc Endovasc Surg*. 2007 Oct;34(4):416-23.
  570. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Riegel B, Robb JF, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Buller CE, Creager MA, Ettinger SM, Faxon DP, Fuster V, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of

- Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. *J Am Coll Cardiol*. 2007 Oct 23;50(17):1707-1732.
571. Farkouh ME, Fuster V Meta-analysis of small trials: proceed with caution. *Nat Clin Pract Cardiovasc Med*. 2007 Dec;4(12):635.
  572. Miller MA, Gomes JA, Fuster V. Risk stratification of sudden cardiac death in hypertrophic cardiomyopathy. *Nat Clin Pract Cardiovasc Med*. 2007 Dec;4(12):667-76.
  573. Ferro D, Loffredo L, Polimeni L, Fimognari F, Villari P, Pignatelli P, Fuster V, Violi F. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. *Arterioscler Thromb Vasc Biol*. 2007 Dec;27(12):2763-8.
  574. Sanz G, Fuster V. [The Spanish National Cardiovascular Research Center: a new phase] *Rev Esp Cardiol*. 2008 Jan;61(1):1-5.
  575. Elmariah S, Smith SC Jr, Fuster V. Late medical versus interventional therapy for stable ST-segment elevation myocardial infarction. *Nat Clin Pract Cardiovasc Med*. 2008 Jan;5(1):42-52.
  576. Beller GA, Bonow RO, Fuster V; American College of Cardiology Foundation; American Heart Association; American College of Physicians Task Force on Clinical Competence and Training. ACCF 2008 Recommendations for Training in Adult Cardiovascular Medicine Core Cardiology Training (COCATS 3) (revision of the 2002 COCATS Training Statement). *J Am Coll Cardiol*. 2008 Jan 22;51(3):335-8.
  577. Farkouh ME, Dangas G, Leon MB, Smith C, Nesto R, Buse JB, Cohen DJ, Mahoney E, Sleeper L, King S 3rd, Domanski M, McKinlay S, Fuster V. Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial. *Am Heart J*. 2008 Feb;155(2):215-23.
  578. Choi BG, Vilahur G, Zafar MU, Cardoso L, Yadegar D, Ibanez B, Tunstead J, Viles-Gonzalez JF, Schaffler MB, Fuster V, Badimon JJ. Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. *Atherosclerosis*. 2008 Feb 21.
  579. Farkouh ME, Fuster V. Meta-analysis of small trials: proceed with caution. *Nat Clin Pract Nephrol*. 2008 Mar;4(3):115.
  580. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. *J Am Coll Cardiol*. 2008 Mar 4;51(9):944-55.
  581. Ibanez B, Vilahur G, Cimmino G, Speidl WS, Pinero A, Choi BG, Zafar MU, Santos-Gallego CG, Krause B, Badimon L, Fuster V, Badimon JJ. Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. *J Am Coll Cardiol*. 2008 Mar 18;51(11):1104-9.
  582. Ibanez B, Cimmino G, Bénézet-Mazuecos J, Gallego CG, Pinero A, Prat-González S, Speidl WS, Fuster V, García MJ, Sanz J, Badimon JJ. Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. *Atherosclerosis*. 2008 Mar 30.
  583. Lubitz SA, Fischer A, Fuster V. Catheter ablation for atrial fibrillation. *BMJ*. 2008 Apr 12;336(7648):819-26.
  584. Choi BG, Vilahur G, Cardoso L, Fritton JC, Ibanez B, Zafar MU, Yadegar D, Speidl WS, Schaffler MB, Fuster V, et al. Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway. *Eur J Clin Invest*. 2008 Apr;38(4):211-7.
  585. Fuster V, Camm H. Screening, stem cells, biomarkers and hypercholesterolemia: our first original clinical research. *Nat Clin Pract Cardiovasc Med*. 2008 May;5(5):237.
  586. Luna F, Alonso V, Fuster V, Edo MA. Child age influence on the seasonal death risk during the first year of life (Spain, 1975-1989). *Am J Hum Biol*. 2008 May-Jun;20(3):278-84.
  587. Rudd JH, Myers KS, Bansilal S, Machac J, Pinto CA, Tong C, Rafique A, Hargeaves R, Farkouh M, Fuster V, Fayad ZA. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. *J Nucl Med*. 2008 Jun;49(6):871-8.



588. Briley-Saebo KC, Shaw PX, Mulder WJ, Choi SH, Vucic E, Aguinaldo JG, Witztum JL, Fuster V, Tsimikas S, Fayad ZA. Targeted Molecular Probes for Imaging Atherosclerotic Lesions With Magnetic Resonance Using Antibodies That Recognize Oxidation-Specific Epitopes. *Circulation*. 2008 Jun 9
589. Dellegrattaglia S, Sanz J, Fuster V, Rajagopalan S. Fatty infiltration of the right ventricle assessed by computed tomography and magnetic resonance imaging. *J Cardiovasc Med (Hagerstown)*. 2008 Jul;9(7):753.
590. Bansilal S, Farkouh ME, Fuster V. Optimal treatment of the diabetic patient with multivessel disease. *Curr Cardiol Rep*. 2008 July: 10(4):272-84
591. Calcagno C, Cornily JC, Hyafil F, Rudd JH, Briley-Saebo KC, Mani V, Goldschlager G, Machac J, Fuster V, Fayad ZA. Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET. *Arterioscler Thromb Vasc Biol*. 2008 Jul;28(7):1311-7.
592. Love BA, Mehta D, Fuster V. Evaluation and management of the adult patient with transposition of the great arteries following atrial-level (Senning or Mustart) repair. *Nature Clin Pract Cardiovasc Med* 2008 Aug;5(8):454-67
593. Fayad ZA, Fuster V. Prologue: relevance of molecular imaging in clinical medicine. *Nature Clin Pract Cardiovasc Med* 2008 Aug;5 Suppl 2:S1
594. Vedanthan R, Fuster V. Cardiovascular disease in Sub-Saharan Africa: a complex picture demanding a multifaceted response. *Nature Clin Pract Cardiovasc Med* 2008 Sep;5(9):516-517
595. Moreno Pr, Purushothaman KR, Purushothaman M, Muntner P, Levy NS, Fuster V, et al. Haptoglobin genotype is a major determinant of the amount of iron in the human atherosclerotic plaque. *J Am Coll Cardiol* 2008 Sep 23;52(13):1049-51
596. Musunuru K, Kral BG, Blumenthal RS, Fuster V, et al. The use of high-sensitivity assays for C-reactive protein in clinical practice. *Nat Clin Pract Cardiovasc Med*. 2008 Oct 5(10):621-35
597. Fuster V, Vedanthan R. Cardiovascular disease and the UN Millennium Development Goals: time to move forward. *Nat Clin Pract Cardiovasc Med*. 2008 Oct;5(10):593
598. Fuster V, Farkouh ME. Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel. *Circulation*. 2008 Oct 14;118(16):1607-8
599. Farkouh ME, Fuster V. Time to welcome the elderly into clinical trials. *Nat Clin Pract Cardiovasc Med*. 2008 Nov;5(11):673
600. Sealove BA, Tiyagura S, Fuster V. Takotsubo cardiomyopathy. *J Gen Intern Med*. 2008 Nov;23(11):1904-8
601. Worthley SG, Zhang ZY, Machac J, Helft G, Tang C, Liew GY, Zaman AG, Worthley MI, Fayad ZA, Buchsbaum MS, Fuster V, Badimon JJ. In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis. *Int J Cardiovasc Imaging*. 2008 Nov 1.
602. Hajjar R, Fuster V. Cardiac cell and gene therapies: two trajectories, one goal. *Nat Clin Pract Cardiovasc Med*. 2008 Dec;5(12):749.
603. Cimmino G, Ibanez B, Vilahur G, Speidl WS, Fuster V, et al. Up-Regulation of Reverse Cholesterol Transport Key Players and Rescue from Global Inflammation by ApoA-I. *J Cell Mol Med*. 2009 Sep;13(9B):3226-35
604. Farkouh ME, Fuster V. Diabetes and aspirin: beware of underpowered negative trials. *Nat Clin Pract Cardiovasc Med*. 2009 Jan;6(1):1.
605. Ibanez B, Cimmino G, Bénézet-Mazuecos J, Santos-Gallego CG, Pinero A, Prat-González S, Speidl WS, Fuster V, et al. Quantification of serial changes in plaque burden using multi-detector computed tomography in experimental atherosclerosis. *Atherosclerosis*. 2009 Jan;202(1):185-91.
606. Thomas JD, Zoghbi WA, Beller GA, Bonow RO, Budoff MJ, Cerqueira MD, Creager MA, Douglas PS, Fuster V, et al. ACCF 2008 Training Statement on Multimodality Noninvasive Cardiovascular Imaging A Report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training Developed in Collaboration With the

- American Society of Echocardiography, the American Society of Nuclear Cardiology, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society for Vascular Medicine. *J Am Coll Cardiol*. 2009 Jan 6;53(1):125-46.
607. Aidi HE, Mani V, Weinshelbaum KB, Aguiar SH, Taniguchi H, Postley JE, Samber DD, Cohen EI, Stern J, van der Geest RJ, Reiber JH, Woodward M, Fuster V, et al. Cross-sectional, prospective study of MRI reproducibility in the assessment of plaque burden of the carotid arteries and aorta. *Nat Clin Pract Cardiovasc Med*. 2009 Jan 27.
  608. Sanz G, Fuster V. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population. *Nat Clin Pract Cardiovasc Med*. 2009 Feb;6(2):101-10.
  609. Fuster V. Prime time for a polypill after myocardial infarction? *Nat Clin Pract Cardiovasc Med*. 2009 Feb;6(2):83.
  610. Fuster V, van der Zee S, Elmariah S, Bonow R. Academic careers in cardiovascular medicine. *Circulation* 2009 Feb;119:754-760.
  611. Fuster V, Bansilal S. Jupiter Strikes Earth *Nature Reviews* 2009 Mar;6(3):159.
  612. Sanz J, Kariisa M, Dellegrottaglie S, Prat-González S, Garcia MJ, Fuster V, Rajagopalan S. Evaluation of pulmonary artery stiffness in pulmonary hypertension with cardiac magnetic resonance *JACC Cardiovasc Imaging* 2009 Mar;2(3):286-95.
  613. Worthley SG, Zhang ZY, Machac J, Helft G, Tang C, Liew GY, Zaman AG, Worthley MI, Fayad ZA, Buchsbaum MS, Fuster V, Badimon JJ. In vivo non-invasive serial monitoring of FDG-PET progression and regression in a rabbit model of atherosclerosis *Int J Cardiovasc Imaging* 2009 Mar;25(3):251-7.
  614. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug 'resistance'. Part 1: mechanisms and clinical measurements *Nat Rev Cardiol*. 2009 Apr;6(4):273-82
  615. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis *J Am Coll Cardiol*. 2009 Apr 14;53(15):1326-37.
  616. Mani V, Muntner P, Gidding SS, Aguiar SH, El Aidi H, Weinshelbaum KB, Taniguchi H, van der Geest R, Reiber JH, Bansilal S, Farkouh M, Fuster V, et al. Cardiovascular magnetic resonance parameters of atherosclerotic plaque burden improve discrimination of prior major adverse cardiovascular events *J Cardiovasc Magn Reson*. 2009 Apr 24;11(1):10.
  617. Gorog DA, Sweeny JM, Fuster V. Antiplatelet drug 'resistance'. Part 2: laboratory resistance to antiplatelet drugs-fact or artifact? *Nat Rev Cardiol*. 2009 May;6(5):365-73.
  618. Vedanthan R, Fuster V. Disease Prevention: The moving target of global cardiovascular health. *Nat Rev Cardiol*. 2009 May;6(5):327-8.
  619. Hulot JS, Fuster V. Antiplatelet therapy: Personalized medicine for clopidogrel resistance? *Nat Rev Cardiol*. 2009 May;6(5):334-6.
  620. Lipinski MJ, Frias JC, Amirbekian V, Briley-Saebo KC, Mani V, Samber D, Abbate A, Aguinaldo JG, Massey D, Fuster V, et al. Macrophage-specific lipid-based nanoparticles improve cardiac magnetic resonance detection and characterization of human atherosclerosis. *JACC Cardiovasc Imaging*. 2009 May;2(5):637-47.
  621. Floris-Moore M, Fayad ZA, Berman JW, Mani V, Schoenbaum EE, Klein RS, Weinshelbaum KB, Fuster V, et al. Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging. *AIDS*. 2009 May 15;23(8):941-9.
  622. Zafar MU, Farkouh ME, Fuster V, Chesebro JH. Crushed Clopidogrel Administered via Nasogastric Tube Has Faster and Greater Absorption than Oral Whole Tablets. *J Interv Cardiol*. 2009 May 28
  623. Fuster V. Doubts about ventricular reconstruction. *Nat Rev Cardiol*. 2009 Jun;6(6):383.
  624. Garcia MJ, Fuster V. An ounce of prevention with a calcium score scan? *JACC Cardiovasc Imaging*. 2009 Jun;2(6):689-91

625. Sipido KR, Tedgui A, Kristensen SD, Pasterkamp G, Schunkert H, Wehling M, Steg PG, Eisert W, Rademakers F, Casadei B, Fuster V, et al. Identifying needs and opportunities for advancing translational research in cardiovascular disease. *Cardiovasc Res*. 2009 Jun 18
626. Moreno PR, Sanz J, Fuster V. Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. *J Am Coll Cardiol*. 2009 Jun 23;53(25):2315-23.
627. Rudd J, Myers K, Bansilal S, Machac J, Woodward M, Fuster V, et al. Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. *Circ Cardiovasc Imaging* 2009 Mar;2(2):107-15.
628. van der Zee S, Fuster V. Cardiovascular disease and chronic kidney disease: from treatment to promoting health *Med Clin (Barc)*. 2009 May;132 Suppl 1:33-7. Spanish.
629. Martín de Francisco AL, Aguilera L, Fuster V. Cardiovascular, renal and other chronic diseases. Early intervention is necessary in chronic kidney disease *Nefrologia* 2009;29(1):6-9. Spanish.
630. Fuster V, Sanz J. Visualizing arterial macrophage warfare with nuclear magnetic resonance, positron-emission tomography and computerized tomography *Rev Esp Cardiol*. 2009 Jun;62 Suppl 2:2-8. Spanish
631. Fuster V. Are predictive risk scores useful? *Nat Rev Cardiol*. 2009 Aug;6(8):493
632. Sirol M, Moreno PR, Purushothaman KR, Vucic E, Amirbekian V, Weinmann HJ, Muntner P, Fuster V, Fayad ZA. Increased neovascularization in advanced lipid-rich atherosclerotic lesions detected by gadofluorine-M-enhanced MRI: implications for plaque vulnerability. *Circ Cardiovasc Imaging*. 2009 Sep;2(5):391-6
633. Fuster V. An ounce of prevention. *Nat Rev Cardiol*. 2009 Sep;6(9):553-4
634. van der Zee S, Baber U, Elmariah S, Winston J, Fuster V. Cardiovascular risk factors in patients with chronic kidney disease. *Nat Rev Cardiol*. 2009 Sep;6(9):580-9
635. Stevens GR, Lala A, Sanz J, Garcia MJ, Fuster V, Pinney S. Exercise performance in patients with pulmonary hypertension linked to cardiac magnetic resonance measures. *J Heart Lung Transplant*. 2009 Sep;28(9):899-905
636. Fuster V, Mearns BM. Lipid lowering: education is key. *Nat Rev Cardiol*. 2009 Oct;6(10):609-10
637. Silvera SS, Aidi HE, Rudd JH, Mani V, Yang L, Farkouh M, Fuster V, Fayad ZA. Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. *Atherosclerosis*. 2009 Nov;207(1):139-43.
638. Fishman ML, McLaughlin MA, Fuster V. Chronic renal insufficiency, cardiovascular disease and mortality in women: a causal relationship or coincidence? *Womens Health (Lond Engl)*. 2009 Nov;5(6):617-23.
639. Mendis S, Fuster V. National policies and strategies for noncommunicable diseases. *Nat Rev Cardiol*. 2009 Nov;6(11):723-7.
640. Fuster V, Mearns BM. The CVD paradox: mortality vs prevalence. *Nat Rev Cardiol*. 2009 Nov;6(11):669
641. Ibanez B, Cimmino G, Prat-González S, Vilahur G, Hutter R, García MJ, Fuster V, et al. The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion. *Int J Cardiol*. 2009 Nov 11.
642. Cimmino G, Chen W, Speidl WS, Giannarelli C, Ibanez B, Fuster V, et al. Safe and sustained overexpression of functional apolipoprotein A-I/high-density lipoprotein in apolipoprotein A-I-null mice by muscular adeno-associated viral serotype 8 vector gene transfer. *J Cardiovasc Pharmacol*. 2009 Nov;54(5):405-11.
643. Fuster V, King A. The dual challenge of BP control. *Nat Rev Cardiol*. 2009 Dec;6(12):729-30
644. Love BA, Parness IA, Fuster V. Membranous septal aneurysm causing right ventricular outflow tract obstruction. *Clin Cardiol*. 2009 Dec;32(12)

645. Galende E, Karakikes I, Edelmann L, Desnick RJ, Kerenyi T, Khoueiry G, Lafferty J, McGinn JT, Brodman M, Fuster V, et al. Amniotic Fluid Cells Are More Efficiently Reprogrammed to Pluripotency Than Adult Cells. *Cloning Stem Cells*. 2009 Dec 17
646. Zafar MU, Paz-Yepes M, Shimbo D, Vilahur G, Burg MM, Chaplin W, Fuster V, et al. Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. *Eur Heart J*. 2010 Jan 22.
647. Underhill HR, Hatsukami TS, Fayad ZA, Fuster V, Yuan C. MRI of carotid atherosclerosis: clinical implications and future directions. *Nat Rev Cardiol*. 2010 Mar;7(3):165-73
648. Fuster V, Mearns BM. Global collaboration needed for AF. *Nat Rev Cardiol*. 2010 Mar;7(3):115-6
649. Baber U, van der Zee S, Fuster V. Anticoagulation for mechanical heart valves in patients with and without atrial fibrillation. *Curr Cardiol Rep*. 2010 Mar;12(2):133-9
650. Hayashi K, Mani V, Nemade A, Aguiar S, Postley JE, Fuster V, et al. Variations in atherosclerosis and remodeling patterns in aorta and carotids. *J Cardiovasc Magn Reson*. 2010 Mar 5;12:10
651. Sanz J, Moreno PR, Fuster V. The Year in Atherothrombosis. *J Am Coll Cardiol* 2010 Apr 6;55(14):1487-98
652. Canadas V, Vilacosta I, Bruna I, Fuster V. Marfan syndrome. Part 1: pathophysiology and diagnosis. *Nat Rev Cardiol*. 2010 May;7(5):256-65.
653. Canadas V, Vilacosta I, Bruna I, Fuster V. Marfan syndrome. Part 2: pathophysiology and diagnosis. *Nat Rev Cardiol*. 2010 May;7(5):266-76.
654. Mearns BM, Fuster V. Highlight dementia risk to reduce CVD. *Nat Rev Cardiol*. 2010 May;7(5):237.
655. Liao SL, Elmariah S, van der Zee S, Sealove BA, Fuster V. Does medical therapy for thoracic aortic aneurysms really work? Are beta-blockers truly indicated? CON. *Cardiol Clin*. 2010 May;28(2):261-9.
656. Ibanez B, Fuster V. Ischaemic conditioning for myocardial salvage after AMI. *Lancet*. 2010 May 15;375(9727):1691; author reply 1692.
657. Fuster V, et al. Promoting cardiovascular and cerebrovascular health. *Stroke*. 2010 Jun;41(6):1079-83
658. Fuster V. From complex multivessel disease to cardiovascular health. *Rev Esp Cardiol*. 2010 Jun;63 Suppl 2:3-11. Spanish
659. Fuster V, and et al. Early Identification of atherosclerotic disease by noninvasive imaging. *Nat Rev Cardiol*. 2010 Jun;7(6):327-33
660. King A, Fuster V. Children are key to CVD prevention. *Nat Rev Cardiol*. 2010 Jun;7(6):297
661. Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. *Circulation*. 2010 Jun 15;121(23):2575-83
662. Sanz J, Fuster V. Update in Cardiology *Ann Intern Med*. 2010 Jun 15;152(12):786-91
663. Rudd JH, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, Tahara N, Fuster V, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? *J Am Coll Cardiol*. 2010 Jun 8;55(23):2527-35
664. Fuster V, et al, General cardiology perspective: decision making regarding revascularization of patients with type 2 diabetes mellitus and cardiovascular disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Circulation*. 2010 Jun 8;121(22):2450-2
665. Osorio J, Fuster V. Valve Interventions—a word of caution. *Nat Rev Cardiol*. 2010 Jul;7(7):355.
666. Farkouh ME, Fuster V. Diabetes: making sense of the rosiglitazone controversy. *Nat Rev Cardiol*. 2010 Jul;7(7):366-7.
667. Muntendam P, McCall C, Sanz J, Falk E, Fuster V. The BioImage Study: Novel Approaches to Risk Assessment in the Primary Prevention of Atherosclerotic Cardiovascular Disease - Study Design and Objectives. *Am Heart J*. 2010 Jul;160(1):49-57.e1
668. Lubitz SA, Benjamin EJ, Ruskin JN, Fuster V, et al. Challenges in the classification of atrial fibrillation. *Nat Rev Cardiol*. 2010 Aug;7(8):451-60.

669. Fernandez-Friera L, Garcia-Alvarez A, Romero A, Fuster V, et al. Lipid-rich obstructive coronary lesions is plaque characterization any important? *JACC Cardiovasc Imaging*. 2010 Aug;3(8):893-5.
670. Speidl WS, Cimmino G, Ibanez B, Elmariah S, Hutter R, Garcia MJ, Fuster V, et al. Recombinant apolipoprotein A-I Milano reapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experiemetal rabbit model. *Eur Heart J*. 2010 Aug;31(16):2049-57
671. Cormode DP, Roessl E, Thran A, Skajaa T, Gordon RE, Schlomka JP, Fuster V, et al. Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. *Radiology*. 2010 Sep;256(3):774-82.
672. Fuster V. Fine-tuning therapy for acute coronary syndromes. *N Engl J Med*. 2010 Sep 2;363(10):976-7.
673. Cimmino G, Ibanez B, Giannarelli C, Prat-González S, Hutter R, Garcia M, Sanz J, Fuster V, et al. Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. *Int J Cardiol*. 2010 Sep 21. [Epub ahead of print]
674. Fuster V, et al. The role of noninvasive imaging in promoting cardiovascular health. *J Nucl Cardiol*. 2010 Oct;17(5):781-90.
675. Fuster V, et al. Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle. *JAMA*. 2010 Oct 27;304(16):1821-30
676. Fuster V. Science, health and education: a priority and a model. *Arch Cardiol Mex*. 2010 oct-dec;80(4):261-271. Spanish.
677. Hyafil F, Vucic E, Cornily JC, Sharma R, Amirbekian V, Blackwell F, Lancelot E, Corot C, Fuster V, et al. Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases. *Eur Heart J*. 2010 Nov 30. [Epub ahead of print]
678. Elmariah S, Delaney JA, O'Brien KD, Budoff MJ, Vogel-Claussen J, Fuster V, et al. Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis). *J Am Coll Cardiol*. 2010 Nov 16;56(21):1752-9.
679. Giannarelli C, Ibanez B, Cimmino G, Garcia Ruiz JM, Faita F, Bianchini E, Zafar MU, Fuster V, et al. Contrast-enhanced ultrasound imaging detects intraplaque neovascularization in an experimental model of atherosclerosis. *JACC Cardiovasc Imaging*. 2010 Dec;3(12):1256-64.
680. Lobatto ME, Fayad ZA, Silvera S, Vucic E, Calcagno C, Mani V, Dickson SD, Nicolay K, Banciu M, Schiffelers RM, Metselaar JM, van Bloois L, We HS, Fallon JT, Rudd JH, Fuster V, et al. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. *Mol Pharm*. 2010 Dec 6;7(6):2020-9.
681. Fernandez-Friera L, Garcia-Alvarez A, Bagheriannejad-Esfahani F, Malick W, Mirelis JG, Sawit ST, Fuster V, et al. Diagnostic value of coronary artery calcium scoring in low-intermediate risk patients evaluated in the emergency department for acute coronary syndrome. *Am J Cardiol*. 2011 Jan;107(1):17-23.
682. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA 3rd, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, et. al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2011 Jan 11;57(2):223-42
683. Vedanthan R, Fuster V. Urgent need for human resources to promote global cardiovascular health. *Nat Rev Cardiol* 2011 Feb;8(2):114-7
684. Viles-Gonzalez JF, Fuster V, Halperin J, Calkins H, Reddy VY. Rhythm control for management of patients with atrial fibrillation: balancing the use of antiarrhythmic drugs and catheter ablation. *Clin Cardiol*. 2011 Jan;34(1):23-9.
685. Franco M, Cooper RS, Bilal U, Fuster V. Challenges and opportunities for cardiovascular disease prevention. *Am J Med*. 2011 Feb;124(2):95-102.
686. Fuster V, Sweeny JM. Aspirin: a historical and contemporary therapeutic overview. *Circulation*. 2011 Feb 22;123(7):768-78.

687. Vaishnava P, Fuster V, Goldman M, Bonow RO. Surgery for asymptomatic degenerative aortic and mitral valve disease. *Nat Rev Cardiol*. 2011 Mar;8(3):173-7.
688. Cimmino G, Giannarelli C, Chen W, Alique M, Santos-Gallego CG, Fuster V, Et Al. Adeno-associated virus serotype 8 ApoA-I gene transfer reduces progression of atherosclerosis in ApoE-KO mice: comparison of intramuscular and intravenous administration. *J Cardiovasc Pharmacol*. 2011 Mar;57(3):325-33.
689. Fuster V, Et. Al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. *Circulation*. 2011 Mar 15;123(10):e269-367.
690. Ibanez B, Cimmino G, Prat-González S, Vilahur G, Hutter R, García MJ, Fuster V, Et Al. The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion. *Int J Cardiol*. 2011 Mar 17;147(3):428-32.
691. Purushothaman KR, Purushothaman M, Muntner P, Lento PA, O'Connor WN, Sharma SK, Fuster V, Moreno PR. Inflammation, neovascularization and intra-plaque hemorrhage are associated with increased reparative collagen content: implication for plaque progression in diabetic atherosclerosis. *Vasc Med*. 2011 Apr;16(2):103-8.
692. Sanz G, Fuster V. Polypill and global cardiovascular health strategies. *Semin Thorac Cardiovasc Surg*. 2011 Spring;23(1):24-9.
693. Muntner P, Mann D, Wildman RP, Shimbo D, Fuster V, Woodward M. Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects. *Am Heart J*. 2011 Apr;161(4):719-25.
694. Kovacic JC, Moreno P, Hachinski V, Nabel EG, Fuster V. Cellular senescence, vascular disease, and aging: part 1 of a 2-part review. *Circulation*. 2011 Apr 19;123(15):1650-60.
695. Kovacic JC, Moreno P, Nabel EG, Hachinski V, Fuster V. Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly. *Circulation*. 2011 May 3;123(17):1900-10.
696. Fuster V, Kelly BB, Vedanthan R. Promoting global cardiovascular health: moving forward. *Circulation*. 2011 Apr 19;123(15):1671-8.
697. Kishore SP, Vedanthan R, Fuster V. Promoting global cardiovascular health ensuring access to essential cardiovascular medicines in low- and middle-income countries. *J Am Coll Cardiol*. 2011 May 17;57(20):1980-7.
698. Moral S, Fernández-Friera L, Stevens G, Guzman G, García-Alvarez A, Nair A, Evangelista A, Fuster V, Garcia MJ, Sanz J. New index alpha improves detection of pulmonary hypertension in comparison with other cardiac magnetic resonance indices. *Int J Cardiol*. 2011 May 17.
699. Klink A, Hyafil F, Rudd J, Faries P, Fuster V, Et Al. Diagnostic and therapeutic strategies for small abdominal aortic aneurysms. *Nat Rev Cardiol*. 2011 Jun;8(6):338-47.
700. Hyafil F, Vucic E, Cornily JC, Sharma R, Amirbekian V, Blackwell F, Lancelot E, Corot C, Fuster V, Et Al. Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases. *Eur Heart J*. 2011 Jun;32(12):1561-71.
701. Fuster V, Sanz G. [Fixed-dose compounds and the secondary prevention of ischemic heart disease]. *Rev Esp Cardiol*. 2011 Jul;64 Suppl 2:3-9.
702. Ibáñez B, Fuster V, Et Al. [Modulation of the beta-adrenergic system during acute myocardial infarction: rationale for a new clinical trial]. *Rev Esp Cardiol*. 2011 Jul;64 Suppl 2:28-33.
703. Corti R, Fuster V. Imaging of atherosclerosis: magnetic resonance imaging. *Eur Heart J*. 2011 Jul;32(14):1709-19b.
704. Garcia-Alvarez A, Fernandez-Friera L, Lau JF, Sawit ST, Mirelis JG, Castillo JG, Pinney S, Anyanwu AC, Fuster V, Sanz J, Garcia MJ. Evaluation of right ventricular function and post-operative findings using

- cardiac computed tomography in patients with left ventricular assist devices. *J Heart Lung Transplant*. 2011 Aug;30(8):896-903.
705. Viles-Gonzalez JF, Fuster V, Halperin JL. New anticoagulants for prevention of stroke in patients with atrial fibrillation. *J Cardiovasc Electrophysiol*. 2011 Aug;22(8):948-55.
  706. Fernandez-Friera L, Garcia-Alvarez A, Guzman G, Bagheriannejad-Esfahani F, Malick W, Nair A, Fuster V, Garcia MJ, Sanz J. Apical right ventricular dysfunction in patients with pulmonary hypertension demonstrated with magnetic resonance. *Heart*. 2011 Aug;97(15):1250-6.
  707. Fayad ZA, Mani V, Woodward M, Kallend D, Bansilal S, Pozza J, Burgess T, Fuster V, Rudd JH, Tawakol A, Farkouh ME. Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. *Am Heart J*. 2011 Aug;162(2):214-221.e2.
  708. Muntner P, Mann D, Wildman RP, Shimbo D, Fuster V, Woodward M. Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects. *Am Heart J*. 2011 Apr;161(4):719-25.
  709. Sanz J, Fuster V. The year in atherothrombosis. *J Am Coll Cardiol*. 2011 Aug 16;58(8):779-91.
  710. Ibanez B, Fuster V, Jiménez-Borreguero J, Badimon JJ. Lethal myocardial reperfusion injury: a necessary evil? *Int J Cardiol*. 2011 Aug 18;151(1):3-11.
  711. Fuster V, Kelly BB, Vedanthan R. Global cardiovascular health: urgent need for an intersectoral approach. *J Am Coll Cardiol*. 2011 Sep 13;58(12):1208-10.
  712. Vucic E, Dickson SD, Calcagno C, Rudd JH, Moshier E, Hayashi K, Mounessa JS, Roytman M, Moon MJ, Lin J, Tsimikas S, Fisher EA, Nicolay K, Fuster V, Fayad ZA. Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. *JACC Cardiovasc Imaging*. 2011 Oct;4(10):1100-9.
  713. Moreno PR, Astudillo L, Elmariah S, Purushothaman KR, Purushothaman M, Lento PA, Sharma SK, Fuster V, Adams DH. Increased macrophage infiltration and neovascularization in congenital bicuspid aortic valve stenosis. *J Thorac Cardiovasc Surg*. 2011 Oct;142(4):895-901.
  714. García-Alvarez A, Fernández-Friera L, Mirelis JG, Sawit S, Nair A, Kallman J, Fuster V, Sanz J. Non-invasive estimation of pulmonary vascular resistance with cardiac magnetic resonance. *Eur Heart J*. 2011 Oct;32(19):2438-45.
  715. Falk E, Sillesen H, Muntendam P, Fuster V. The high-risk plaque initiative: primary prevention of atherothrombotic events in the asymptomatic population. *Curr Atheroscler Rep*. 2011 Oct;13(5):359-66.
  716. Kovacic JC, Fuster V. From treating complex coronary artery disease to promoting cardiovascular health: therapeutic transitions and challenges, 2010-2020. *Clin Pharmacol Ther*. 2011 Oct;90(4):509-18.
  717. Lobatto ME, Fuster V, Fayad ZA, Mulder WJ. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. *Nat Rev Drug Discov*. 2011 Oct 21;10(11):835-52.
  718. Fayad ZA, Mani V, Woodward M, Kallend D, Abt M, Burgess T, Fuster V, Et Al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. *Lancet*. 2011 Oct 29;378(9802):1547-59.
  719. Franco M, Cooper R, Bilal U, Fuster V. [Control of coronary heart disease risk factors and evidence-based therapies: joint efforts for coronary heart disease prevention in Spain]. *Rev Esp Cardiol*. 2011 Nov;64(11):962-4.
  720. Domanski M, Lloyd-Jones D, Fuster V, Grundy S. Can we dramatically reduce the incidence of coronary heart disease? *Nat Rev Cardiol*. 2011 Nov 1;8(12):721-5.
  721. Bucarius J, Duivenvoorden R, Mani V, Moncrieff C, Rudd JH, Calcagno C, Machac J, Fuster V, Farkouh ME, Fayad ZA. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. *JACC Cardiovasc Imaging*. 2011 Nov;4(11):1195-205.
  722. Vaishnava P, Narayan R, Fuster V. Understanding systemic inflammation, oral hygiene, and cardiovascular

- disease. *Am J Med.* 2011 Nov;124(11):997-9.
723. Sanz G, Fuster V, Guzmán L, Guglietta A, Arnáiz JA, Martínez F, Sarria A, Roncaglioni MC, Taubert K. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. *Am Heart J.* 2011 Nov;162(5):811-817.e1.
724. Klink A, Heynens J, Herranz B, Lobatto ME, Arias T, Sanders HM, Strijkers GJ, Merckx M, Nicolay K, Fuster V, Et Al. In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular magnetic resonance imaging. *J Am Coll Cardiol.* 2011 Dec 6;58:2522-30
725. Cimmino G, Ibanez B, Giannarelli C, Prat-González S, Hutter R, Garcia M, Sanz J, Fuster V, Badimon JJ. Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol. *Int J Cardiol.* 2011 Dec 15;153(3):256-61.
726. Islami F, Mańczuk M, Vedanthan R, Vatten L, Polewczyk A, Fuster V, Et Al. A cross-sectional study of cardiovascular disease and associated factors. *Ann Agric Environ Med.* 2011 Dec 22;18(2):255-9.
727. Fernández-Friera L, Fuster V, Sanz J. Characterization of a mediastinal thymic seminoma using cardiac magnetic resonance *Rev Esp Cardiol.* 2012 Jan;65(1):97.
728. Giannarelli C, Cimmino G, Connolly TM, Ibanez B, Garcia Ruiz JM, Alique M, Zafar MU, Fuster V, Et Al. Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis. *Eur Heart J.* 2012 Jan;33(2):264-73.
729. Fayad ZA, Mani V, Fuster V. The time has come for clinical cardiovascular trials with plaque characterization as an endpoint *Eur Heart J.* 2012 Jan;33(2):160-1.
730. Nair AP, Timoh T, Fuster V. Contemporary medical management of systolic heart failure. *Circ J.* 2012;76(2):268-77.
731. Ibanez B, Giannarelli C, Cimmino G, Santos-Gallego CG, Alique M, Pinero A, Vilahur G, Fuster V, et.al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). *Atherosclerosis.* 2012 Jan;220(1):72-7.
732. Sanz J, García-Alvarez A, Fernández-Friera L, Nair A, Mirelis JG, Sawit ST, Pinney S, Fuster V. Right ventriculo-arterial coupling in pulmonary hypertension: a magnetic resonance study. *Heart* 2012 Feb;98(3):238-43.
733. Kovacic JC, Lee P, Baber U, Karajgikar R, Evrard SM, Moreno P, Mehran R, Fuster V, Et Al. Inverse relationship between body mass index and coronary artery calcification in patients with clinically significant coronary lesions. *Atherosclerosis.* 2012 Mar;221(1):176-82.
734. Purushothaman KR, Krishnan P, Purushothaman M, Wiley J, Alviar CL, Ruiz FJ, Zubatov Y, Kini AS, Sharma SK, Fuster V, Moreno PR. Expression of angiotensin-converting enzyme 2 and its end product angiotensin 1-7 is increased in diabetic atheroma: implications for inflammation and neovascularization. *Cardiovasc Pathol.* 2012 Jun 28. [Epub ahead of print]
735. Fuster V, Torres, M. CNIC: Achieving Research Excellence Through Collaboration. *Rev Esp Cardiol.* 2012;65(6):511–516
736. Fuster V. An Alarming Threat to Secondary Prevention: Low Compliance (Lifestyle) and Poor Adherence (Drugs). *Rev Esp Cardiol.* 2012 Jul;65S2:10-16.
737. Sillesen H, Muntendam P, Adourian A, Entekin R, Garcia M, Falk E, Fuster V. Carotid plaque burden as a measure of subclinical atherosclerosis: comparison with other tests for subclinical arterial disease in the High Risk Plaque BioImage study. *JACC Cardiovasc Imaging.* 2012 Jul;5(7):681-9.
738. Purushothaman KR, Purushothaman M, Levy AP, Lento PA, Evrard S, Kovacic JC, Briley-Saebo KC, Tsimikas S, Witztum JL, Krishnan P, Kini A, Fayad ZA, Fuster V, Et Al. Increased expression of oxidation-specific epitopes and apoptosis are associated with haptoglobin genotype: possible implications for plaque progression in human atherosclerosis. *J Am Coll Cardiol.* 2012 Jul;10;60:112-9.
739. Franco M, Bilal U, Guallar E, Sanz G, Gómez AF, Fuster V, Cooper R. Systematic review of three decades



- of Spanish cardiovascular epidemiology: improving translation for a future of prevention. *Eur J Prev Cardiol.* 2012 Jul 13.
740. Sameer Bansilal, Rajesh Vedanthan, Mark Woodward, Rupa Iyengar, Marilyn Hunn, Marcelle Lewis, Lesley Francis, Alexander Charney, Claire Graves, Michael E. Farkouh, Valentin Fuster Cardiovascular Risk Surveillance to Develop a Nationwide Health Promotion Strategy: The Grenada Heart Project. *Global Heart* 2012 Jul;7:87-94.
741. Kushner T, Halperin JL, Nair AP, Fuster V, Love BA. Peripheral pulmonary artery stenosis masquerading as pulmonary hypertension: a diagnostic and therapeutic challenge. *Vasc Med.* 2012 Aug;17(4):235-8.
742. Elmariah S, Delaney JA, Bluemke DA, Budoff MJ, O'Brien KD, Fuster V, Kronmal RA, Halperin JL. Associations of LV hypertrophy with prevalent and incident valve calcification: Multi-Ethnic Study of Atherosclerosis. *JACC Cardiovasc Imaging.* 2012 Aug;5(8):781-8.
743. Vucic E, Calcagno C, Dickson SD, Rudd JH, Hayashi K, Bucarius J, Moshier E, Mounessa JS, Roytman M, Moon MJ, Lin J, Ramachandran S, Tanimoto T, Brown K, Kotsuma M, Tsimikas S, Fisher EA, Nicolay K, Fuster V, Fayad ZA. Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin. *JACC Cardiovasc Imaging.* 2012 Aug;5(8):819-28.
744. Castillo JG, Anyanwu AC, Fuster V, Adams DH. A near 100% repair rate for mitral valve prolapse is achievable in a reference center: implications for future guidelines. *J Thorac Cardiovasc Surg.* 2012 Aug;144(2):308-12.
745. Galper MW, Saung MT, Fuster V, Et Al. Effect of computed tomography scanning parameters on gold nanoparticle and iodine contrast. *Invest Radiol.* 2012 Aug;47(8):475-81.
746. Fernández-Jiménez R, López-Romero P, Suárez-Barrientos A, García-Rubira JC, Fernández-Ortiz A, Fuster V, Troponin release overestimates infarct size in presence of left ventricular hypertrophy. *J Am Coll Cardiol.* 2012 Aug 14;60(7):640-1
747. Yaniz-Galende E, Chen J, Chemaly ER, Liang L, Hulot JS, McCollum L, Arias T, Fuster V. Stem Cell Factor Gene Transfer Promotes Cardiac Repair After Myocardial Infarction via In Situ Recruitment and Expansion of c-kit+ Cells. *Circ Res.* 2012 Aug 29.
748. Chinitz JS, Halperin JL, Reddy VY, Fuster V. Rate or Rhythm Control for Atrial Fibrillation: Update and Controversies. *Am J Med.* 2012 Aug 29.
749. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. *J Am Coll Cardiol.* 2012 Sep 4;60(10):932-42.
750. Fuster V, Bhatt DL, Califf RM, Michelson AD, Et Al. Guided antithrombotic therapy: current status and future research direction: report on a national heart, lung and blood institute working group. *Circulation.* 2012 Sep 25;126(13):1645-62.
751. Gangireddy SR, Halperin JL, Fuster V, Reddy VY. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. *Eur Heart J.* 2012 Nov;33(21):2700-8.
752. Ibanez B, Fuster V, Macaya C, Sánchez-Brunete V, Et Al. Study design for the "effect of METOpromolol in CARDioprotection during an acute myocardial Infarction" (METOCARD-CNIC): A randomized, controlled parallel-group, observer-blinded clinical trial of early pre-reperfusion metoprolol administration in ST-segment elevation myocardial infarction. *Am Heart J.* 2012 Oct;164(4):473-480.e5.
753. Bansilal S, Farkouh ME, Hueb W, Ogdie M, Dangas G, Lansky AJ, Cohen DJ, Magnuson EA, Ramanathan K, Tanguay JF, Muratov V, Sleeper LA, Domanski M, Bertrand ME, Fuster V. The Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial: Clinical and angiographic profile at study entry. *Am Heart J.* 2012 Oct;164(4):591-9.
754. Mirelis JG, Garcia-Alvarez A, Fernandez-Friera L, Sawit S, Hinojar R, Fuster V, Et Al. Respiratory ventricular area changes measured with real-time cardiac magnetic resonance: A new, accurate, and reproducible approach for the diagnosis of pericardial constriction. *Int J Cardiol.* 2012 Oct 3. S0167-

5273(12)01208-9.

755. *Céspedes J, Briceño G, Farkouh ME, Vedanthan R, Baxter J, Leal M, Boffetta P, Woodward M, Hunn M, Dennis R, Fuster V. Targeting Preschool Children to Promote Cardiovascular Health: Cluster Randomized Trial. Am J Med. 2013 Jan;126(1):27-35.e3.*
756. Moral S, Fernández-Friera L, Stevens G, Guzman G, García-Alvarez A, Nair A, Evangelista A, Fuster V, Et Al. New index alpha improves detection of pulmonary hypertension in comparison with other cardiac magnetic resonance indices. *Int J Cardiol.* 2012 Nov 1;161(1):25-30.
757. Purushothaman M, Krishnan P, Purushothaman KR, Baber U, Tarricone A, Perez JS, Wiley J, Kini A, Sharma SK, Fuster V, Moreno PR. Genotype-dependent impairment of hemoglobin clearance increases oxidative and inflammatory response in human diabetic atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2012 Nov;32(11):2769-75
758. Giannarelli C, Cimmino G, Ibanez B, Chiesa G, Garcia-Prieto J, Santos-Gallego CG, Alique-Aguilar M, Fuster V, Sirtori C, Badimon JJ. Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term. *Thromb Haemost.* 2012 Oct 23;108(6).
759. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, Yang M, Cohen DJ, Rosenberg Y, Solomon SD, Desai AS, Gersh BJ, Magnuson EA, Lansky A, Boineau R, Weinberger J, Ramanathan K, Sousa JE, Rankin J, Bhargava B, Buse J, Hueb W, Smith CR, Muratov V, Bansilal S, King S 3rd, Bertrand M, Fuster V; the FREEDOM Trial Investigators. Strategies for Multivessel Revascularization in Patients with Diabetes. *N Engl J Med.* 2012 Dec 20;367(25):2375-84.
760. Zafar MU, Santos-Gallego C, Vorchheimer DA, Viles-Gonzalez JF, Elmariah S, Giannarelli C, Sartori S, Small DS, Jakubowski JA, Fuster V, Badimon JJ. Platelet Function Normalization after a Prasugrel Loading Dose: Time-dependent Effect of Platelet Supplementation. *J Thromb Haemost.* 2012 Nov 8. [Epub ahead of print]
761. Sanz G, Fuster V. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill. *Mt Sinai J Med.* 2012 Nov;79(6):683-8.
762. Kovacic JC, Fuster V. Atherosclerotic risk factors, vascular cognitive impairment, and Alzheimer disease. *Mt Sinai J Med.* 2012 Nov;79(6):664-73.
763. Sillesen H, Fuster V. Predicting coronary heart disease: from framingham risk score to ultrasound bioimaging. *Mt Sinai J Med.* 2012 Nov;79(6):654-63.
764. Otsuka F, Fuster V, Narula J, Virmani R. Omnipresent atherosclerotic disease: time to depart from analysis of individual vascular beds. *Mt Sinai J Med.* 2012 Nov;79(6):641-53.
765. Kelly BB, Narula J, Fuster V. Recognizing global burden of cardiovascular disease and related chronic diseases. *Mt Sinai J Med.* 2012 Nov;79(6):632-40.
766. Fuster V, Narula J, Kelly BB. Promoting global cardiovascular and cerebrovascular health. *Mt Sinai J Med.* 2012 Nov;79(6):625-31
767. Moral S, Fernández-Friera L, Stevens G, Guzman G, García-Alvarez A, Nair A, Evangelista A, Fuster V, Garcia MJ, Sanz J. New index alpha improves detection of pulmonary hypertension in comparison with other cardiac magnetic resonance indices. *Int J Cardiol.* 2012 Nov 1;161(1):25-30.
768. Gangireddy SR, Halperin JL, Fuster V, Reddy VY. Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit. *Eur Heart J.* 2012 Nov;33(21):2700-8.
769. Kovacic JC, Fuster V. Smoking gun theory: angiographically normal or mild coronary plaque as a cause of myocardial infarction. *Circulation.* 2012 Dec 18;126(25):2918-20.
770. Giannarelli C, Cimmino G, Ibanez B, Chiesa G, Garcia-Prieto J, Santos-Gallego CG, Alique-Aguilar M, Fuster V, Sirtori C, Badimon JJ. Acute ApoA-I Milano administration induces plaque regression and stabilisation in the long term. *Thromb Haemost.* 2012 Dec;108(6):1246-8.
771. Chatterjee S, Chaudhuri D, Vedanthan R, Fuster V, Ibanez B, Bangalore S, Mukherjee D. Int J Cardiol. Early intravenous beta-blockers in patients with acute coronary syndrome-A meta-analysis of randomized

- trials. 2012 Nov 17.: S0167-5273(12)01425-8.
772. Yaniz-Galende E, Chen J, Chemaly E, Liang L, Hulot JS, McCollum L, Arias T, Fuster V, Zsebo KM, Hajjar RJ. Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells. *Circ Res*. 2012 Nov 9;111(11):1434-45.
  773. Chinitz JS, Halperin JL, Reddy VY, Fuster V. Rate or rhythm control for atrial fibrillation: update and controversies. *Am J Med*. 2012 Nov;125(11):1049-56.
  774. Purushothaman M, Krishnan P, Purushothaman KR, Baber U, Tarricone A, Perez JS, Wiley J, Kini A, Sharma SK, Fuster V, Moreno PR. Genotype-dependent impairment of hemoglobin clearance increases oxidative and inflammatory response in human diabetic atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2012 Nov;32(11):2769-75.
  775. Islami F, Pourshams A, Vedanthan R, Poustchi H, Kamangar F, Golozar A, Etemadi A, Khademi H, Freedman ND, Merat S, Garg V, Fuster V, Et. Al. Smoking water-pipe, chewing nass and prevalence of heart disease: a cross-sectional analysis of baseline data from the Golestan Cohort Study, Iran. *Heart*. 2012 Dec 20.
  776. Magnuson EA, Farkouh ME, Fuster V, Et. Al. Cost-Effectiveness of Percutaneous Coronary Intervention with Drug Eluting Stents versus Bypass Surgery for Patients with Diabetes and Multivessel Coronary Artery Disease: Results from the FREEDOM Trial. *Circulation*. 2012 Dec 31.
  777. Sillesen H, Entekin R, Garcia M, Falk E, Fuster V. Reply. *JACC Cardiovasc Imaging*. 2013 Jan;6(1):130.
  778. Román-Busto J, Tasso M, Caravello G, Fuster V, Zuluaga P. Genetics of population exchange along the historical Portuguese-Spanish border. *J Biosoc Sci*. 2013 Jan;45(1):79-93.
  779. Purushothaman KR, Krishnan P, Purushothaman M, Wiley J, Alviar CL, Ruiz FJ, Zubatov Y, Kini AS, Sharma SK, Fuster V, Moreno PR. Expression of angiotensin-converting enzyme 2 and its end product angiotensin 1-7 is increased in diabetic atheroma: implications for inflammation and neovascularization. *Cardiovasc Pathol*. 2013 Jan;22(1):42-8.
  780. Bini J, Izquierdo-Garcia D, Mateo J, Machac J, Narula J, Fuster V, Fayad ZA. Preclinical Evaluation of MR Attenuation Correction Versus CT Attenuation Correction on a Sequential Whole-Body MR/PET Scanner. *Invest Radiol*. 2013 Jan 4.
  781. Chinitz JS, Vaishnav P, Narayan RL, Fuster V. Atrial fibrillation through the years: contemporary evaluation and management. *Circulation*. 2013 Jan 22;127(3):408-16.
  782. Fuster V, Zuluaga P, Colantonio SE, Román-Busto J. Factors determining the variation in birth weight in Spain (1980-2010). *Ann Hum Biol*. 2013 Feb 7.
  783. Bini J, Izquierdo-Garcia D, Mateo J, Machac J, Narula J, Fuster V, Fayad ZA. Preclinical Evaluation of MR Attenuation Correction Versus CT Attenuation Correction on a Sequential Whole-Body MR/PET Scanner. *Invest Radiol*. 2013;48(5):313-322.
  784. Kahn MR, Robbins MJ, Kim MC, Fuster V. Management of cardiovascular disease in patients with kidney disease. *Nat Rev Cardiol*. 2013;10(5):261-73.
  785. Silvestre-Roig C, Fernández P, Esteban V, Pello OM, Indolfi C, Rodríguez C, Rodríguez-Calvo R, López-Maderuelo MD, Bauriedel G, Hutter R, Fuster V, Ibáñez B, Redondo JM, Martínez-González J, Andrés V. Inactivation of nuclear factor- $\gamma$  inhibits vascular smooth muscle cell proliferation and neointima formation. *Arterioscler Thromb Vasc Biol*. 2013;33(5):1036-45.
  786. Prati F, Uemura S, Souteyrand G, Virmani R, Motreff P, Di Vito L, Biondi-Zoccai G, Halperin J, Fuster V, Ozaki Y, Narula J. OCT-based diagnosis and management of STEMI associated with intact fibrous cap. *JACC Cardiovasc Imaging*. 2013 Mar;6(3):283-7.
  787. Narula J, Nakano M, Virmani R, Kolodgie FD, Petersen R, Newcomb R, Malik S, Fuster V, Finn AV. Histopathologic characteristics of atherosclerotic coronary disease and implications of the findings for the invasive and noninvasive detection of vulnerable plaques. *J Am Coll Cardiol*. 2013 Mar 12;61(10):1041-51.
  788. Castillo JG, Castellano JM, Fuster V, Adams DH. A very unusual cause of mechanical left ventricular outflow tract obstruction. *Eur J Cardiothorac Surg*. 2013 Mar 26.

789. Gorog DA, Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. *J Am Coll Cardiol*. 2013 Mar 26
790. Fuster V. Profile: The Centro Nacional de Investigaciones Cardiovasculares Carlos III. Interview by Emma Wilkinson. *Eur Heart J*. 2013 Mar;34(10):705-6.
791. Farkouh ME, Domanski M, Fuster V. Revascularization strategies in patients with diabetes. *N Engl J Med*. 2013 Apr 11;368(15):1455-6.
792. Farkouh ME, Boden WE, Bittner V, Muratov V, Hartigan P, Ogdie M, Bertolet M, Mathewkutty S, Teo K, Maron DJ, Sethi SS, Domanski M, Frye RL, Fuster V Risk factor control for coronary artery disease secondary prevention in large randomized trials. *J Am Coll Cardiol*. 2013 Apr 16;61(15):1607-15
793. Zafar MU, Santos-Gallego, C, Vorchheimer, D.A, Viles-Gonzalesz, J.F., Elmariah, S., Giannarelli, C., Sartori, S., Small, D.S., Jakubowski, J.A., Fuster, V., Badimon, J.J. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. *J. of Thrombosis and Haemostasis*. April (in-press).
794. American College of Cardiology Foundation; American Heart Association; European Society of Cardiology; Heart Rhythm Society, Wann LS, Curtis AB, Ellenbogen KA, Estes NA, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey J, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann LS. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. *Circulation*. 2013 May 7;127(18):1916-26. doi: 10.1161/CIR.0b013e318290826d. Epub 2013 Apr 1. No abstract available
795. Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Le Heuzey JY, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013 May 7;61(18):1935-44. doi: 10.1016/j.jacc.2013.02.001. Epub 2013 Apr 1. Review. No abstract available.
796. Kini AS, Baber U, Kovacic JC, Limaye A, Ali ZA, Sweeny J, Maehara A, Mehran R, Dangas G, Mintz GS, Fuster V, Narula J, Sharma SK, Moreno PR. Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). *J Am Coll Cardiol*. 2013 Jul 2;62(1):21-9. doi: 10.1016/j.jacc.2013.03.058. Epub 2013 May 1.
797. Hutter R, Speidl WS, Valdiviezo C, Sauter B, Corti R, Fuster V, Badimon JJ. Macrophages transmit potent proangiogenic effects of oxLDL in vitro and in vivo involving HIF-1 $\alpha$  activation: a novel aspect of angiogenesis in atherosclerosis. *J Cardiovasc Transl Res*. 2013 Aug;6(4):558-69. doi: 10.1007/s12265-013-9469-9. Epub 2013 May 10.
798. Castellano JM, Vaishnava P, Castillo JG, Anyanwu AC, Fuster V. Coronary vasospasm attributable to fibromuscular dysplasia: the long bridge to transplant. *Circ Heart Fail*. 2013 May;6(3):e31-2. doi: 10.1161/CIRCHEARTFAILURE.112.000090. No abstract available.
799. Arias T, Chen J, Fayad ZA, Fuster V, Hajjar RJ, Chemaly ER. Comparison of echocardiographic measurements of left ventricular volumes to full volume magnetic resonance imaging in normal and diseased rats. *J Am Soc Echocardiogr*. 2013 Aug;26(8):910-8. doi: 10.1016/j.echo.2013.04.016. Epub 2013 May 23.
800. Peñalvo JL, Santos-Beneit G, Sotos-Prieto M, Martínez R, Rodríguez C, Franco M, López-Romero P, Pocock S, Redondo J, Fuster V. A cluster randomized trial to evaluate the efficacy of a school-based

- behavioral intervention for health promotion among children aged 3 to 5. *BMC Public Health*. 2013 Jul 15;13(1):656. doi: 10.1186/1471-2458-13-656.
801. Kahn MR, Robbins MJ, Kim MC, Fuster V. The role of fibrates in chronic kidney disease and diabetes mellitus. *Nat Rev Cardiol*. 2013 Sep;10(9):547. doi: 10.1038/nrcardio.2013.15-c2. Epub 2013 Jul 30. No abstract available.
802. Dangas GD, Maehara A, Evrard SM, Sartori S, Li JR, Chirumamilla AP, Nomura-Kitabayashi A, Gukathasan N, Hassanin A, Baber U, Fahy M, Fuster V, Mintz GS, Kovacic JC. Coronary artery calcification is inversely related to body morphology in patients with significant coronary artery disease: a three-dimensional intravascular ultrasound study. *Eur Heart J Cardiovasc Imaging*. 2014 Feb;15(2):201-9. doi: 10.1093/ehjci/jet139. Epub 2013 Jul 31.
803. Sanz J, Moreno PR, Fuster V. The year in atherothrombosis. *J Am Coll Cardiol*. 2013 Sep 24;62(13):1131-43. doi: 10.1016/j.jacc.2013.06.045. Epub 2013 Jul 31. Review. No abstract available.
804. Calcagno C, Ramachandran S, Izquierdo-Garcia D, Mani V, Millon A, Rosenbaum D, Tawakol A, Woodward M, Bucarius J, Moshier E, Godbold J, Kallend D, Farkouh ME, Fuster V, Rudd JH, Fayad ZA. The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. *Eur J Nucl Med Mol Imaging*. 2013 Dec;40(12):1884-93. doi: 10.1007/s00259-013-2518-4. Epub 2013 Aug 14.
805. García-Álvarez A, Fernández-Friera L, García-Ruiz JM, Nuño-Ayala M, Pereda D, Fernández-Jiménez R, Guzmán G, Sanchez-Quintana D, Alberich-Bayarri A, Pastor-Escuredo D, Sanz-Rosa D, García-Prieto J, Gonzalez-Mirelis JG, Pizarro G, Jimenez-Borreguero LJ, Fuster V, Sanz J, Ibáñez B. Noninvasive monitoring of serial changes in pulmonary vascular resistance and acute vasodilator testing using cardiac magnetic resonance. *J Am Coll Cardiol*. 2013 Oct 22;62(17):1621-31. doi: 10.1016/j.jacc.2013.07.037. Epub 2013 Aug 14.
806. Ibanez B, Macaya C, Sánchez-Brunete V, Pizarro G, Fernández-Friera L, Mateos A, Fernández-Ortiz A, García-Ruiz JM, García-Álvarez A, Iñiguez A, Jiménez-Borreguero J, López-Romero P, Fernández-Jiménez R, Goicolea J, Ruiz-Mateos B, Bastante T, Arias M, Iglesias-Vázquez JA, Rodriguez MD, Escalera N, Acebal C, Cabrera JA, Valenciano J, Pérez de Prado A, Fernández-Campos MJ, Casado I, García-Rubira JC, García-Prieto J, Sanz-Rosa D, Cuellas C, Hernández-Antolín R, Albarrán A, Fernández-Vázquez F, de la Torre-Hernández JM, Pocock S, Sanz G, Fuster V. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. *Circulation*. 2013 Oct 1;128(14):1495-503. doi: 10.1161/CIRCULATIONAHA.113.003653. Epub 2013 Sep 3.
807. Hutter R, Huang L, Speidl WS, Giannarelli C, Trubin P, Bauriedel G, Klotman ME, Fuster V, Badimon JJ, Klotman PE. Novel small leucine-rich repeat protein podocan is a negative regulator of migration and proliferation of smooth muscle cells, modulates neointima formation, and is expressed in human atheroma. *Circulation*. 2013 Nov 26;128(22):2351-63. doi: 10.1161/CIRCULATIONAHA.113.004634. Epub 2013 Sep 16.
808. Sanz G, Fuster V. Prevention: Polypills for cardiovascular prevention: a step forward? *Nat Rev Cardiol*. 2013 Dec;10(12):683-4. doi: 10.1038/nrcardio.2013.157. Epub 2013 Oct 8.
809. Allijn IE, Leong W, Tang J, Gianella A, Mieszawska AJ, Fay F, Ma G, Russell S, Callo CB, Gordon RE, Korkmaz E, Post JA, Zhao Y, Gerritsen HC, Thran A, Proksa R, Daerr H, Storm G, Fuster V, Fisher EA, Fayad ZA, Mulder WJ, Cormode DP. Gold nanocrystal labeling allows low-density lipoprotein imaging from the subcellular to macroscopic level. *ACS Nano*. 2013 Nov 26;7(11):9761-70. doi: 10.1021/nn403258w. Epub 2013 Oct 17.
810. Abdallah MS, Wang K, Magnuson EA, Spertus JA, Farkouh ME, Fuster V, Cohen DJ; FREEDOM Trial Investigators. Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. *JAMA*. 2013 Oct 16;310(15):1581-90. doi:

- 10.1001/jama.2013.279208.
811. Duivenvoorden R, Mani V, Woodward M, Kallend D, Suchankova G, Fuster V, Rudd JH, Tawakol A, Farkouh ME, Fayad ZA. Relationship of serum inflammatory biomarkers with plaque inflammation assessed by FDG PET/CT: the dal-PLAQUE study. *JACC Cardiovasc Imaging*. 2013 Oct;6(10):1087-94. doi: 10.1016/j.jcmg.2013.03.009.
812. Elmariah S, Budoff MJ, Delaney JA, Hamirani Y, Eng J, Fuster V, Kronmal RA, Halperin JL, O'Brien KD. Risk factors associated with the incidence and progression of mitral annulus calcification: the multi-ethnic study of atherosclerosis. *Am Heart J*. 2013 Nov;166(5):904-12. doi: 10.1016/j.ahj.2013.08.015. Epub 2013 Sep 26.
813. Céspedes J, Briceño G, Farkouh ME, Vedanthan R, Baxter J, Leal M, Boffetta P, Hunn M, Dennis R, Fuster V. Promotion of cardiovascular health in preschool children: 36-month cohort follow-up. *Am J Med*. 2013 Dec;126(12):1122-6. doi: 10.1016/j.amjmed.2013.06.021.
814. Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula The MOGE(S) classification for a phenotype-genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation. *J Am Coll Cardiol*. 2013 Dec 3;62(22):2046-72. doi: 10.1016/j.jacc.2013.08.1644. Epub 2013 Nov 18. No abstract available. Erratum in: *J Am Coll Cardiol*. 2014 Jan 21;63(2):191-4.
815. Fernández-Ortiz A, Jiménez-Borreguero LJ, Peñalvo JL, Ordovás JM, Moco-roa A, Fernández-Friera L, Laclaustra M, García L, Molina J, Mendiguren JM, López-Melgar B, de Vega VM, Alonso-Farto JC, Guallar E, Sillesen H, Rudd JH, Fayad ZA, Ibañez B, Sanz G, Fuster V. The Progression and Early detection of Subclinical Atherosclerosis (PESA) study: rationale and design. *Am Heart J*. 2013 Dec;166(6):990-8. doi: 10.1016/j.ahj.2013.08.024. Epub 2013 Oct 10.
816. Bucierius J, Mani V, Moncrieff C, Machac J, Fuster V, Farkouh ME, Tawakol A, Rudd JH, Fayad ZA. Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. *Eur J Nucl Med Mol Imaging*. 2014 Feb;41(2):369-83. doi: 10.1007/s00259-013-2569-6. Epub 2013 Nov 23.
817. Peñalvo JL, Sotos-Prieto M, Santos-Beneit G, Pocock S, Redondo J, Fuster V. The Program SI! intervention for enhancing a healthy lifestyle in preschoolers: first results from a cluster randomized trial. *BMC Public Health*. 2013 Dec 20;13:1208. doi: 10.1186/1471-2458-13-1208.
818. Bujak R, García-Álvarez A, Rupérez FJ, Nuño-Ayala M, García A, Ruiz-Cabello J, Fuster V, Ibañez B, Barbas C. Metabolomics reveals metabolite changes in acute pulmonary embolism. *J Proteome Res*. 2014 Feb 7;13(2):805-16. doi: 10.1021/pr400872j. Epub 2014 Jan 8.
819. Hulot JS, Stillitano F, Salem JE, Kovacic JC, Fuster V, Hajjar RJ. Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes. *Stem Cell Res Ther*. 2014 Jan 9;5(1):1. [Epub ahead of print]
820. Tahara N, Mukherjee J, de Haas HJ, Petrov AD, Tawakol A, Haider N, Tahara A, Constantinescu CC, Zhou J, Boersma HH, Imaizumi T, Nakano M, Finn A, Fayad Z, Virmani R, Fuster V, Bosca L, Narula J. 2-deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis. *Nat Med*. 2014 Feb;20(2):215-9. doi: 10.1038/nm.3437. Epub 2014 Jan 12.
821. Mirelis JG, Paetsch I, Jahnke C, Ibañez B, Fleck E, Alonso-Pulpon LA, Fuster V, Gebker R. Impact of diastolic wall stress on the diagnostic value of visually interpreted dobutamine stress MR imaging. *Int J Cardiol*. 2014 Mar 1;172(1):e39-42. doi: 10.1016/j.ijcard.2013.12.085. Epub 2014 Jan 4. No abstract available.
822. Bucierius J, Mani V, Wong S, Moncrieff C, Izquierdo-Garcia D, Machac J, Fuster V, Farkouh ME, Rudd JH, Fayad ZA. Arterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT study. *Eur J Nucl Med Mol Imaging*. 2014 May;41(5):934-45. doi: 10.1007/s00259-013-2653-y. Epub 2014 Jan 18.
823. Duivenvoorden R, Tang J, Cormode DP, Mieszawska AJ, Izquierdo-Garcia D, Ozcan C, Otten MJ, Zaidi N,

- Lobatto ME, van Rijs SM, Priem B, Kuan EL, Martel C, Hewing B, Sager H, Nahrendorf M, Randolph GJ, Stroes ES, Fuster V, Fisher EA, Fayad ZA, Mulder WJ. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. *Nat Commun.* 2014;5:3065. doi: 10.1038/ncomms4065. Erratum in: *Nat Commun.* 2014;5:3531.
824. Viles-Gonzalez JF, Enriquez AD, Castillo JG, Coffey JO, Pastori L, Reddy VY, Adams DH, Fuster V. Incidence, predictors, and evolution of conduction disorders and atrial arrhythmias after contemporary mitral valve repair. *Cardiol J.* 2014 Mar 27. doi: 10.5603/CJ.a2014.0016. [Epub ahead of print]
825. de Haas HJ, Arbustini E, Fuster V, Kramer CM, Narula J. Molecular imaging of the cardiac extracellular matrix. *Circ Res.* 2014 Feb 28;114(5):903-15. doi: 10.1161/CIRCRESAHA.113.302680. Review.
826. Kovacic JC, Castellano JM, Farkouh ME, Fuster V. The relationships between cardiovascular disease and diabetes: focus on pathogenesis. *Endocrinol Metab Clin North Am.* 2014 Mar;43(1):41-57. doi: 10.1016/j.ecl.2013.09.007.
827. Izquierdo-Garcia D, Sawiak SJ, Knesaurek K, Narula J, Fuster V, Machac J, Fayad ZA. Comparison of MR-based attenuation correction and CT-based attenuation correction of whole-body PET/MR imaging. *Eur J Nucl Med Mol Imaging.* 2014 Mar 21. [Epub ahead of print]
828. Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula MOGE(S) nosology in low-to-middle-income countries. *J. Nat Rev Cardiol.* 2014 May;11(5):307. doi: 10.1038/nrcardio.2013.219-c1. Epub 2014 Mar 25. No abstract available.
829. Dellegrottaglie S, García-Alvarez A, Guarini P, Perrone-Filardi P, Fuster V, Sanz J. Prevalence and severity of ventricular dysfunction in patients with HIV-related pulmonary arterial hypertension. *Heart Lung.* 2014 May-Jun;43(3):256-61. doi: 10.1016/j.hrtlng.2014.02.007. Epub 2014 Mar 27.
830. Pizarro G, Fernández-Friera L, Fuster V, Fernández-Jiménez R, García-Ruiz JM, García-Álvarez A, Mateos A, Barreiro MV, Escalera N, Rodríguez MD, de Miguel A, García-Lunar I, Parra-Fuertes JJ, Sánchez-González J, Pardillos L, Nieto B, Jiménez A, Abejón R, Bastante T, de Vega VM, Cabrera JA, López-Melgar B, Guzman G, García-Prieto J, Mirelis JG, Zamorano JL, Albarrán A, Goicolea J, Escaned J, Pocock S, Iñiguez A, Fernández-Ortiz A, Sánchez-Brunete V, Macaya C, Ibanez B. Long term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial. *J Am Coll Cardiol.* 2014 Mar 24. pii: S0735-1097(14)01682-9. doi: 10.1016/j.jacc.2014.03.014. [Epub ahead of print]
831. Sotos-Prieto M, Santos-Beneit G, Pocock S, Redondo J, Fuster V, Peñalvo JL. Parental and self-reported dietary and physical activity habits in pre-school children and their socio-economic determinants. *Public Health Nutr.* 2014 Apr 3:1-11. [Epub ahead of print]
832. Vedanthan R, Kamano JH, Horowitz CR, Ascheim D, Velazquez EJ, Kimaiyo S, Fuster V. Nurse management of hypertension in rural Western Kenya: implementation research to optimize delivery. *Ann Glob Health.* 2014 Jan-Feb;80(1):5-12. doi: 10.1016/j.aogh.2013.12.002. Epub 2013 Dec 25.
833. Wiley B, Fuster V. The Concept of the Polypill in the Prevention of Cardiovascular Disease. *Ann Glob Health.* 2014 January - February;80(1):24-34. doi: 10.1016/j.aogh.2013.12.008. Epub 2013 Dec 25. Review.
834. Vedanthan R, Kamano JH, Naanyu V, Delong AK, Were MC, Finkelstein EA, Menya D, Akwanalo CO, Bloomfield GS, Binanay CA, Velazquez EJ, Hogan JW, Horowitz CR, Inui TS, Kimaiyo S, Fuster V. Optimizing linkage and retention to hypertension care in rural Kenya (LARK hypertension study): study protocol for a randomized controlled trial. *Trials.* 2014 Apr 27;15(1):143. doi: 10.1186/1745-6215-15-143.
836. Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula J. Reply: The MOGE(S) Classification for a Phenotype-Genotype Nomenclature of Cardiomyopathy: More Questions Than Answers? *J Am Coll Cardiol.* 2014 Jun 17;63(23):2584-6. doi: 10.1016/j.jacc.2014.03.028. Epub 2014 Apr 23. No abstract available.

837. Pereda D, García-Alvarez A, Sánchez-Quintana D, Nuño M, Fernández-Friera L, Fernández-Jiménez R, García-Ruiz JM, Sandoval E, Aguero J, Castellá M, Hajjar RJ, Fuster V, Ibáñez B. Swine Model of Chronic Postcapillary Pulmonary Hypertension with Right Ventricular Remodeling: Long-Term Characterization by Cardiac Catheterization, Magnetic Resonance, and Pathology. *J Cardiovasc Transl Res*. 2014 Apr 26. [Epub ahead of print]
838. Castellano JM, Sanz G, Fuster V. Evolution of the polypill concept and ongoing clinical trials. *Can J Cardiol*. 2014 May;30(5):520-6. doi: 10.1016/j.cjca.2014.02.016. Epub 2014 Feb 27. Review.
839. Shah N, Badheka AO, Grover PM, Patel NJ, Chothani A, Mehta K, Hoosien M, Singh V, Savani GT, Deshmukh A, Rathod A, Patel N, Panaich SS, Arora S, Schwartz C, Blisker M, Coffey JO, Mitrani RD, Fuster V, Viles-Gonzalez JF. Influence of left ventricular remodeling on atrial fibrillation recurrence and cardiovascular hospitalizations in patients undergoing rhythm-control therapy. *Int J Cardiol*. 2014 Jun 15;174(2):288-92. doi: 10.1016/j.ijcard.2014.04.011. Epub 2014 Apr 13.
840. Fuster V, Kovacic JC. Acute coronary syndromes: pathology, diagnosis, genetics, prevention, and treatment. *Circ Res*. 2014 Jun 6;114(12):1847-51. doi: 10.1161/CIRCRESAHA.114.302806. Epub 2014 May 13. No abstract available.
841. Castellano JM, Narula J, Castillo J, Fuster V. Promoting Cardiovascular Health Worldwide: Strategies, Challenges, and Opportunities. *Rev Esp Cardiol*. 2014 May 24. pii: S0300-8932(14)00174-2. doi: 10.1016/j.recesp.2014.01.024. [Epub ahead of print] English, Spanish.
842. Mohanty BD, Looser PM, Gokanapudy LR, Handa R, Mohanty S, Choi SS, Goldman ME, Fuster V, Halperin JL. Controversies regarding the new oral anticoagulants for stroke prevention in patients with atrial fibrillation. *Vasc Med*. 2014 May 30;19(3):190-204. [Epub ahead of print] Review.
843. Vedanthan R, Seligman B, Fuster V. Global perspective on acute coronary syndrome: a burden on the young and poor. *Circ Res*. 2014 Jun 6;114(12):1959-75. doi: 10.1161/CIRCRESAHA.114.302782.
844. Shah N, Badheka AO, Grover PM, Patel NJ, Chothani A, Mehta K, Hoosien M, Singh V, Savani GT, Deshmukh A, Rathod A, Patel N, Panaich SS, Arora S, Schwartz C, Blisker M, Coffey JO, Mitrani RD, Fuster V, Viles-Gonzalez JF. Influence of left ventricular remodeling on atrial fibrillation recurrence and cardiovascular hospitalizations in patients undergoing rhythm-control therapy. *Int J Cardiol*. 2014 Jun 15;174(2):288-92. doi: 10.1016/j.ijcard.2014.04.011. Epub 2014 Apr 13.
845. Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, Marwick T, Pinney S, Bellazzi R, Favalli V, Kramer C, Roberts R, Zoghbi WA, Bonow R, Tavazzi L, Fuster V, Narula Reply: The MOGE(S) Classification for a Phenotype-Genotype Nomenclature of Cardiomyopathy: More Questions Than Answers? *J Am Coll Cardiol*. 2014 Jun 17;63(23):2584-6. doi: 10.1016/j.jacc.2014.03.028. Epub 2014 Apr 23. No abstract available.

### Books-Editor

1. Fuster V, ed. *Diseases of the Heart (Enfermedades de Corazon)*. En el libro: *Medicina Interna Pro Farreras-Rozman, 7a Edicion Edit Marin, Barcelona, 1972;250-402;1978 (9<sup>th</sup> edition);1982 (11<sup>th</sup> Edition)*.
2. Brandenburg RO, Fuster V, Giuliani ER, McGoon DC, eds. *Cardiology: Fundamentals and Practice*. St. Louis, MO: Year Book Medical Publishers; 1987;1991(2<sup>nd</sup> edition)
3. Fuster V, Verstraete M, eds. *Thrombosis in Cardiovascular Disorders*. Philadelphia, PA: W.B. Saunders Company; 1992:1-565.
4. Fuster V, Ross R, Topol EJ, eds. *Atherosclerosis and Coronary Artery Disease*. Philadelphia, PA: Lippincott-Raven; 1996:1285-1297.
5. Fuster V, ed. *Syndromes of Atherosclerosis. Correlations of Clinical Imaging and Pathology*. Armonk, NY: Futura Publishing; 1996:1-558.
6. Fuster V, ed. *The Vulnerable Atherosclerotic Plaque: Understanding, Identification and Modification*. Armonk, NY: Futura Publishing Company, Inc.; 1998.



7. Verstraete M, Fuster V, Topol EJ, eds. *Cardiovascular Thrombosis*. Philadelphia, PA: Lippincott-Raven; 1998:1-871.
8. Nash IS, Fuster V, eds. *Efficacy of Myocardial Infarction Therapy-An Evaluation of Clinical Trials Evidence*. New York: Marcel Dekker; 1999:1-493.
9. Fuster V, Alexander RW, O'Rourke R, eds. *Hurst's the Heart*. 10<sup>th</sup> Edition. New York: McGraw Hill; 2001:1-2567.
10. Fuster V , ed., *Assessing and Modifying the Vulnerable Atherosclerotic Plaque*. Armonk, NY: Futura Publishing Company, Inc.; 2002:1-379.
11. Gresele P, Page C, Fuster V, Vermynen J. *Platelets in Thrombotic and Non-Thrombotic Disorders*. United Kingdom: Cambridge University Press; 2002.
12. Kukin M, Fuster V., eds. *Oxidative Stress and Cardiac Failure*. Armonk, New York: Futura Publishing Company, Inc.;2003:1-291.
13. Lardo A.C., Fayad Z.A., Fuster V., Chronos N.A. *Cardiovascular Magnetic Resonance: Established and Emerging Applications*. London: Martin Dunitz; 2003.
14. Fuster V, Topol E, Nabel, E, eds. *Atherothrombosis and Coronary Artery Disease*. 2<sup>nd</sup> Edition Philadelphia, PA: Lippincott-Raven; 2004.
15. Fuster V, Alexander RW, O'Rourke R, eds. *Hurst's the Heart*. 11<sup>th</sup> Edition. New York: McGraw Hill; 2004.
16. Viles-Gonzalez J, Badimon J, Fuster V. Pathogenesis of Atherosclerosis (chapter 3). *Antioxidants and Cardiovascular Disease*. 2<sup>nd</sup> Edition, Montreal Canada. Springer 2006.
17. Fuster V. *La Ciencia de la Salud*. Planeta Ed. 2006, Spain (Best Seller for 9 months), 2009 (English version) Harper Collins Ed, New York
18. Fuster V. et al, *Hurst's the Heart* 12<sup>th</sup> Edition, 2007, The McGraw-Hill companies, Inc.
19. Gresele et al. *Platelets in Hematologic and Cardiovascular Disorders* Hematology 3<sup>rd</sup> Edition. 2007
20. Fuster V, Sampedro JL. *La Ciencia y la Vida*. Plaza Janes Ed. 2008, Spain
21. Fuster V, Rojas Marcos L, *Corazon y Mente*. Planeta Espasa Ed, 2008, Spain
22. Fuster V, ed., *The AHA Guidelines and Scientific Statements Handbook*. Wiley-Blackwell Ed, 2009, London
23. Vilacosta I, San Roman JA, Fuster V. *Insuficiencia Cardiaca*. Menarini, 2010, Spain
24. Fuster V. Corbella, J. *The Heart Manual*, HarperCollins, 2010, New York
25. Fuster V. et al, *Hurst's the Heart* 12<sup>th</sup> Edition, 2011, The McGraw-Hill companies, Inc., New York
26. Fuster V. Emma Reverter El Circulo de la Motivacion. Planeta Ed. 2013, Spain